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ABSTRACT

Economic Evaluation of Prophylactic Antiemetic Regimens for Prevention of
Chemotherapy-Induced Nausea and Vomiting (CINV)

Reema R Mody
New antiemetic agents, aprepitant and palonosetron have been approved for prevention of
chemotherapy-induced nausea and vomiting (CINV). The objectives of the two phases of the
study were: 1) to conduct cost-effectiveness analysis of antiemetic regimens for prevention of
CINV in patients receiving highly emetogenic chemotherapy (HEC) and in patients receiving
moderately emetogenic chemotherapy (MEC) using decision models, and 2) to determine the
monetary value of improved emesis control and conduct cost-benefit analysis of the new
antiemetic regimens. Regimen A, one of the four antiemetic strategies included in the HEC
decision model was a combination of aprepitant and the standard regimen of
ondansetron+dexamethasone. The other three regimens had standard regimen in the acute phase
but differed in the delayed phase regimens: regimen B - dexamethasone only, regimen C dexamethasone+metoclopramide and regimen D - dexamethasone+ondansetron. The four
antiemetic strategies for prevention of CINV due to MEC were: regimen 1) IV palonosetron, 2)
IV ondansetron, 3) ondansetron+dexamethasone in acute phase, only dexamethasone in delayed
phase, 4) ondansetron+dexamethasone in acute and delayed phase. The outcome measure was
the incremental cost-effectiveness ratios (ICER) measured as cost/patient with complete control
of emesis. For the HEC model, the ICER of regimen A compared to C was $3,363.18 and
$2,881.61 per patient with complete control of emesis, from payer and societal perspectives
respectively. One-way and probabilistic sensitivity analyses indicated that the conclusions were
relatively stable to variations in multiple parameters. For MEC model, regimen 1 was found to
be most cost-effective with ICER of $3,582.48 and $3,549.02, from payer and societal
perspectives respectively. Overall, the ICER results showed that the regimen A and regimen 1
could be considered cost-effective therapies for prevention of CINV. In phase II, a contingent
valuation survey was developed and administered to 120 cancer patients who were either
receiving or had received chemotherapy. The results showed that respondents were willing-topay on average $83.50 for a single dose of palonosetron and $89.90 for a three-day regimen of
aprepitant. Phase II qualitative results also emphasized that cancer patients receiving
chemotherapy placed a high importance on receiving even a modest improvement in the control
of CINV.
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CHAPTER ONE
INTRODUCTION

1.1: Epidemiology of Chemotherapy-Induced Nausea and Vomiting (CINV)
Chemotherapy, one of the mainstays in the treatment of cancer has two main goals: 1) to
control the progression of tumors and increase survival and 2) to improve health-related quality
of life (HRQOL). In 2001, approximately 1.4 million cancer patients in the United States (US)
received chemotherapy. It is also estimated that almost 600,000 of the approximately 1.4 million
newly diagnosed cancer patients per year are candidates for cancer chemotherapy (Plosker &
Benfield, 1996). However, chemotherapy drugs are associated with a number of adverse effects
such as nausea, vomiting, anemia, neutropenia, alopecia, constipation, diarrhea and stomatitis
(DeVita, Hellman, & Rosenberg, 2001).
Chemotherapy-induced nausea and vomiting (CINV) are perceived among the most
distressing side effects of chemotherapy by patients with cancer (Boer-Dennert et al., 1997;
Griffin et al., 1996). A study conducted in 1983, assessing patients’ perceptions of side effects of
cancer chemotherapy, before the introduction of 5-HT3 receptor antagonists (5-HT3 RAs), showed
that nausea and vomiting were ranked as the most distressing side effects (Coates, et al., 1983).
More recent studies showed that CINV is still ranked among the top five distressing side effects
of chemotherapy, despite the development of efficacious antiemetic agents (Boer-Dennert et al.,
1997; Griffin et al., 1996). However, a study conducted (Carelle et al., 2002) in French patients
showed that patients’ perceptions of the side effects of cancer chemotherapy had changed, with
fatigue and psychosocial concerns predominating compared to emesis and nausea.
The actual incidence and severity of nausea and vomiting is difficult to determine due to:
type of chemotherapy given, dose, schedule, individual patient characteristics, health condition of
patients who receive the chemotherapy drugs, underassessment by clinicians and underreporting
by patients (Doherty, 1999; Osoba, et al., 1997a). Irrespective of various factors, approximately
60% to 80% of all cancer patients receiving chemotherapy experience some degree of nausea and
vomiting (King, 1997). Based on the time of its occurrence, CINV can be classified into acute,
delayed and anticipatory CINV (Refer Chapter 2 for definitions). Among patients treated with
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highly emetogenic (HE) chemotherapy (such as cisplatin) and not receiving any prophylaxis for
CINV, the incidence of acute and delayed emesis is more than 90% and between 60-90%,
respectively. Similarly, in patients receiving moderately emetogenic (ME) chemotherapy agents
(such as carboplatin, cyclophosphamide or doxorubicin), the incidence of acute and delayed
emesis is between 30-90% and 20-33% respectively (Gralla, 1997; Gralla et al., 1999; Hesketh,
1999).
1.2: Impact of CINV on Clinical, Humanistic and Economic Outcomes
Impact on clinical outcomes
Uncontrolled and suboptimally controlled CINV may lead to physiological consequences
such as fluid and electrolyte disturbances, dehydration, esophageal tears, weight loss, aspiration
pneumonia and liver function abnormalities (Bender et al., 2002). The goal for chemotherapy
patients is to maintain adequate nutritional intake to prevent weight loss and to maintain protein
stores and muscle mass. However, prolonged or delayed nausea and vomiting may lead to
inadequate nutritional intake leading to weight loss and muscle wasting (Brown et al., 2001).
Poor emesis control can also lead to anticipatory nausea and vomiting in 10-30% of the patients
(Boakes, Tarrier, Barnes, & Tattersall, 1993). It can also lead to psychological effects that may
lead to depression and anxiety. Though hospitalizations for complications of emesis are rare
(Feldman & Dixon, 2000), failure to control treatment-related nausea and vomiting can lead to
20-50% of patients delaying or refusing possible lifesaving chemotherapy (Herrstedt, 2002;
Schnell, 2003).
Impact on humanistic outcomes
Health-related quality of life (HRQOL) is a subjective, multidimensional perspective of
well-being that is influenced by disease and treatment (Grant, 1997). It is an important outcome
measure of patient response to cancer and cancer treatment. CINV affects the physical,
psychological, spiritual and social well-being of the patient (Grant, 1997). A review article of
various observational studies showed that, after adjusting for HRQOL before chemotherapy,
CINV was associated with a decrease in HRQOL of patients with emesis compared to patients
without emesis (Ballatori & Roila, 2003).
Osoba et al.(Osoba et al., 1997b) studied the effect of post-chemotherapy nausea and
vomiting on HRQOL among 802 cancer patients receiving HE and ME chemotherapy. The
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patients completed the European Organization for Research and Treatment of Cancer (EORTC)
core Quality of Life Questionnaire before and 7 days after the first chemotherapy dose, and on
the first day of the second cycle of chemotherapy. It was found that the group with nausea and
vomiting showed significantly worse physical, cognitive and social functioning as compared to
the group that did not experience nausea or vomiting. The group with nausea and vomiting also
had worse scores on global quality of life, fatigue, anorexia, insomnia and dyspnea. Patients with
only nausea tended to have less worsening in functioning and symptoms than those having both
nausea and vomiting. Increased severity of vomiting (> 2 episodes) was associated with
worsening of global quality of life and anorexia compared with one to two episodes of vomiting.
Lindley et al. (Lindley et al., 1992) conducted a study among 122 patients with various
cancers, receiving different chemotherapy and antiemetic regimens to evaluate the impact of
CINV on quality of life (QOL). The Functional Living Index – Emesis (FLIE), a validated
instrument was administered at baseline and three days after chemotherapy to study the impact of
CINV on physical activities, social and emotional function and ability to enjoy meals. There was
a significant decrease in the mean QOL score of patients who experienced emesis compared to
the non-emesis patient group. CINV also has an impact on daily life such as maintaining
hobbies, preparing a meal or carrying out minor tasks around the house etc. A cross-sectional
multinational study conducted to assess the impact of CINV on daily life showed that 77% of
patients who suffered from nausea and 53% of those suffering from vomiting reported a negative
impact on their daily life (Glaus et al., 2004).
Though studies have shown that CINV has a significant impact on patients’ HRQOL, it is
difficult to quantify the impact of uncontrolled CINV on intangible effects such as HRQOL,
patient distress and suffering. These intangible effects can be valued either by using monetary
values or by using economic and psychometric scaling techniques.
Impact on economic outcomes
In addition to its clinical impact, uncontrolled nausea and vomiting also have significant
economic burden. Uncontrolled CINV and subsequent medical complications can lead to
increase in the direct, indirect and intangible costs associated with CINV. Direct costs associated
with CINV include cost of prophylactic and rescue medications, health care personnel costs,
extended hospitalizations and material costs, whereas indirect costs include lost or reduced
patient/caregiver productivity and lost income (Miller & Kearney, 2004; Pendergrass, 1998).
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The intangible costs associated with uncontrolled CINV include decreased QOL, patient distress
and patient suffering.
The information on costs of CINV is limited due to very few published studies. Before
the introduction of costlier and more effective 5-HT3RAs to prevent CINV, the direct and indirect
costs associated with CINV in Canadian cancer centers were approximately US $127 per patient
(O'Brien et al., 1993). The direct costs associated with CINV included cost of prophylactic and
rescue medications, nurse time, physician time, hospital admissions, and material costs. Indirect
costs which accounted for two-thirds of the total costs included the out-of-pocket expenses for
the purchase of nonprescription medicines, travel costs, and patient or caregiver time away from
work. The study also reported a total loss of 198 hours of paid employment and 409 hours of
unpaid employment, among 72 patients who experienced emesis. An additional loss of 186
hours was found among caregivers.
A more recent, prospective, cross-sectional, cost-of-illness study conducted in German
cancer centers showed that the most frequently used resources due to delayed emesis were rescue
medications, outpatient hospital and physician office visits (Ihbe-Heffinger et al., 2004). In
2002, the mean direct and indirect costs per treatment cycle with CINV per patient was
€77.30±146.59 (US $93.37±177.06). In this study, one patient required hospitalization and three
patients lost workdays due to delayed CINV. However, this study did not consider cost
associated with lost personal time from daily activities and lost unpaid work due to CINV. In
another study, Roila and colleagues (2000) showed that of patients who experienced CINV, 23%
were unable to go to work, 22% reported they were unable to prepare meals, and 12% were
unable to take prescribed medications. The impact of CINV on work productivity and daily life
activities were not quantified in this study. Thus, uncontrolled CINV poses a significant
economic burden on the patient in the form of direct medical and indirect costs. The intangible
costs associated with uncontrolled or suboptimally controlled CINV have not been assessed
satisfactorily. Though there are only a few cost-of-burden studies in the area of CINV, it is
difficult to compare the results due to variation in methodology employed, study setting, study
country and availability of various antiemetic agents.
1.3: Prevention Strategies for CINV
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The most important point about managing CINV is that preventing CINV is more
effective than treating it (Markman, 2002). Antiemetic agents administered before chemotherapy
are effective in reducing the incidence of acute emesis, but it is difficult to completely control
CINV once it has begun. Thus, prophylaxis with appropriate antiemetic agents is very critical in
preventing acute, delayed and anticipatory emesis during the first and subsequent cycles of
chemotherapy. One of the goals of antiemetic therapy is to achieve complete control in all
settings, beginning with the initial cycle of chemotherapy, thus improving patient compliance,
quality of life, and preventing development of anticipatory and refractory nausea and vomiting
during subsequent cycles of chemotherapy.
Various classes of drugs such as phenothiazines, butryophenones, substituted
benzamides, cannabinoids, steroids and 5-HT3 receptor antagonists (5-HT3 RA) are available to
control the incidence of CINV (Gralla, 1997). Due to the side effect profile of older antiemetic
agents such as phenothiazines, butyrophenones and substituted benzamides, these are primarily
used as rescue medications for breakthrough emesis.
5-HT3 Receptor Antagonists (5-HT3 RAs)
Due to its high efficacy and favorable toxicity profile compared to other antiemetic
agents, 5-HT3 RAs are currently the first-line agents and the gold standard for prevention of
CINV in patients receiving HE or ME chemotherapy (Gralla et al., 1999; Schnell, 2003). These
agents exert their antiemetic activity by antagonism of 5-HT3 receptors. As monotherapy, the 5HT3 RAs provide complete acute antiemetic protection, i.e. no nausea, no vomiting and no use of
rescue medications, in 40-60% of patients receiving cisplatin based chemotherapy and 60-80% of
patients receiving ME chemotherapy (Schnell, 2003). In patients receiving high-dose cisplatinbased chemotherapy regimens, 5-HT3 RAs provides complete antiemetic protection in the acute
phase in 25-60% of patients (Audhuy et al., 1996; Beck et al., 1992; P. Hesketh et al., 1996;
Marty et al., 1995; Navari et al., 1995). Three 5-HT3 RAs are currently available in the US for
prevention of emesis: dolasetron (Anzemet), granisetron (Kytril) and ondansetron (Zofran).
Several randomized, controlled studies have shown that ondansetron, granisetron and dolasetron
have equivalent complete control rates, defined as complete absence of nausea or vomiting,
among patients receiving HE or ME chemotherapy (Berger & Clark-Snow, 2001; Gralla et al.,
1998; Hesketh, 2000).
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Though the existing antiemetic regimens provide reasonably good protection against
acute emesis, they do not provide adequate protection against delayed emesis, with
approximately 50% of patients experiencing delayed emesis (Olver et al., 1996). In addition, 5HT3 RAs have not demonstrated sustainable efficacy in controlling CINV over repeated cycles of
chemotherapy (de Wit et al., 1996; de Wit et al., 1998). Due to the shortcomings of the existing
antiemetic agents, newer agents with better efficacy were needed and have been recently
introduced in the market. Two such antiemetic agents are aprepitant (Emend®) and palonosteron
(Aloxi®).
New Antiemetic Agents
Aprepitant (Emend®)
Aprepitant is the first oral selective nonpeptide NK-1 receptor antagonist indicated for
use in combination with a 5-HT3RA and a corticosteroid for prevention of acute and delayed
emesis due to HE chemotherapy regimens (Emend® Monograph). Aprepitant, in a dose of 125
mg, is recommended as a part of combination antiemetic regimen with a corticosteroid and a 5HT3 RA prior to chemotherapy (day one) and a dose of 80 mg on day two and three. The results
of two large phase III clinical trials showed that the aprepitant based regimen had superior
antiemetic efficacy as compared to the standard regimen in patients receiving high-dose cisplatin
(≥70mg/m2) (Hesketh et al., 2003; Poli-Bigelli et al., 2003).
Studies also showed that the antiemetic efficacy of aprepitant is maintained over multiple
cycles of chemotherapy (de Wit et al., 2003; de Wit et al., 2004). But aprepitant has not been
shown to mitigate ongoing emetic symptoms and has not been tested for continuous use for
duration greater than five days in patients receiving emetogenic chemotherapy. Although
addition of aprepitant improved overall antiemetic protection, the 2005 average wholesale price
(AWP) of $309.00 for a three-day regimen (Red Book, 2005) makes it expensive compared to the
other antiemetic agents used for prevention of acute and delayed emesis following administration
of HE chemotherapy.
Palonosetron (Aloxi®)
Palonosetron, a 5-HT3 RA, is an injectable antiemetic agent with a higher binding affinity
to the 5-HT3 receptors, a higher potency and a longer half-life compared to the older 5-HT3 RAs.
It is indicated for prevention of acute emesis due to HE regimens and prevention of acute and
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delayed emesis due to ME regimens (Aloxi® Monograph). In patients receiving HE
chemotherapy, including cisplatin, a single 0.25 mg intravenous (IV) dose of palonosetron was at
least as effective as a 32 mg IV dose of ondansetron for acute and delayed emesis. In patients
receiving ME chemotherapy, a 0.25 mg IV dose of palonosetron is at least as effective as a 100
mg IV dose of dolasetron, but the former regimen provides superior antiemetic protection in the
delayed phase (Eisenberg et al., 2003; Gralla et al., 2003). Compared to the older 5-HT3 RAs,
palonosetron provides the convenience of a single dose schedule for prevention of emesis. More
clinical trials of combination antiemetic regimens with palonosetron need to be carried out to
establish whether it is more efficacious than the combination of a corticosteroid with either
metoclopramide or a 5-HT3 RA for protection of delayed emesis due to HE chemotherapy. With
the 2005 AWP of a 0.25mg 5 ml single dose vial at $340.20 (Red Book, 2005), palonosetron is
expensive as compared to the older 5-HT3 RAs.
1.4: Combination antiemetic regimens and Recommendations for Antiemetic Use
Combination of two or more antiemetic agents provides better efficacy than a single
antiemetic agent in prevention of CINV following the administration of HE and ME
chemotherapy. Several professional organizations such as the Multinational Association of
Supportive Cancer Care (MASCC), the American Society of Clinical Oncology (ASCO), the
American Society of Health-System Pharmacists (ASHP), the National Comprehensive Cancer
Network (NCCN), and the Canadian Medical Association have published guidelines and
evidence-based recommendations for the use of antiemetics in management of CINV (ASHP,
1999; ESMO, 2001; Gralla et al., 1999; MASCC, 1998; NCCN, 1997).
The 1999 ASCO and ASHP guidelines recommended a combination of dexamethasone
and a 5-HT3 RA (standard regimen) for prevention of acute emesis in patients receiving HE
chemotherapy (ASHP, 1999; Gralla et al., 1999). A combination regimen of dexamethasone
with either metoclopramide or a 5-HT3 RA was recommended for prevention of delayed CINV
following HE chemotherapy. With the introduction of aprepitant, new guidelines have been
proposed by the NCCN and the MASCC for management of CINV. In patients receiving HE
chemotherapy, a three-drug combination of aprepitant, dexamethasone and a 5-HT3 RA is
recommended for control of acute emesis. A combination of aprepitant and a corticosteroid, such
as dexamethasone is now recommended for delayed emesis following HE chemotherapy.
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In patients receiving ME chemotherapy regimens, combination of a corticosteroid and a
5-HT3 RA is recommended for prevention of acute emesis (ASHP, 1999; Gralla et al., 1999).
Previous guidelines have recommended the use of either dexamethasone alone or combination of
dexamethasone with a 5-HT3 RA or metoclopramide for prevention of delayed emesis due to ME
chemotherapy (ASHP, 1999; Gralla et al., 1999). The 2005 NCCN and 2004 MASCC guidelines
recommend using palonosetron as the 5-HT3 RA for prevention of acute emesis and either
dexamethasone alone or a 5-HT3 RA alone for prevention of delayed emesis. If aprepitant was
included in the antiemetic regimen during the acute phase, a combination of aprepitant and
dexamethasone is recommended for prevention of delayed emesis (MASCC, 2004; NCCN,
2005).
1.5: Utilization of Prophylactic Antiemetics in Clinical Practice
As discussed earlier, various guidelines for appropriate prevention and management of
CINV have been published. Results from observational studies showed that guideline
recommendations were not transferred completely into clinical practice (DURTO, 2003). Studies
have shown that despite evidence from randomized clinical trials and publication of various
guidelines and recommendations, there is underutilization of antiemetic drugs to prevent delayed
emesis (Mertens et al., 2003; Roila, 2004; Roila, Donati, Tamberi, & Margutti, 2002).
A drug utilization study was undertaken to determine if the 1999 MASCC antiemetic
guidelines for prevention of CINV were followed in clinical practice. The study was conducted
among 87 Italian oncological centers in breast cancer patients undergoing chemotherapy with
moderate to high emetic potential (DURTO, 2003). The study results showed that all
chemotherapy patients received prophylactic antiemetics for acute emesis whereas only about
60% received prophylactic antiemetics for the delayed phase. Fifty six percent of patients
received a combination of 5-HT3RA and corticosteroid, the MASCC-recommended prophylaxis
for acute emesis. The MASCC-recommended prophylaxis for delayed phase, a 5-HT3RA, a
corticosteroid or their combination was prescribed to 46% of patients. However, only 19.2% of
patients received the ASCO and ESMO recommended prophylaxis for delayed emesis, such as, a
corticosteroid alone or combined with either 5-HT3RA or metoclopramide (ESMO, 2001; Gralla
et al., 1999). Thus, the study results show that there are discrepancies between the
recommendations for utilization of antiemetic regimens and their actual utilization in daily
clinical practice.
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Fabi and colleagues conducted a prospective, observational, longitudinal study to
determine the appropriate prevention of delayed emesis in clinical practice (Fabi et al., 2003).
The study results indicated that the clinical practice did not conform to the MASCCrecommended guidelines for prevention of nausea and vomiting. There were reports of
underutilization of prophylaxis for prevention of delayed emesis and overtreatment with 5HT3RA in patients receiving chemotherapy with low emetic potential (Fabi et al., 2003; IGAR,
1998b). This inappropriate use of costly agents such as 5-HT3RAs leads to increased costs to the
health care system without a proportionate increase in the health benefits to patients. The present
study makes an attempt to compare the regimen commonly employed in clinical practice as one
of the strategies in the decision model designed to assess the cost-effectiveness of the new
regimen.
1.6: Economics of Prevention of CINV
The introduction of serotonin receptor antagonists in the early 1990’s made a significant
impact on the prophylaxis and management of CINV. Compared to the older antiemetic agents,
regimens with 5-HT3RAs have resulted in better emesis control in patients receiving HE and ME
chemotherapy. However, at the same time, these agents were costly compared to the older
antiemetic agents. Rising health care expenditures coupled with limited resources have led to an
increased interest in conducting economic evaluations of healthcare interventions, a method in
which both costs and benefits of interventions are evaluated to make resource allocation
decisions. In addition to using effectiveness information, it has become necessary to incorporate
the economic aspects to determine the appropriateness of using new healthcare interventions in
an increasingly cost-conscious environment. An important question that needs to be addressed is
whether there are increased clinical, economic and humanistic benefits that will offset the
increased cost of preventing CINV. Cost effectiveness analysis (CEA) is a technique applied
when a choice must be made between two or more competing alternatives for which the expected
health gain can be measured as one outcome measure, such as complete control of emesis.
A recent review of economic evaluations of antiemetic agents showed that the majority of
the studies were conducted after the introduction of 5-HT3RAs (Lachaine & Crott, 2003). A
large proportion of these studies have been carried out in patients receiving HE chemotherapy
(Ballatori et al., 1994; Becker et al., 1996; Buxton & O'Brien, 1992; Cunningham et al., 1993;
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Sands, Roberts, Marsh, & Gill, 1992; Stewart, Dahrouge, Coyle, & Evans, 1999; Tejedor, Idoate,
Jimenez, Sierrasesumaga, & Giraldez, 1999; Zbrozek, Cantor, Cardenas, & Hill, 1994), with
some conducted in patients receiving ME chemotherapy (Cox & Hirsch, 1993; Johnson &
Bosanquet, 1995; Johnson, Nash, Carpenter, & Sistek, 1993; Kwong & Parasuraman, 1999).
Also, most of these studies have only evaluated the costs and benefits of antiemetic therapy
during the acute phase of CINV. The economics of using combination antiemetic regimens for
the delayed phase have not been adequately studied. Most of the economic evaluations
conducted in the past compared 5-HT3RAs to traditional agents such as metoclopramide or one
5-HT3RA against another. The results from these studies showed that the additional cost due to
use of 5-HT3RAs is offset by a favorable side effect profile, lower personnel and administration
costs and improved efficacy. These studies are explained in detail in Chapter 2.
Recently, three studies evaluating the cost effectiveness of aprepitant given with the
standard regimen have been presented at international symposiums and published in abstract
format (Deuson, 2004; Ehlken et al., 2004; Moore, Tumeh, Wojtanowski, & Flowers, 2005).
Ehlken and colleagues conducted a cost-effectiveness evaluation of the three-drug regimen of
aprepitant, dexamethasone and 5-HT3 RA during the acute phase and combination of aprepitant
and dexamethasone for the delayed phase (Deuson, 2004; Ehlken et al., 2004; Moore et al.,
2005). The comparator for the economic evaluation was the standard regimen for the acute phase
and dexamethasone for the delayed phase. In addition to the alternative used in the above
economic evaluation, a comprehensive economic evaluation of antiemetics for prevention of
CINV following HE chemotherapy comparing the new MASCC recommended regimen, old
ASCO regimens and clinical practice is needed.
To our knowledge, there is only one published pharmacoeconomic analysis of
palonosetron in patients receiving ME chemotherapy. The study was conducted from the payer’s
perspective and concluded that palonsetron is a cost-effective treatment strategy compared to the
older 5-HT3RAs (Vanscoy, Rubenstein, Smith, Weber, & Rihn, 2004). Notable also, the study
did not compare the new regimen to previous ASCO-recommended guidelines and clinical
practice for prevention of CINV following ME chemotherapy.
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1.7: Need for the Study
CINV is a significant problem among cancer patients especially those receiving HE and
ME chemotherapy. With the advent of new cytotoxic agents and colony stimulating factors, both
of which facilitate more aggressive, and therefore potentially more emetogenic drug therapy,
effective management of CINV by health professionals is imperative. As discussed earlier,
uncontrolled or suboptimally controlled emesis has a considerable impact on clinical, economic
and QOL outcomes. Though hospitalization due to severe emesis is rare, cost of prophylactic
and rescue antiemetic medications pose a significant economic burden for third-party payers,
hospitals and patients. With the advent of managed care, it is estimated that more than 70% of
chemotherapy is administered in the outpatient setting in freestanding cancer centers, community
oncology offices, comprehensive cancer centers, and ambulatory infusion suites (Average
Wholesale Price, 2003).
Antiemetic agents used for prevention of CINV also form a substantial portion of the
pharmacy budgets of managed care organizations, hospitals and cancer centers. The growing US
market for the 5-HT3 RAs is approximately $1.4 billion and includes the more than $800 million
market for CINV prevention and treatment. With the entry of new agents such as aprepitant and
palonosetron, new antiemetic guidelines and recommendations have been proposed by
organizations such as the MASCC and the NCCN. These new guidelines recommend
combination regimens, which include the new antiemetic drugs in addition to the old standard
regimen. Though the new antiemetic regimens are more effective in controlling emesis, they
increase the financial burden on managed care, hospital formulary budgets and patients.
Oncology practitioners now have a number of new antiemetic regimens for use in preventing
acute and delayed CINV. Since supportive care, which includes prevention of emesis is not
perceived to directly affect cure, they are often targets for cost containment policies (Rubenstein,
1995a, 1995b). While, these policies focus on the high immediate drug procurement costs, they
fail to incorporate the economic impact of therapies over the full course of the treatment in their
reimbursement decisions (Rubenstein, 1995a, 1995b). An economic evaluation of supportive
care therapies that incorporates a comprehensive assessment of direct, indirect and intangible
costs and benefits of treatment will help demonstrate the value of the product.
Though cisplatin is no longer a widely used chemotherapy agent, economic evaluation of
regimens for prevention of CINV following cisplatin administration is necessary because
11
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practically all patients receiving it experience emesis if prophylactic treatment is not given. On
the other hand, though the incidence and severity of emesis is lower in patients receiving ME
chemotherapy, it represents the largest group of cancer patients who experience nausea and
vomiting. Earlier economic evaluations compared different 5-HT3 RAs with one another (five
studies), or compared 5-HT3 RA containing regimens with regimens containing older antiemetic
agents (15 studies) such as metoclopramide, diphenhydramine, dexamethasone,
methylprednisolone, and prochlorperazine. In addition, almost half of the economic evaluations
were limited to acute nausea and vomiting following administration of chemotherapy (Lachaine
& Laurier, 2002). A majority of the economic evaluations have compared treatment regimens
that are no longer relevant and do not reflect the actual clinical practice of CINV management.
Thus, an economic evaluation comparing new antiemetic guidelines to guidelines recommended
prior to the introduction of new antiemetic agents, and also to widely used regimens in clinical
practice for prevention of both acute and delayed emesis is required.
Cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and cost-benefit analysis
(CBA) which combines information on the health benefits, health risks and costs of health care
services, are approaches that can incorporate and complement evidence on effectiveness for
informed policy decision making. CINV has a significant impact on the QOL but has no known
impact on survival of cancer patients. Thus antiemetic regimens that control acute and delayed
CINV may lead to a significant qualitative improvement in survival but no quantitative change at
all. Since HRQOL is now recognized as a primary outcome for the evaluation of supportive care
therapies (Uyl-de Groot, Wait, & Buijt, 2000), it is necessary to incorporate the impact of CINV
and its treatment on intangible outcomes such as HRQOL, patient suffering and distress in the
form of preferences or utilities. Due to this, traditional cost-effectiveness analysis using life
years gained may not be the most appropriate outcome measure in antiemetic economic
evaluations. Cost per completely controlled patient is important from the payer and hospital
perspective but outcome measures such as quality-adjusted life years (QALYS) or willingness-topay (WTP) that incorporate the effect of disease and treatment on QOL are more appropriate for
use in antiemetic economic evaluations from a societal and patient perspective.
Zbrozek et al. (1995) performed a cost utility analysis comparing ondansetron with
metoclopramide using efficacy data from published clinical trials. To calculate the incremental
cost per QALY, a relative difference of 0.00014 QALY between two antiemetic agents was
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arbitrarily estimated. The incremental cost per QALY in patients receiving high-dose cisplatin
was US$407,667 and in patients receiving moderate-dose cisplatin was US$372,255. CINV lasts
for about 5-7 days following chemotherapy administration and can be classified as an acute
health condition. The use of QALYs to value morbidity for short-term condition such as CINV
has both measurement and evaluation problems (Bala & Zarkin, 2000) which are explained in
Chapter 2. The evaluation problem arises because the multiplicative product of the utility weights
and life-years gained is extremely small leading to high cost per QALY estimates. Thus, CUA
also may not be an appropriate economic evaluation method for determining the value of
antiemetic regimens for prevention of CINV. Therefore, CBA where costs and benefits of the
health care interventions are compared in monetary values is being proposed to be the most
appropriate method for valuing antiemetic regimens for prevention of CINV, an acute health
condition with significant impact on HRQOL.
In a CBA, benefits are measured in monetary values by determining the willingness-topay (WTP) for the outcomes due to the new health care intervention. Dranitsaris et al (2001b)
conducted a multinational study to determine the WTP for improved emesis control due to NK-1
receptor antagonists, following cisplatin-based chemotherapy. The study showed that there were
considerable differences in cancer patients’ valuation of improved emetic control between
countries. Thus it is necessary to evaluate the WTP for improved emetic control, specifically
among patients in the United States. The study was conducted before the benefits of NK-1
receptor antagonists were established in randomized clinical trials. Now, WTP amounts can be
determined for the actual benefit provided by the new antiemetic agents as results from phase III
randomized clinical trials of NK-1 receptor antagonists are available. Though this study
determined the WTP for improved emesis control, it was not used for further economic
evaluation of the antiemetic regimens. Thus, it is necessary to determine the value of improved
emesis control in the US and use those values in a cost-benefit study of new antiemetic regimens.
The current study is a comprehensive economic evaluation of antiemetic regimens for
prevention of CINV following highly and moderately emetogenic chemotherapy. The current
study conducted cost-effectiveness evaluations of new antiemetic regimens compared to the
previous guidelines and clinical practice for prevention of CINV following chemotherapy. Costbenefit analysis using the contingent valuation method was done to compare the new regimen to
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the standard regimen for prevention of CINV following highly and moderately emetogenic
chemotherapy.
1.8: Research Objectives
1) What are the incremental costs and consequences of introducing the three-drug regimen
(aprepitant in addition to the standard regimen) for prevention of CINV following HE regimen
from the payer and societal perspective?
2) What are the incremental costs and consequences of introducing palonosetron for prevention
of CINV following ME chemotherapy regimen from the payer and societal perspective?
3) What is the monetary value that patients place on improved emesis control due to the new
antiemetic regimen for prevention of CINV due to HE chemotherapy?
4) What is the monetary value that patients place on improved emesis control due to the
introduction of palonosetron as the new antiemetic regimen for prevention of CINV due to ME
chemotherapy?
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1.9: Conceptual Framework of the Study
The purpose of this study is to conduct a comprehensive economic evaluation of
antiemetic agents for prevention of CINV. The study will be conducted in two phases. Figure 11 shows a schematic representation of the conceptual framework of the study. Phase I involves
construction of a decision analytic model to compare the incremental costs and benefits
associated with prophylactic antiemetic regimens for prevention of CINV. The incremental
cost-effectiveness ratios (ICER) for the antiemetic regimens will also be determined in Phase I.
Phase II will determine the monetary value that patients place on the improved emesis control
due to the new antiemetic regimens for prevention of CINV following highly emetogenic and
moderately emetogenic chemotherapy. Phase II also involves conducting cost-benefit analyses
of the new antiemetic regimens using the monetary value of benefits determined by using the
WTP methodology.
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Figure 1-1: Conceptual Framework for Economic Evaluation of Prophylactic Antiemetic Regimens for
Prevention of CINV
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Phase I
CINV can be managed by different prophylactic antiemetic regimens and the challenge is
to quantify the effects and identify the regimens that deliver maximum benefit in the most
efficient manner. Phase I involves constructing two decision analytical models to systematically
compare the different prophylactic antiemetic regimens for prevention of CINV due to HE and
ME chemotherapy. The alternative antiemetic regimens are discussed in the section titled
“Economics of Prevention of CINV” and later in Chapter 3, Methods. The CEA will be
conducted from the payer and societal perspective.
A hypothetical cohort of patients with cancer who are receiving their first cycle of
cisplatin-based HE chemotherapy will be considered for the HE model. Another hypothetical
cohort of patients with cancer who are receiving their first cycle of ME chemotherapy such as
cyclophosphamide, plus an anthracyclines such as doxorubicin, epirubicin etc. will be considered
for the ME model. The cohorts will be tracked for a period of 5 days to coincide with the time
period for which patients usually experience CINV during a cycle of chemotherapy and for
which relevant clinical data from studies are available. For both HE and ME models, the primary
outcomes of Phase I are 1) number of patients with complete control defined as no emesis and no
rescue medications over the 5-day period and 2) costs.
The effectiveness of the various antiemetic regimens included in the models will be
obtained from the published literature. The resource costs include cost of prophylactic antiemetic
regimens, drug administration costs, cost of managing breakthrough emesis and indirect costs.
The costs included for calculation of cost-effectiveness ratios will be based on the perspective of
the analysis. The incremental cost per completely controlled patient will be calculated for each
strategy relative to the next most costly strategy as the difference in the total costs of the two
regimens divided by the difference in the effectiveness of the two regimens
Incremental cost-effectiveness ratios (ICER) =

∆ Total Costs
∆ Effectiveness

The incremental analysis helps in determining if the additional benefit offered by the new
regimen is worth the additional cost of delivering the intervention. To test the impact of
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uncertainties in the effectiveness and cost parameters on the results, one way sensitivity analysis
and probabilistic sensitivity analysis will be used.
Phase II
Phase II of the study involves using the contingent valuation (CV) method to determine
the monetary value that patients place on improved emesis control due to the new regimens. The
CV method is a direct measurement of WTP using a survey based measure to elicit monetary
values by presenting hypothetical scenarios about the healthcare intervention under evaluation.
The maximum WTP for improved emesis control is determined for two scenarios: improved
emesis control due to addition of aprepitant to the standard regimen for prevention of CINV
following HE chemotherapy and improved emesis control due to palonosetron for prevention of
CINV due to ME chemotherapy. An ex-post/user-based perspective will be used to construct the
CV survey. A payment card method will be used to determine the maximum WTP for the two
scenarios. The study population will include patients above 18 years of age who are currently
receiving their first or subsequent cycles of chemotherapy, or have received it within the past
three months are and are able to understand and speak English.
Face to face interviews will be conducted with the patients who agree to participate in the
study. In addition to the maximum WTP, information on age, gender, education, annual
household income, number of members in the household, type of insurance, marital status, and
employment status will be collected. The survey also elicits information about the level of
importance placed on improved emesis control, preference of new versus the old regimens,
reasons for the preference and level of difficulty in understanding and answering the WTP
questions. The amount indicated by the respondents on the payment card was taken as the
monetary value placed by the patients on improved emesis control. Multivariate semilogarithmic regression models were used to assess the association between WTP amount and
annual household income, which is also the method used to establish construct validity of the
WTP survey.
The WTP amounts obtained using the CV method will be used to conduct CBA for the
new regimens for prevention of CINV following HE and ME chemotherapy. The net benefit of
the new regimens will be calculated as the difference between the incremental costs and
incremental benefits of the new regimens compared to the standard regimens used for prevention
of CINV.
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1.10: Study Goals and Objectives
The overall goal of the study was to conduct a comprehensive economic evaluation of
prophylactic antiemetic regimens for prevention of CINV following administration of HE and
ME chemotherapy. The aim of the study was to determine the cost-effectiveness of new
antiemetic regimens compared to the regimens recommended by previous guidelines and used in
clinical practice. The study also involved determining the monetary value of improved emesis
control offered by the new antiemetic regimens.
Objectives for Phase I
Objective 1.1:
To develop a decision analytical model that identifies the costs and effectiveness of
alternative regimens for prevention of CINV in cancer patients receiving HE chemotherapy.
Objective 1.2:
To develop a decision analytical model that identifies the costs and effectiveness of
alternative regimens for prevention of CINV in cancer patients receiving ME chemotherapy.
Objective 1.3:
To determine the incremental costs and benefits of using the new antiemetic regimen
(aprepitant with standard regimen) versus the older regimens for prevention of CINV in cancer
patients receiving HE chemotherapy.
Objective 1.4:
To determine the incremental costs and benefits of using the new antiemetic regimen
(palonosetron) versus the older regimens for prevention of CINV in cancer patients receiving ME
chemotherapy.

Objectives for Phase II
Objective 2.1:
To determine the monetary value that cancer patients place on improved emesis control
due to addition of aprepitant to the standard regimen following HE chemotherapy using the CV
method.
Objective 2.2:
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To determine the monetary value that cancer patients place on improved emesis control
with the introduction of palonosetron instead of the standard regimen following ME
chemotherapy using the CV method.
Objective 2.3:
To determine the association between maximum WTP for improved emesis control
following HE chemotherapy and respondents’ demographic and clinical characteristics (age,
gender, martial status, education, annual household income, number of members in the
household, employment status, insurance status, type of cancer, previous experience of
chemotherapy and previous experience of emesis due to chemotherapy).
Objective 2.4:
To determine the association between maximum WTP for improved emesis control
following ME chemotherapy and respondents’ demographic and clinical characteristics (age,
gender, martial status, education, annual household income, number of members in the
household, employment status, insurance status, type of cancer, previous experience of
chemotherapy and previous experience of emesis due to chemotherapy).
Objective 2.5:
To conduct a CBA to estimate the net benefit of adding aprepitant to the standard
regimen for prevention of CINV following HE chemotherapy.
Objective 2.6:
To conduct a CBA to estimate the net benefit of using palonosetron instead of the
standard regimen for prevention of CINV following ME chemotherapy.

1.11: Significance of Study
The economics of prevention of CINV using antiemetic agents needs to be studied in the
light of higher costs of the antiemetic drugs. Introduction of newer interventions in addition to
the existing ones can threaten drug formulary budgets of third-party payers, hospitals and cancer
centers. Consequently, there is a growing pressure to evaluate all new interventions before
implementation. Clinical practice guidelines recommend the use of treatment strategies based on
effectiveness of the intervention, which should be the primary requirement for its acceptance in
health care. However, effectiveness alone is not a sufficient criterion to initiate services in most
practical health care contexts, emphasizing the important role of the cost-effectiveness approach
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in policy decisions. Thus, the study results will have relevance to different players in the health
care sector, namely patients, physicians, hospitals, third party payers and society as a whole.
Society/policy makers
The results of the CEA and CBA analysis which combines information on health
benefits, health risks and costs of health care services will assist informed policy decision
making. The WTP estimates will provide important information about the value placed on CINV
and improved emesis control due to new antiemetic agents. Willingness-to-pay can be used to
calculate the benefit to cost ratio for comparing treatment of CINV with other health care
interventions for resource allocation decisions.
Payers
Many policy decisions are made at the local levels namely the health plan, hospital or
health maintenance organization (HMO) level. These policy decisions include inclusion of drugs
on the local or regional formulary of the HMO or health plan. HMOs and managed care
organizations (MCOs) can utilize the ICER to aid formulary decision making. The decision
analytical models developed in this study can be applied to provide ICER for different
subpopulations of specific managed card plans.
Health care professionals
The results will also have relevance to clinical decision-making. In clinical practice,
physicians and other decision-makers can use the study results to determine whether costs
associated with each antiemetic regimen are worth the benefits provided by the therapies. The
study can also help physicians, other health care professionals and researchers in developing
clinical practice guidelines, which incorporate not only benefits and risk but also costs of
antiemetic therapy.
Hospitals
CEA/CBA results will have relevance to the hospital policy makers to determine the
impact of new interventions on their formulary budgets. The study results will provide the
incremental cost per successfully treated patient on new antiemetic regimen compared to
standard regimen. Net benefit (WTP – Cost) is a more relevant outcome measure to the hospital
policy makers to create a monetary rank order based on user value as new products are
introduced into clinical practice.
Scientific literature
Finally, the study will be a valuable addition to the scientific literature in the field of
supportive cancer care, pharmacoeconomics, and economic evaluation methodologies. In the
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recent years, researchers have developed a renewed interest in CBA as a method for assessing the
value of an intervention and WTP results from the study will be a timely contribution to the field.
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CHAPTER TWO

LITERATURE REVIEW

2.1: Pathophysiology of Chemotherapy-Induced Nausea and Vomiting (CINV)
Chemotherapy-induced nausea and vomiting (CINV) are perceived among the most
distressing and feared side effects of chemotherapy by patients with cancer (Boer-Dennert et al.,
1997; Griffin et al., 1996). It is estimated that between 60-80% of cancer patients receiving
chemotherapy experience nausea and/or vomiting if prophylactic antiemetic drugs are not used
(DeVita et al., 2001; King, 1997).
The exact mechanism by which chemotherapy induces nausea and vomiting is not clearly
understood. Different chemotherapy agents act on various sites and cause nausea and vomiting
by diverse mechanisms of action (Stewart, 1991). Chemotherapy agents cause nausea and
vomiting by direct or indirect activation of the chemoreceptor trigger zone (CTZ), peripheral
stimulation of the gastrointestinal tract, direct cerebral activation, vestibular mechanisms and
alterations of taste and smell. It is suggested that the most common mechanism is through the
activation of the CTZ. The interaction between chemotherapy and the CTZ releases various
neurotransmitters that activate the vomiting center (Berger & Clark-Snow, 2001). Some of the
neurotransmitters released are dopamine, serotonin, histamine, and substance P (Bender et al.,
2002). Though a single neurotransmitter is not responsible for all CINV, serotonin and 5hydroxytryptamine (5-HT) play an important role in the pathophysiology of acute CINV.
Substance P, another neurotransmitter found in the gastrointestinal tract and the CTZ of the area
postrema, exerts its emetic effects by binding to a specific neuroreceptor, NK1 (Olver, 2004).
Antiemetic agent, aprepitant exert its antiemetic effect by antagonism of the NK1 receptors and is
found to have better antiemetic control during delayed CINV, compared to previous regimens.
Some terms associated with CINV and their definitions are presented in Table 2-1.
CINV can be classified into five distinct syndromes based on the time of occurrence during a
chemotherapy cycle (Bender et al., 2002; Navari, 2003). These five syndromes are described in
Table 2-2.
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Table 2-1: Chemotherapy-Induced Nausea and Vomiting Related Terms and Their
Definitions
Terms

Definitions

Nausea

Nausea is a subjective, unobservable phenomenon of an unpleasant sensation
experienced in the back of the throat and the epigastrium that may or may not
culminate in vomiting.

Vomiting

Vomiting is the forceful expulsion of the contents of the stomach, duodenum, or
jejunum through the oral/nasal cavity.

Retching

Retching is an associated phenomenon that is described as an attempt to vomit
without bringing anything up.

24

LITERATURE REVIEW

Reema Mody

Table 2-2: Chemotherapy-Induced Nausea and Vomiting Related Syndromes and Their
Definitions
CINV Syndromes

Definitions

Acute CINV

Occurs within the first 24 hours after administration of chemotherapy.

Delayed CINV

Defined as nausea and vomiting occurring more than 24 hours (days two
to seven of chemotherapy cycle) after the administration of emetogenic
chemotherapy (Kris et al., 1985; Tavorath & Hesketh, 1996).

Anticipatory CINV

Occurs within one week prior to the actual administration of
chemotherapy and is linked to repeated associations with chemotherapy
side effects and environmental stimuli. For example, certain tastes,
sensations, smells, or even thoughts experienced by patients who receive
chemotherapy may evoke nausea and/or vomiting.

Breakthrough CINV

Occurs either in the acute or delayed phases of emesis, in spite of patients
being treated with prophylactic antiemetic therapy. Rescue therapy is
usually administered to control breakthrough CINV.

Refractory CINV

Occurs during subsequent cycles of chemotherapy when antiemetic
prophylaxis or rescue therapy has failed in earlier cycles.
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2.2: Factors Associated with Increased Risk of CINV
A number of patient, disease and treatment-related characteristics have been identified as
potential factors associated with increased risk of nausea and vomiting following chemotherapy.
These factors are important for developing antiemetic treatment guidelines and tailoring
antiemetic regimens to achieve the maximum emetic control in patients receiving chemotherapy.
Disease and Treatment-related Factors
Emetogenicity of the Chemotherapy Agents
The emetogenic potential of the chemotherapy agent, defined, as the intrinsic capacity of
a chemotherapy agent to produce an emetic episode in a patient who is receiving the agent, is the
most important predictor of CINV (Lindley, Bernard, & Fields, 1989; Osoba et al., 1997a; Pater
et al., 1994). Hesketh et al. (Hesketh, 1999; Hesketh et al., 1997) and the expert consensus by the
American Society of Health-System Pharmacists (ASHP) (ASHP, 1999) have classified the
available chemotherapy agents into five levels of emetogenicity based on the proportion of
patients who experience acute emesis in absence of effective antiemetic prophylaxis. Table 2-3
shows the classification of single chemotherapy agents into the various levels based on their
emetogenicity. Chemotherapy agents in level 5 are termed as highly emetogenic (HE)
chemotherapy and regimens with cisplatin are specifically termed as cisplatin-based HE
chemotherapy. Chemotherapy agents classified under levels 3 and 4 are termed as moderately
emetogenic (ME) chemotherapy. The chemotherapy agents that fall under levels 1 and 2 have
low potential of causing CINV.
For combination chemotherapy regimens, the level of emetogenicity is determined based
on an algorithm which combines the emetogenicity of the single agents (DeVita et al., 2001;
Hesketh et al., 1997). Table 2-4 describes the algorithm used to calculate the emetogenicity of
combination chemotherapy.

26

LITERATURE REVIEW

Reema Mody

Table 2-3: Classification of Emetogenicity of Single Chemotherapy Agents
Level

Frequency of Acute Emesis
(%)*

5

> 90 %

Chemotherapy Agents
Carmustine > 250 mg/m2
Cisplatin ≥ 50 mg/m2
Cyclophosphamide > 1,500 mg/m2
Dacarbazine
Mechlorethamine
Streptozotocin

4

60-90 %

Amifostine > 500 mg/m2
Busulfan > 4mg/d
Carboplatin
Carmustine < 250 mg/m2
Cisplatin < 50mg/m2
Cyclophosphamide >750 ≤ 1,500 mg/m2
Cytarabine ≥ 1g/m2
Doxorubicin > 60 mg/m2
Epirubicin > 90 mg/m2
Melphalan > 50 mg/m2
Methotrexate > 1,000 mg/m2
Procarbazine (oral)

3

30-60 %

Cyclophosphamide ≤ 750 mg/m2
Cyclophosphamide (oral)
Doxorubicin 20-60 mg/m2
Epirubicin ≤ 90 mg/m2
Hexamethylmelamine (oral)
Idarubicin
Ifosfamide
Irinotecan
Methotrexate 250-1000 mg/m2
Mitoxantrone < 15 mg/m2

* Proportion of patients who experience emesis in the absence of effective antiemetic prophylaxis
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Table 2-3 (Continued): Classification of Emetogenicity of Single Chemotherapy Agents
Level

Frequency of Acute Emesis
(%)*

2

10-30%

Chemotherapy Agents
Capecitabine
Cytarabine 100-200 mg/m2
Docetaxel
Etoposide
5-Fluorouracil < 1000 mg/m2
Gemcitabine
Methotrexate > 50 mg/m2 < 250 mg/m2
Mitomycin
Paclitaxel
Topotecan

1

< 10%

Alpha Interferon
Bleomycin
Chlorambucil (oral)
Dexrazoxane
Fludarabine
Gemtuzumab
Hydroxyurea
Imatinib
Methotrexate ≤ 50 mg/m2
Rituximab
Vinblastine
Vincristine
Vinorelbine

* Proportion of patients who experience emesis in the absence of effective antiemetic prophylaxis
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Table 2-4: Algorithm for Determining Emetogenicity of Combination Chemotherapy
Regimens
TO DETERMINE THE LEVEL OF EMETOGENICITY OF THE COMBINATION REGIMEN:
First identify the drug in the combination regimen with the highest emetic potential based on the
Hesketh classification. To this level add the emetogenic potential of other drugs in the regimen based
on the following:
1. Level 1 agent does not add to the emetogenic potential of the combination regimen.
2. One or more agents of level 2 in the combination regimen will increase the emetic potential
by 1 level.
3. Each agent of level 3 or 4 in the combination regimen will increase the emetic potential by 1
level, with maximum level reaching level 5.
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For a classification schema to be more relevant and serve as a basis for treatment
recommendations, it must also account for the ability of certain chemotherapy agents to produce
delayed emesis. The potential for a chemotherapy agent to cause delayed emesis is proportionate
to its ability to cause acute emesis. In the absence of prophylaxis for delayed emesis, the
incidence of delayed emesis is 60-90% in patients treated with cisplatin and 20-33% in those
receiving carboplatin, cyclophosphamide or doxorubicin (Gralla, 1997; Gralla et al., 1999;
Hesketh, 1999). Though emesis in the acute phase is a strong predictor for incidence of delayed
emesis, 40% of patients suffer from delayed emesis despite complete protection in the acute
phase (de Wit, 2003). Individual risk assessment is imperative and because chemotherapy is
most commonly administered in cycles over a period of time, it is also important that assessment
be maintained throughout the treatment period.
Previous Exposure to Emetogenic Chemotherapy
Patients with uncontrolled emesis in earlier cycles of chemotherapy are more likely to
experience emesis in subsequent cycles in spite of prophylactic antiemetic administration. Poorly
controlled nausea and vomiting in previous cycles also increases the likelihood of anticipatory
nausea and vomiting.
Other Possible Disease-related Factors
Performance status (as measured by the European Cooperative Oncology Group (ECOG)
Performance Status Scale), tumor burden and stage of disease may be associated with incidence
of CINV. The ECOG performance status scale is used to assess how a cancer patient’s disease is
progressing, assess how the disease affects the daily living abilities of the patient, and determine
appropriate treatment and prognosis (Oken et al., 1982). The assessment is conducted on a scale
of 0-5 where 0 indicates that the patient is fully active, and able to carry on all activities without
restriction. A score of 5 on the scale indicated death. Osoba et al. (Osoba et al., 1997a) found
that 57% of patients with a ECOG performance status of either 1 or 2 experienced CINV
compared to 49% of patients with ECOG performance status of 0 or normal. A large tumor
burden especially in patients with ovarian cancer or abdominal malignancies also may increase
the likelihood of experiencing emesis (Doherty, 1999). A prospective longitudinal study
designed to study factors predicting development of CINV in Chinese breast cancer patients
receiving moderately emetogenic chemotherapy found that later stage of disease increased the
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risk of longer duration of acute nausea and greater frequency of acute nausea and vomiting
(Molassiotis, Yam, Yung, Chan, & Mok, 2002).
Patient-related Factors
Patient-related factors such as age, gender, history of alcohol use, motion sickness,
previous exposure to chemotherapy, and prior experience of emesis may increase or decrease the
risk of developing CINV (Doherty, 1999; Osoba et al., 1997a). Elderly patients tend to tolerate
chemotherapy better than younger patients. Women, younger than 50 years of age require
aggressive antiemetic regimens since they are more likely to experience nausea and vomiting
compared to men. Patients with prior history of emesis during pregnancy or due to motion
sickness are also at an increased risk of experiencing CINV. In patients receiving cisplatin, those
who have a history of chronic alcohol ingestion, greater than 100g/day (approximately five
alcoholic beverages per day) appear to experience less intense nausea and vomiting (Goodman,
1997).
Certain psychosocial and behavioral factors such as stress, negative attitude towards
chemotherapy (Tsavaris et al., 2000), anxiety (Molassiotis et al., 2002) and pretreatment
expectations of nausea and vomiting (Andrykowski et al., 1988; Jacobsen et al., 1988; Roscoe,
Hickok, & Morrow, 2000) may also lead to increased risk of emesis.
Factors Specifically Associated with Increased Risk of Delayed CINV
The level of protection achieved in the acute phase of the first chemotherapy cycle is a
very important prognostic factor for incidence of delayed emesis in the same and subsequent
chemotherapy cycles (IGAR, 1994). Independent of the type of antiemetic treatment received for
acute or delayed emesis, complete protection from nausea and vomiting in the acute phase
significantly reduces the risk of developing emesis in the delayed phase (Schnell, 2003).
Delayed CINV is more frequently seen in patients receiving HE chemotherapy. Some other
possible factors associated with increased risk of delayed emesis include cisplatin > 90mg/m2,
younger age, female gender, and larger tumor burden (Roila et al., 2002).
It is important to identify the prognostic or risk factors that predict the likelihood of
cancer patients developing acute, delayed and anticipatory CINV. These factors will aid in
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developing a risk profile for the patients at the greatest risk of CINV and tailor antiemetic
regimens for prevention of CINV based on individual risk profile.
2.3: Prevention Strategies for CINV
The most important point about managing CINV is that preventing CINV is more
effective than treating it (Markman, 2002). Antiemetic agents administered before chemotherapy
are effective in reducing the incidence of acute emesis, but it is difficult to completely control
CINV once it has begun. One of the goals of antiemetic therapy is to achieve complete control in
all settings, beginning with the initial cycle of chemotherapy, thus improving patient compliance,
quality of life, and preventing development of anticipatory and refractory nausea and vomiting
during subsequent cycles of chemotherapy. The other goals of antiemetic therapy are to provide
maximum convenience for patients and staff, to eliminate potential side effects of the agents, and
to minimize the cost of treatment of CINV (Berger & Clark-Snow, 2001). Inappropriate control
of acute emesis leads to breakthrough, delayed, refractory and anticipatory emesis in the same
and subsequent chemotherapy cycles.
The currently available antiemetic agents have not been adequately tested for
breakthrough, refractory and anticipatory emesis (King, 1997). In addition to pharmacological
interventions, nonpharmacologic interventions can be used to prevent anticipatory nausea and
vomiting or control CINV. Nonpharmacologic interventions are “techniques that unite the mind
and body by using psychologic interventions to control physiologic responses” (Bender et al.,
2002; King, 1997). These include behavioral interventions, such as relaxation, self-hypnosis,
cognitive distraction, acupuncture, acupressure and music therapy (Bender et al., 2002; King,
1997). Since the focus of the study is the use of pharmacological interventions,
nonpharmacological interventions will not be discussed.
Assessment of Efficacy of Antiemetic Agents
Vomiting or emesis can be assessed by calculating the number of emetic episodes
experienced by patients each day during the period of interest, usually 5-7 days. The percentage
of patients with no emetic episode (with or without nausea) during the acute, delayed and overall
phase is the primary outcome measure for control of emesis (Kris et al., 2005). The gold
standard for determining the efficacy of antiemetic agents is the complete prevention of all
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emesis and nausea (Hesketh, Gralla, du, & Tonato, 1998). It is suggested that control of emesis
and nausea should be reported separately due to the subjective nature of nausea. The assessment
of intensity of nausea is measured using visual analog scales (VAS) or descriptive ordinal scales.
A four-point descriptive ordinal scale measuring intensity of nausea as none, mild, moderate, and
severe has been found to have a high correlation with a VAS (Hesketh et al., 1998).
A more stringent criterion for determining the efficacy of antiemetic agents is total
control – complete control of both emesis and nausea. In clinical trials, complete control of
nausea was approximately 10% lower compared to complete control of emesis (Hesketh et al.,
1998). Thus, when ‘total control’ is used as an outcome measure, the total control rates are
reported to be very similar to the complete control rates of nausea. Also, nausea and vomiting
depend on different pathophysiological mechanisms and thus they should be separately evaluated
in clinical trials. Other secondary measures include complete protection, defined as proportion of
patients with minimal or no nausea, no vomiting or retching and no use of rescue medication in
the post-chemotherapy period. Outcome measures based on the number of emetic episodes:
major control (< 3 emetic episode), minor control (3-5 emetic episodes) and failure (> 5 emetic
episodes), are also sometimes reported in clinical trials.
Pharmacotherapy for Prevention of CINV
Various classes of drugs such as phenothiazines, butryophenones, substituted
benzamides, cannabinoids, steroids and 5-HT3 receptor antagonists (5-HT3 RA) are available to
control the incidence of CINV (Gralla, 1997). Some older classes of drugs such as
phenothiazines, benzodiazepines and butyrophenones are used as rescue medications for
breakthrough emesis. Newer antiemetic agents such as aprepitant and palonosetron have been
introduced recently.
Older Antiemetic Agents
A) Phenothiazines (Phenergan®, Compazine®)
Phenothiazines such as prochlorperazine, promethazine and thiethylperazine block the
vomiting impulses by antagonizing the dopamine receptors (Flake, Scalley, & Bailey, 2004).
These agents have tranquilizing and antiemetic effects and are used in combination antiemetic
regimens for prevention of nausea and vomiting due to mildly emetogenic chemotherapy
(Goodman, 1997). Phenothiazines are also given as rescue medications for breakthrough nausea
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and vomiting. Phenothiazines may increase risk of extrapyramidal symptoms, especially in
patients aged 30 years or younger (Goodman, 1997). Some other common side effects include
sedation, lethargy and skin sensitization (ASHP, 1999).
B) Butyrophenones (Haldol®)
Butyrophenones are major tranquilizers but are less effective in preventing nausea and
vomiting compared to other antiemetics such as 5-HT3 RA. But these agents are particularly
useful when anxiety and anticipatory symptoms aggravate the degree and intensity of nausea and
vomiting. Butyrophenones such as haloperidol and droperidol may be used in combination with
5-HT3 RA. However, adverse effects such as extrapyramidal symptoms, and dystonic reactions
can be severe with butyrophenones (Goodman, 1997).
C) Substituted Benzamides
Substituted benzamides such as metoclopramide in high dosages were found to
effectively block 5-HT3 receptors and were widely used for preventing CINV. But high doses of
metoclopramide can cause extrapyramidal symptoms in up to 5% of patients (Schnell, 2003).
With the advent of 5-HT3 RA which are more effective and less toxic in prevention of cisplatininduced emesis, metoclopramide is now used only in combination with other antiemetic agents or
as rescue medication for breakthrough emesis (Goodman, 1997; NCCN, 2005). Some guidelines
recommend oral metoclopramide in combination with corticosteroids for prevention of delayed
emesis due to HE and ME chemotherapy (Gralla et al., 1999; NCCN, 2005). The dose of
metoclopramide ranges from 20mg and 40mg to be given two to four times a day for three or
four days for control of delayed CINV.
D) Benzodiazepines
Benzodiazepines such as lorazepam and diazepam may have an antiemetic effect due to
their anxiolytic and amnesic effects. The temporary amnesic effects of benzodiazepines make it
useful in patients who suffer anticipatory nausea and vomiting and the anxiolytic effects make it
useful in patients awaiting their first chemotherapy. It was found that lorazepam reduced the
incidence of anticipatory nausea and vomiting and acute emesis induced by cisplatin (Malik et
al., 1995). These agents have little antiemetic efficacy as single agents and are recommended as
adjuncts to other antiemetics (DeVita et al., 2001).
E) Cannabinoids
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Cannabinoids such as dronabinol can be used as an option in patients with CINV which is
refractory to conventional antiemetic treatment and as an adjuvant to other antiemetics. This
class of drugs may be useful in younger patients without cardiac or psychiatric illness and/or in
patients who are sensitive to phenothiazines (Goodman, 1997). Some common side effects of
dronabinol include drowsiness, euphoria and vision difficulties (ASHP, 1999).
F) Corticosteroids
Corticosteroids are effective as single agents or in combination for prevention of CINV.
Dexamethasone is the most widely studied corticosteroid and is an effective, convenient and
inexpensive anti-emetic useful in both acute and delayed emesis with chemotherapy of mild,
moderate and severe emetic potential. A meta-analysis of randomized clinical trials showed that
single agent dexamethasone was significantly superior to placebo or no treatment in complete
control of acute and delayed CINV among patients receiving different types of chemotherapy
regimens (Ioannidis, Hesketh, & Lau, 2000). The pooled results of three studies comparing
dexamethasone to metoclopramide showed that the former provided better control of acute CINV
(Ioannidis et al., 2000). In patients receiving cyclophosphamide or anthracycline-based
chemotherapy, dexamethasone has been shown to be equal or superior to metoclopramide or
equal to 5-HT3 RAs (Herrstedt et al., 2005) in providing acute antiemetic control.
As an antiemetic, dexamethasone has been administered in doses ranging from 4 mg to
20 mg for a period of one to five days for prevention of acute and delayed CINV following
highly emetogenic and moderately emetogenic chemotherapy. A comparison study of
intravenous (IV) dexamethasone in dosages ranging from 4 mg to 20 mg to control acute emesis
was conducted among patients receiving cisplatin-based chemotherapy (IGAR, 1998a). The
study results showed that a single 20 mg IV dose before chemotherapy was considered as the
most efficacious dose for prevention of acute cisplatin-induced acute emesis. In another
randomized, double-blind clinical trial to determine optimum dose of IV dexamethasone in
patients receiving ME chemotherapy such as anthracyclines, carboplatin or cyclophosphamide, a
single dose of 8 mg was recommended as sufficient for acute control of emesis (IGAR, 2004).
Though single agent dexamethasone is effective in controlling emesis in patients
receiving ME chemotherapy and low doses of cisplatin, it is ineffective for patients receiving
higher doses of cisplatin (Herrstedt, 2004). Since corticosteroids improve the antiemetic effects
of other antiemetics, they are ideal drugs for use in combination chemotherapy. Dexamethasone,
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in combination with 5-HT3RAs showed increased effectiveness in prevention of acute CINV
following administration of both HE and ME chemotherapy (Joss et al., 1994). Continuous use
of corticosteroids for a period of four to five days may cause adverse effects such as insomnia,
anxiety, or euphoria (Goodman, 1997).
G) 5-HT3 receptor antagonists (5-HT3 RAs)
Due to its high efficacy and favorable toxicity profile compared to other antiemetic
agents, 5-HT3RAs are currently the first-line agents and the gold standard for prevention of
CINV in patients receiving HE or ME chemotherapy (Gralla et al., 1999; Schnell, 2003). The 5HT3RAs specifically prevent the binding of the neurotransmitter, serotonin to the 5- HT3
receptors on the vagal nerves that trigger the emetic response. Due to the specific nature of its
binding, it precludes the severe and distressing side effects associated with conventional
antiemetics such as metoclopramide. The 5-HT3RAs provide complete acute antiemetic
protection, i.e. no nausea, no vomiting and no use of rescue medications in 40-60% of patients
receiving cisplatin based chemotherapy and 60-80% of patients receiving ME chemotherapy
(Schnell, 2003). In patients receiving high-dose cisplatin-based chemotherapy regimens, 5HT3RAs provide complete antiemetic protection in the acute phase in 25-60% of patients
(Audhuy et al., 1996; Beck et al., 1992; Hesketh et al., 1996; Marty et al., 1995; Navari et al.,
1995).
Three 5-HT3 RAs are currently available in the United States for prevention of emesis:
dolasetron (Anzemet®), granisetron (Kytril®) and ondansetron (Zofran®). All three agents are
available in both injectable and oral formulations. The injectable formulations of all three agents
are indicated for use with highly and moderately emetogenic chemotherapy, whereas only the
oral route of granisetron and ondansetron are indicated for use with highly emetogenic
chemotherapy. Oral administration of a 5-HT3RA and dexamethasone provide similar clinical
outcomes as IV administration. The administration of 5-HT3 RAs by the oral route is
recommended whenever appropriate if the gastrointestinal tract is intact and compliance is
assured. Studies have also shown that the oral dosage form of 5-HT3 RA have equivalent
efficacy to its intravenous form (Berger & Clark-Snow, 2001). Several randomized, controlled
studies have shown that ondansetron, granisetron and dolasetron have equivalent complete
control rates, defined as complete absence of nausea or vomiting, among patients on HE or ME
chemotherapy (Berger & Clark-Snow, 2001; Gralla et al., 1998; Hesketh, 2000). For the purpose
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of this study, ondansetron is used as representative of the 5-HT3RA class of antiemetics and is
discussed below in detail.
Ondansetron (Zofran®)
a) For Highly Emetogenic Chemotherapy
Ondansetron was the first 5-HT3RA to be approved in the US for prevention of nausea
and vomiting in patients receiving chemotherapy. There is conflicting data regarding the single
optimal dose of ondansetron for prevention of acute emesis from cisplatin. A study by Beck and
colleagues, comparing various doses of ondansetron for prevention of acute CINV showed that
32 mg dose was superior to 8 mg, particularly in patients receiving high dose cisplatin (>
100mg/m2) (Beck et al., 1992). However, in another study, Seynaeve and colleagues showed that
a single dose of 8 mg was equally effective to a 32 mg dose for prevention of acute emesis from
cisplatin (Seynaeve et al., 1992). A number of other studies show results that support the
equivalent efficacy of 8 mg dose to 32 mg dose of ondansetron (IGAR, 1995b). There are also
controversies regarding the single vs. multiple administration of ondansetron for prevention of
acute emesis following cisplatin. Clinical trial results suggest that increasing the number of
doses does not improve efficacy and multiple-dose administration does not improve outcomes
(Hesketh et al., 1996; Seynaeve et al., 1992). The study by Beck and colleagues also showed that
a single IV dose of ondansetron was as effective as multiple dosing regimen of ondansetron
(Beck et al., 1992).
Based on the results of a recent systematic literature review, the dosing recommendations
of ondansetron for prevention of acute nausea and vomiting due to high emetic risk
chemotherapy is a single oral dose of 24mg of ondansetron or single IV dose of 8mg (Jordan,
Kasper, & Schmoll, 2005; M. G. Kris et al., 2005).
b) For Moderately Emetogenic Chemotherapy
For ME chemotherapy, the recommended adult oral dose of ondansetron is a single dose
of 8 mg. For delayed emesis following ME chemotherapy, one 8 mg ondansetron tablet can be
administered twice a day for 1-2 days following chemotherapy (ZOFRAN Prescribing
Information Monograph). But dosing recommendations are not without controversy, and based
on literature search, Herrstedt and colleagues have recommended 8 mg tablets twice daily for
acute emesis or one single 8 mg IV dose of ondansetron (Herrstedt et al., 2005). There are no
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randomized controlled studies to compare a single oral dose of ondansetron to a multiple dosing
regimen for prevention of CINV following administration of ME chemotherapy.
For Prevention of Delayed CINV
The dosing regimen of ondansetron for prevention of delayed CINV due to HE and ME
chemotherapy is not clearly outlined. It is seen from various randomized clinical trials with
uniform antiemetic prophylaxis of the acute phase, that the control of cisplatin-induced delayed
emesis with single agent 5-HT3RAs is not significantly different than placebo (Gandara, Harvey,
Monaghan, Perez, & Hesketh, 1993; Pater et al., 1997; Smyth, 1992). The efficacy of single
agent granisetron compared to placebo for delayed emesis due to HE chemotherapy has been
studied in 533 patients receiving cisplatin. In the delayed phase, the patients were randomized to
receive either placebo or one of three doses (2.5mg, 5mg or 10mg) of oral granisetron twice a day
until day seven after chemotherapy. The study results reported no significant differences in the
efficacy of delayed emetic control among the various groups (Smyth, 1992). Thus, this suggests
that as single agents, 5-HT3RAs have minimal to modest activity against cisplatin-induced
delayed emesis (Gandara et al., 1993; Kris et al., 2005).
Antiemetic Efficacy for Multiple Cycles of Chemotherapy
The emesis protection provided by the combination regimen of 5-HT3RAs and
dexamethasone decreases with each subsequent cycles of chemotherapy (de Wit et al., 1996; de
Wit et al., 1998). A study conducted among 125 patients receiving six cycles of cisplatin-based
chemotherapy reported that the antiemetic efficacy provided by combination of granisetron and
dexamethasone decreased over subsequent cycles of chemotherapy. The initial complete acute
emesis protection decreased from 66% to 39% in the sixth cycle and initial delayed emesis
protection decreased from 52% to 43% in the sixth cycle (de Wit et al., 1996; de Wit et al.,
1998).
Side Effects of 5-HT3RA
Reports of clinical trial results and practical clinical experience showed that 5-HT3 RAs
are well-tolerated (Hesketh, 2000). There are no significant differences in the side effect profile
of ondansetron, granisetron and dolasetron (Anastasia, 2000). The most common adverse events
reported for all three 5-HT3 RAs are headache, constipation and diarrhea (Audhuy et al., 1996;
Bleiberg, Spielmann, Falkson, & Romain, 1995; Ettinger et al., 1996; Gralla et al., 1998). They
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do not produce the extrapyramidal symptoms associated with dopaminergic antagonists such as
metoclopramide. Other adverse events include transient changes in the blood pressure and
clinically asymptomatic changes in the electrocardiographic parameters (Audhuy et al., 1996;
Hesketh et al., 1996; Plosker & Goa, 1991). Transient changes in blood pressure resolve without
treatment and are considered clinically insignificant.
New Antiemetic Agents
H) Aprepitant (Brand Name: Emend®)
Aprepitant is the first oral selective nonpeptide neurokinin (NK-1) receptor antagonist
indicated for use in combination with a 5-HT3 RA and corticosteroid for prevention of acute and
delayed emesis due to HE chemotherapy regimens. Aprepitant prevents substance P from
binding to the NK-1 receptors in the brain stem and thus resulting in inhibition of emesis
(Bountra et al., 1996; Dando & Perry, 2004). Although aprepitant is more efficacious, the 2005
average wholesale price (AWP) of $309.00 for a three-day regimen makes it expensive compared
to the other antiemetic agents used for prevention of acute and delayed emesis following
administration of HE chemotherapy.
a) For Highly Emetogenic Chemotherapy
Two large phase III clinical trials have been conducted to determine the antiemetic
efficacy of aprepitant in patients receiving high-dose cisplatin (≥70mg/m2) (Hesketh et al., 2003;
Poli-Bigelli et al., 2003). One group of patients received standard antiemetic therapy consisting
of IV ondansetron 32 mg and oral dexamethasone 20 mg on day one and oral dexamethasone 8
mg twice daily on day two to four. The other group received oral aprepitant 125 mg in addition
to the standard therapy on day one and aprepitant 80 mg and oral dexamethasone 8 mg on days
two and three and oral dexamethasone 8 mg on day four. The overall complete response (no
emesis and no use of rescue therapy) rates reported in the two clinical trials were 62.7% and
72.7% for the aprepitant group compared to 43.3% and 52.3% of the standard regimen group.
Complete response rates in the delayed phase were achieved in 67.7% and 75.4% of patients in
the aprepitant group compared to 46.8% and 55.8% in the standard regimen group. These results
show the superior efficacy of the aprepitant-based regimen in control of acute and delayed CINV
compared to the standard regimen.
b) For Moderately Emetogenic Chemotherapy
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Randomized clinical trials assessing efficacy of aprepitant in prevention of CINV
following moderately emetogenic chemotherapy have been recently published. Warr and
colleagues conducted a study among 857 chemotherapy naïve breast cancer patients receiving
cyclophosphamide and either doxorubicin or epirubicin (Warr et al., 2005). The standard
regimen group received two doses of 8 mg oral ondansetron on days one to three and 20 mg oral
dexamethasone on day one. The aprepitant group received 125 mg of oral aprepitant, 8 mg of
oral ondansetron twice daily, and 12 mg oral dexamethasone on day one. The aprepitant group
also received 80 mg oral aprepitant on days two and three. The study results showed that
compared to the standard regimen, more patients in the aprepitant group reported complete
response during the acute phase, delayed phase and the overall study period. Thus, aprepitant
added to the standard regimen has demonstrated better control of CINV compared to the standard
regimen in patients receiving ME chemotherapy.
c) For Multiple Cycles of Chemotherapy
The antiemetic efficacy of aprepitant in addition to the standard regimen for prevention
of CINV due to HE chemotherapy has been found to be sustained over multiple cycles of
chemotherapy (de Wit et al., 2003; de Wit et al., 2004). De Wit and colleagues reported results
from pooled analysis of multiple-cycle extensions of two large phase III aprepitant clinical trials
(de Wit et al., 2003; de Wit et al., 2004). Chemotherapy naïve cancer patients receiving their
first cycle of cisplatin were randomized to either the standard regimen group: IV ondansetron 32
mg and dexamethasone 20 mg on day one, dexamethasone 8 mg twice daily on days two to four,
or aprepitant group: aprepitant 125 mg, IV ondansetron 32 mg, dexamethasone 12 mg on day
one, aprepitant 80 mg on day two and three and dexamethasone 8 mg on days two to four. The
patients received these regimens for six cycles and the end point of no emesis and no significant
nausea was assessed for each cycle. A cumulative probabilities approach incorporating a model
for transitional probabilities was used to analyze the data. The results showed that the estimated
rates of no emesis and no significant nausea was higher for the aprepitant group compared to the
standard group for all cycles of chemotherapy.
d) For Breakthrough CINV
Aprepitant has not been shown to mitigate ongoing emetic symptoms and has not been
tested for continuous use for duration greater than five days in patients receiving emetogenic
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chemotherapy. It should not be used to treat established nausea and vomiting regardless of its
etiology and should not be prescribed on a PRN basis (Kohler & Hughes, 2003).
e) Adverse effects
The most common adverse events that occurred more frequently in the aprepitant group
compared to the standard group include: asthenia/fatigue, dizziness, diarrhea, cough and hiccups
(Hesketh et al., 2003; Poli-Bigelli et al., 2003).
I) Palonosetron (Brand Name: Aloxi®)
Palonosetron is a 5-HT3 RA available as an injectable antiemetic agent. Palonosetron
differs from older 5-HT3 RAs since it has a higher binding affinity to the 5-HT3 receptors, higher
potency and a longer half-life. It is indicated for prevention of acute emesis due to HE regimens
and prevention of acute and delayed emesis due to ME regimens. In the US, the recommended
dose of palonosetron for the prevention of CINV is a single IV infusion of 0.25 mg
approximately 30 minutes before the start of chemotherapy. Compared to other 5-HT3RAs,
palonosetron provides convenience for prevention of emesis due to its single dose schedule. The
2005 AWP of a 0.25mg 5 ml single dose vial is $340.20.
a) For Highly Emetogenic Chemotherapy
Currently for patients receiving HE chemotherapy, palonosetron has only been indicated
for prevention of acute CINV. In a study of 650 patients receiving HE chemotherapy, two doses
(0.25 mg or 0.75 mg) of palonosetron were compared to a single 32 mg dose of ondansetron.
The study results showed no differences in the acute or delayed complete response rates between
the three study groups. Thus, it can be concluded that a single 0.25 mg IV dose of palonosetron
was at least as effective as a 32 mg IV dose of ondansetron for acute and delayed emesis
following HE chemotherapy (Aapro, Bertoli, Lordick, Bogdanova, & Macciocchi, 2003).
Studies comparing palonosetron to other regimens for prevention of acute and delayed CINV due
to HE chemotherapy are currently lacking. More clinical trials of combination antiemetic
regimens with palonosetron need to be carried out to establish whether it is more efficacious than
the combination of corticosteroid with either metoclopramide or a 5-HT3 RA for protection of
delayed emesis due to HE chemotherapy.
b) For Moderately Emetogenic Chemotherapy
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The efficacy of palonosetron as part of various different regimens has been extensively
studied in patients receiving ME chemotherapy. The results from a study conducted among 569
patients receiving ME chemotherapy showed that a 0.25 mg IV dose of palonosetron provided
significantly higher antiemetic control compared to a single 100 mg IV dose of dolasetron
(Eisenberg et al., 2003). The study results showed that the single dose of palonosetron is as
effective as a single dose of dolasetron in preventing acute CINV but the former regimen
provides better emetic control in the delayed phase. In the delayed phase, approximately 57% of
patients who received palonosetron reported achieving complete response as compared to 39% of
patients who received dolasetron.
Gralla and colleagues conducted a multicenter, randomized, double blind study to
compare two doses (0.25 mg or 0.75 mg) of IV palonosetron and a single IV dose of 32 mg
ondansetron among 570 patients receiving ME chemotherapy (Gralla et al., 2003). The results
indicated that a single IV dose of palonosetron provided significantly higher acute and delayed
emetic control compared to a single IV dose of ondansetron. A phase II open label study was
conducted to determine the efficacy of a single dose of palonosetron combined with a three-day
regimen of aprepitant to prevent CINV in patients receiving moderately to moderately-high
emetogenic chemotherapy. The preliminary results of the study showed that the combination
was safe and may improve the overall prevention of CINV (Grote et al., 2004).
c) For Multiple Cycles of Chemotherapy
To date, only one noncomparative trial has been conducted to evaluate the efficacy of
palonosetron in preventing CINV over repeated cycles of moderately to highly emetogenic
chemotherapy (Cartmell et al., 2003). A single 0.75 mg IV dose of palonosetron with or without
corticosteroids was given to the participants. The results showed that the efficacy of
palonosetron was maintained during acute, delayed and overall phases during four cycles of
chemotherapy (Cartmell et al., 2003).
d) Adverse Effects
The side effect profile of palonosetron is similar to that of the other 5-HT3RAs with
headache and constipation being among the most frequently reported side effects in clinical trials
(Eisenberg et al., 2003; Gralla et al., 2003). Other serious side effects occur with a very low
frequency and were similar in the palonosetron and the comparator group.
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Combination antiemetic regimens and Recommendations for Antiemetic Use
Combination of two or more antiemetic agents provides better efficacy in prevention of
CINV following administration of HE and ME chemotherapy than use of a single antiemetic
agent. Several professional organizations such as the Multinational Association of Supportive
Cancer Care (MASCC), the American Society of Clinical Oncology (ASCO), the American
Society of Health-System Pharmacists (ASHP), the National Comprehensive Cancer Network
(NCCN), and the Canadian Medical Association have published guidelines and evidence-based
recommendations for the use of antiemetics in management of CINV (ASHP, 1999; ESMO,
2001; Gralla et al., 1999; MASCC, 1998; NCCN, 1997).
Highly Emetogenic Chemotherapy
Acute Phase
Several randomized double-blind clinical trials have been conducted to compare single
agent 5-HT3RA with a combination of 5-HT3 RA and dexamethasone for prevention of CINV in
patients receiving HE chemotherapy (Heron, Goedhals, Jordaan, Cunningham, & Cedar, 1994;
IGAR, 1995a; Latreille et al., 1995; Olver et al., 1996). The results from these studies have
unequivocally shown that the combination of a 5-HT3 RA and dexamethasone provides superior
antiemetic efficacy in the acute phase compared to 5-HT3 RA alone. Thus, previous guidelines
have recommended a combination of 5-HT3 RA and corticosteroids before chemotherapy for
control of acute emesis in patients receiving HE chemotherapy regimens (ASHP, 1999; Gralla et
al., 1999).
Based on the results of randomized clinical trials (Chawla et al., 2003; Hesketh et al.,
2003; Poli-Bigelli et al., 2003), new guidelines from the MASCC and the NCCN now
recommend a triple combination of aprepitant, a 5-HT3RA and dexamethasone for prevention of
acute emesis due to HE chemotherapy (MASCC, 2004; NCCN, 2005). The use of palonosetron
as a part of the triple combination regimen with aprepitant and dexamethasone has been
recommended for prevention of acute emesis by the NCCN 2005 guidelines (NCCN, 2005).
Though this regimen is a part of the new recommendations, randomized, double blind clinical
trials determining its efficacy as compared to the triple combination regimen containing other 5HT3RAs have not yet been published.
Delayed Phase
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The recommendations for prevention of delayed emesis following HE chemotherapy are
not as clear cut as those for the acute phase. The incidence of delayed emesis in patients
receiving cisplatin-based chemotherapy is reduced from 90% to 40-50% by the use of
corticosteroids alone, or combined with metoclopramide or a 5-HT3RA (IGAR, 1997; Kris et al.,
1989; Latreille et al., 1998b; Navari, 2003). The 1999 American Society of Clinical Oncology
(ASCO) and the American Society of Health-System Pharmacists (ASHP) guidelines
recommended a combination of corticosteroid and either metoclopramide or 5-HT3 RA for
prevention of delayed emesis in patients receiving HE chemotherapy (ASHP, 1999; Gralla et al.,
1999).
Early clinical trial results showed that the combination of dexamethasone and
metoclopramide had higher antiemetic efficacy during the delayed phase as compared to
dexamethasone alone (Kris et al., 1989). Several other studies have reported that the
combination of a 5-HT3RA and dexamethasone has similar efficacy as dexamethasone alone
(Goedhals, Heron, Kleisbauer, Pagani, & Sessa, 1998; Latreille et al., 1998a; Tsukada, Hirose,
Yokoyama, & Kurita, 2001). Thus based on the evidence, it can be concluded that the
combination of dexamethasone and metoclopramide has better efficacy than dexamethasone
alone and similar efficacy to dexamethasone and 5-HT3 RA combination. Also, dexamethasone
and 5-HT3 RA combination does not provide any additional antiemetic benefit compared to
dexamethasone alone.
The introduction of aprepitant led to the development of new guidelines and
recommendations for prevention of delayed CINV following HE chemotherapy. The MASCC
and NCCN recommends (MASCC, 2004; NCCN, 2005) using a combination of dexamethasone
and aprepitant to prevent delayed emesis based on its superiority to dexamethasone alone
(Hesketh et al., 2003; Poli-Bigelli et al., 2003). This combination has not been compared for its
antiemetic efficacy to other combination regimens previously recommended. Since head-to-head
clinical trials are not available, decision analytical models can be used to combine data from
diverse sources to compare various antiemetic regimens to determine their cost-effectiveness
(CE) compared to the new regimen. The dexamethasone and 5-HT3RA combination needs to be
studied as an alternative strategy for delayed emesis in the CE model due to its widespread use in
clinical practice.
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Moderately Emetogenic Chemotherapy
Acute Phase
A study was conducted among 428 patients receiving ME chemotherapy to compare three
antiemetic regimens: dexamethasone alone, granisetron alone, and combination of
dexamethasone and granisetron for prevention of acute emesis (IGAR, 1995a). The results
showed that patients who received the combination regimen were found to have complete
protection from both nausea and vomiting (70%) more frequently compared to patients receiving
dexamethasone (49%) and granisetron (43%) alone. Thus, a combination of a 5-HT3RA and
dexamethasone was recommended by previous guidelines (ASHP, 1999; Gralla et al., 1999).
The 2005 NCCN guidelines (NCCN, 2005) reiterate the recommendations of the previous
guidelines and gives preference to palonosetron based on the results of the recent clinical trials
(Eisenberg et al., 2003; R. Gralla et al., 2003).

Delayed Phase
In the absence of prophylactic antiemetic agents, the incidence of delayed emesis was 2025% among patients receiving ME chemotherapy, such as cyclophosphamide plus either
doxorubicin or epirubicin. But other studies have placed the incidence of delayed emesis in
patients receiving ME chemotherapy without prophylactic antiemetic regimens as high as 70%.
(IGAR, 2000b; Navari, 2003). Previous guidelines have recommended the use of either
dexamethasone alone or combination of dexamethasone with a 5-HT3RA or metoclopramide for
prevention of delayed emesis due to ME chemotherapy (ASHP, 1999; Gralla et al., 1999). With
the introduction of new antiemetic agents, aprepitant and palonosetron, new guidelines have been
published. The 2005 NCCN and 2004 MASCC guidelines recommend either dexamethasone
alone or a 5-HT3 RA alone or combination of aprepitant and dexamethasone if aprepitant was
given during the acute phase (MASCC, 2004; NCCN, 2005).
2.4: Economic Evaluation of Antiemetics for Prevention of CINV
The introduction of serotonin receptor antagonists in the early 1990’s made a significant
impact on the prophylaxis and management of CINV. Antiemetic regimens with 5-HT3RAs have
resulted in better antiemetic control in patients receiving HE and ME chemotherapy compared to
the older antiemetic agents. But these agents are costly compared to the older antiemetic agents.
The introduction of the new antiemetic agents, which provide better antiemetic control for
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prevention of delayed emesis compared to only 5-HT3RAs, has further increased the cost of
prophylactic combination antiemetic regimens. Rising health care expenditure coupled with
limited resources have led to an increased interest in conducting economic evaluations of
healthcare interventions, a method in which both costs and benefits of interventions are evaluated
to make resource allocation decisions. The next two sections outline some of the previous
economic evaluations conducted to compare various antiemetic regimens for prevention of CINV
following HE and ME chemotherapy.
A recent review of cost-effectiveness studies of antiemetics for CINV included 20 studies
(Lachaine & Crott, 2003). Out of these 20 studies, 15 studies conducted cost-effectiveness
analysis (CEA) comparing 5-HT3RAs to traditional antiemetics such as metoclopramide and 5
studies compared 5-HT3RAs against one another. A large number of these were limited to the
acute phase of nausea and vomiting following administration of chemotherapy (Ballatori et al.,
1994; Buxton & O'Brien, 1992; Cunningham et al., 1993; Sands et al., 1992).
For Highly Emetogenic Chemotherapy
A majority (14 studies) of the previous economic evaluations have been conducted for
patients receiving HE chemotherapy. Ballatori and colleagues conducted a retrospective CEA
using data from a study in cancer patients receiving cisplatin (Ballatori et al., 1994). The trial
compared the antiemetic efficacy of an intravenous regimen of dexamethasone with either
ondansetron or metoclopramide for prevention of acute emesis for three cycles of chemotherapy
(IGAR, 1992). A hospital perspective was adopted for the study and the incremental costeffectiveness ratio (ICER) was US$369 (1991 costs) for each additional patient with complete
emesis control obtained by the ondansetron group. The impact of delayed emesis was not
considered in the study. Also, the study was conducted based on multi-dosing regimens of
antiemetics and studies since then have shown the equivalent efficacy of multi-dosing regimens
to single-dose regimens of 5-HT3RAs (Beck et al., 1992; Ettinger et al., 1996). Costeffectiveness analysis based on single-dose regimens may lead to decreased personnel and drug
administration costs and alter the ICER of the comparators. Thus, there is a need to conduct
economic evaluations of new antiemetic regimens to the previous standard regimens using the
optimal dosing regimens.
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Economic evaluations comparing 5-HT3RAs against one another have been conducted
(Barrajon & de las, 2000; Becker et al., 1996). Two of those studies can be considered as cost
minimization analyses since the efficacy of the comparators were considered to be equivalent and
there were only cost differences (Barrajon & de las, 2000; Becker et al., 1996). Economic
evaluations comparing 5-HT3RAs to traditional antiemetics such as metoclopramide for
prevention of acute CINV following HE chemotherapy showed that the higher costs of 5HT3RAs are compensated for by superior efficacy, less side effects and lower personnel and
administration costs (Ballatori et al., 1994; Buxton & O'Brien, 1992; Cunningham et al., 1993;
Sands et al., 1992). However, to our knowledge, none of the prior economic evaluations of
antiemetics for prevention of CINV following highly emetogenic chemotherapy were conducted
for delayed emesis or for the overall period of emesis.
Recently, three studies evaluating the cost-effectiveness of aprepitant given with standard
regimen have been presented at international symposiums and published in abstract format
(Deuson, 2004; Ehlken et al., 2004; Moore et al., 2005). Ehlken and colleagues conducted a
CEA of adding aprepitant to the standard regimen of ondansetron and dexamethasone in patients
undergoing highly emetogenic chemotherapy in office-based settings in Germany. The study
was conducted from the payer’s perspective. A decision analytic model was constructed to
determine the costs and benefits associated with the two alternative strategies. The outcome
measures were patients with complete control of emesis, i.e. no emesis and no rescue
medications, and quality-adjusted life years (QALY). The effectiveness of the antiemetic
regimens were obtained from phase III trials of aprepitant and the German tariffs and prices were
used to value the health care resources associated with CINV. The results showed that 43% of
the higher cost of aprepitant was offset by lower resource use. The incremental cost per QALY
of aprepitant compared to the standard regimen was calculated to be €21,764. The results of
sensitivity analyses showed that the results were sensitive to costs of hospitalizations and rescue
medications. The authors concluded that the use of aprepitant in office-based settings in
Germany was cost-effective.
Due to the inability to access the entire study, it is difficult to determine the source of
utilities used in the estimation of QALYs. As discussed earlier, there is no consensus about the
best method to generate utilities for short-term health states. The cost per QALY estimates
obtained from the above study may be sensitive to the method used for utility elicitation. The
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CEA in the study was based on the regimens used during the clinical trial, aprepitant and
dexamethasone compared to dexamethasone alone for the delayed phase. But this does not reflect
clinical practice where a combination of dexamethasone with a 5-HT3RA is most commonly
employed.
Another study was conducted to determine the cost-effectiveness of three regimens from
the payer’s perspective: standard therapy, adding aprepitant to the standard regimen (strategy 1)
and adding aprepitant when CINV occurs (strategy 2) (Moore et al., 2005). The study used a
Markov model to compare the two alternative strategies for a hypothetical cohort of patients
receiving four cycles of HE chemotherapy. The outcomes measures used were healthy-days
equivalent and QALYs. The probabilities and utilities for the model were obtained from the
published clinical trials. The costs were based on resource use for CINV management using
Medicare reimbursement rates for hospital and physician services and the average wholesale
price (AWP) for medications. Compared to the standard regimen, the ICERs were
$172,789/QALY for strategy 1 and $160,236/QALY for strategy 2. The probabilistic Monte
Carlo trials showed that using the $50,000/QALY threshold, strategy 1 was not cost-effective in
89.7% of the trials. The authors concluded that aprepitant should be used after CINV occurs or
should be used in high-risk populations for it to be cost effective.
For Moderately Emetogenic Chemotherapy
Several cost-effectiveness analyses of different antiemetic regimens for prevention of
CINV due to ME chemotherapy have been conducted (Cox & Hirsch, 1993; Kwong &
Parasuraman, 1999; Lachaine & Laurier, 2002; Lachaine, Laurier, Langleben, & Vaillant, 1999).
Kwong and Parasuraman conducted a retrospective CEA of oral ondansetron and
prochlorperazine for prevention of CINV in patients receiving ME chemotherapy. The outcome
measure was defined as the number of patients who had no emetic episodes and no adverse
events during the three day study period. The study was conducted from a third-party payer
perspective. A decision analytic model was constructed to outline the outcomes of the treatment
alternatives. The data on the probabilities of complete relief during the study period, of adverse
effects, of requiring rescue medications, and hospitalizations were obtained from published
clinical trials. The medication costs were based on the 1996 average wholesale price, and the
hospitalization costs were based on expenses per inpatient day reported in the American Hospital
Association’s 1994 annual survey of hospitals. The incremental CEA showed that the cost of one
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additional effectively treated patient with ondansetron was $258. The cost-effectiveness results
were sensitive to variations in the duration of antiemetic therapy, total cost of antiemetic rescue
medications and percentage of patients using ondansetron as rescue medication.
Recently, Vanscoy and colleagues conducted a pharmacoeconomic analysis of
palonosetron in patients receiving ME chemotherapy from the payer perspective and concluded
that palonosetron is a cost-effective treatment strategy compared to the older 5-HT3RAs
(Vanscoy et al., 2004).
2.5: Willingness-To-Pay (WTP)
Valuation of health gains produced by new interventions can be conducted by qualityadjusted life year (QALY) or willingness-to-pay (WTP) methodology. The QALY is a measure
of health outcome which simultaneously captures improvement in HRQOL and gains in survival
(Drummond, O'Brien, Stoddart, & Torrance, 1997). QALYs are calculated as the product of the
change in utility value induced by the treatment and duration of the treatment effect. The utilities
assigned to a specific state of health can be estimated using techniques such as Standard Gamble
(SG), Time Trade-Off (TTO) or Rating Scale, or by means of pre-scored health state sorting
systems (i.e. Health Utilities Index). The standard gamble (SG) method asks the respondent the
probability of death that they are willing to accept to move from the diseased state to perfect
health. The time trade-off (TTO) method requires the respondent to specify the number of years
of life in perfect health that would be equivalent to the given number of years in the given health
state.
CINV is an acute condition lasting for a period of 5-7 days. The impact of CINV on
survival has not been established in clinical trials but it has a significant impact on morbidity
which is reflected in HRQOL. The use of QALYs to value morbidity for short-term condition
such as CINV has both measurement and evaluation problems (Bala & Zarkin, 2000). The
measurement problems correspond to problems associated with eliciting the utility value for the
health state in question in a valid and reliable fashion. In the SG method, the patients’ preference
for either maintaining a fixed intermediate health state or taking a gamble with perfect health and
death as possible outcomes is determined. But for acute conditions like CINV, it is difficult for
respondents to consider and evaluate the probability of immediate death that would be acceptable
to them to move from a disease state that lasts for 5-7 days to perfect health. A study by Franic
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and colleagues found that respondents were extremely risk averse with acute conditions such as
CINV and the primary factor contributing to the refusal to gamble was the focus on death in the
SG method (Franic & Pathak, 2003).
Two methods to overcome the problem of using death as a negative anchor for utility
elicitation for CINV-related health states is to use the cascading or chained SG method or
chained TTO method (Furlong, Feeney, & Torrance, 1990; Jansen, Kievit, Nooij, & Stiggelbout,
2001; Jansen et al., 1998). In these methods, a surrogate negative anchor health state is used
instead of death. The surrogate negative anchor is a health state severe enough for the patient to
be able to visualize this state in relation to the gamble of perfect health and immediate death.
The other health states are then evaluated in comparison with perfect health vs. surrogate
negative anchor state. The scores thus obtained are then adjusted in proportion to the utility of
the surrogate negative anchor health state which has been determined using the traditional utility
elicitation methods (Grunberg, Srivastava, Grunberg, & Weeks, 2002; Jansen et al., 1998). One
of the drawbacks of this approach is that patients who are presented with an anchor health state
find it irrelevant to the situation of interest. The results of chained TTO or SG methods may also
be affected by the anchor state used in the chaining procedure (Bala & Zarkin, 2000).
In addition to measurement problems, the use of QALYs for acute health conditions has
evaluation issues which correspond to problems in using the elicited health utility value to make
optimal health care coverage decisions. Zbrozek et al. (1995) performed a cost utility analysis
comparing ondansetron with metoclopramide using efficacy data from published clinical trials.
To calculate the incremental cost per QALY, a relative difference of 0.00014 QALY between
two antiemetic agents was arbitrarily estimated. The incremental cost per QALY in patients
receiving high-dose cisplatin was US$407,667 and in patients receiving moderate-dose cisplatin
was US$372,255. One of the reasons for such a high incremental cost-effectiveness ratio (ICER)
is that the multiplicative product of the utility weights and life-years gained, which in the case of
CINV is small due to the acute nature of the health condition, leads to high cost per QALY
estimates. Thus, an alternative technique to valuing health benefits produced by new
interventions is the WTP methodology.
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Monetary Valuation of Health Outcomes
The WTP methodology directly estimates the value of health gains in monetary terms
which can be then used to conduct cost-benefit analysis (CBA). CBA is a method of economic
evaluation in which health benefits are valued in monetary terms. There are three methods to the
monetary valuation of health outcomes or benefits: a) human capital approach, b) revealed
preferences and c) contingent valuation (CV) (Drummond et al., 1997). The human capital
approach is not recommended to measure health outcomes in monetary terms since it is
production-based and is not consistent with the principles of welfare economics. The revealed
preference method is an indirect measurement method, which has been used in wage-risk trade
off studies (Gafni, 1991). These studies are undertaken to understand the association between
health risk associated with particular jobs and the wages that individuals require to accept the job.
Though this method is based on actual consumer behavior, it is context and job-specific and
cannot be applied widely (Drummond et al., 1997).
The contingent valuation (CV) method is based on stated preferences where the
respondents are asked to value goods in a contingent or hypothetical market using survey
measures (O'Brien & Gafni, 1996). Contingent valuation involves direct measurement in which
respondents are asked to provide either their maximum WTP to maintain the current level of
utility or minimum willingness to accept (WTA) to make the utility equal to what it would have
been after the change. WTP is a method to determine the monetary value that patients place on
health improvements, for example, improved emetic control. WTP estimates for improved emetic
control can provide important evidence to managed care and hospital formulary committees to
justify budgetary increases for new antiemetic agents such as aprepitant and palonosetron. The
individual can be assumed to take into account all the attributes of the commodity while
considering their maximum WTP.
2.6: Methodological Issues in WTP
Willingness-to-pay using the CV method is based on the premise that the maximum
amount of money an individual is willing to pay for a commodity is an indicator of the utility or
satisfaction to them of that commodity. In implementing the CV method to determine WTP for
improved emesis control, the following methodological issues need discussion: global versus
restricted measurement of benefits, perspective of analysis (ex-ante and ex-post user), payment
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vehicle (out-of-pocket, or increases in insurance premiums or increases in tax payments), and
format of the WTP question (single open-ended, or multiple close-ended questions) (O'Brien &
Viramontes, 1994; Smith, Olsen, & Harris, 1999a)
Global vs. restricted approach
The three broad categories of benefits that arise from any health care program include: 1)
intangible benefits which are the value of the improved health to the consumer of the program,
for example: prevention of nausea and vomiting, impact of intervention on improving HRQOL;
2) future health care costs avoided, for example: cost of breakthrough emesis, additional
physician visits, hospitalization, any cost to patient and/or health care sector associated with
suboptimal control of emesis; 3) increased productive output due to improved health status, for
example: work productivity.
In the restricted approach to WTP, the respondents are asked to value only the intangible
health benefits for which market values do not exist. The future health care savings and
increased productive outputs are valued using market prices (Drummond et al., 1997). One of
the problems with the restricted approach is development of valuation scenarios that can isolate
the health effects of the intervention from other effects such as out-of-pocket costs, income lost
due to time off work etc. (Currie et al., 2002). On the other hand, the global approach to WTP
asks the respondents to take into account all the potential benefits of the commodity while
considering their maximum WTP. While using the global approach to assessing WTP,
respondents should be told explicitly to consider income effects due to work absence due to
disease (emesis) or its treatment (side effects of antiemetics), cost offsets due to improved emesis
control etc. Depending upon the complexity and amount of information presented, there may be
substantial cognitive burden placed on the study respondents.
Perspective of the WTP analysis
WTP can be measured using either the ex-post/user-based perspective or the exante/insurance-based perspective. In the ex-post or user-based approach, respondents know that
they are consumers of the treatment, i.e. either patients who already have the disease in question
(cancer and receiving chemotherapy) or individuals presented with hypothetical scenarios with a
certainty of having the disease in question and only the treatment outcomes are uncertain
(probability of complete control of emesis). This method captures only the user values since the
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valuation involves certain use of the program and only uncertainty in the outcomes of the health
program. Respondents for WTP surveys based on user perspective can include patients or
caregivers, random sample of general population and convenient samples. General population
and convenient samples are provided with scenarios where they are asked to assume to have the
disease in question and state their WTP for uncertain health outcomes.
In the ex-ante perspective, along with the uncertain treatment outcomes, the valuation
needs to incorporate the probability of contracting the disease and needing the service in question
in the future. Thus, in this perspective the respondents are provided with the probabilities of
being diagnosed with cancer in the future, requiring chemotherapy and complete control of
emesis due to the antiemetic interventions. WTP surveys with ex-ante perspective are conducted
in random samples of the general population or convenient samples to include currently diseased
individuals, currently non-diseased who are at future risk of disease, and currently non-diseased
who are not themselves at personal risk of the disease. The respondents are asked their WTP as
increase in insurance premiums to ensure coverage for the health intervention for a specified
disease. In countries with national health care system funded by tax monies, respondents are
asked their WTP as increase in tax payment amounts over their lifetime.
It is thought that the WTP questions in the context of health care should be framed in the
form of hypothetical insurance purchasing since users typically do not pay for medical services at
the point of consumption and due to its ability to capture user, option and externalities values
(Gafni, 1991). But respondents may have difficulty understanding the multiple uncertainties
involved in the hypothetical scenario for determining WTP for improved emesis control based on
ex-ante perspective. These could include: incidence of cancer in a specified period of time,
probability of receiving HE or ME chemotherapy, probability of emesis with chemotherapy and
uncertainty associated with antiemetic regimen outcomes. These compound probabilities can
pose substantial cognitive burden for the respondents. It can also be argued that the patients who
are experiencing the condition are the best candidates to provide the value of the benefits
provided by the related health interventions. Thus, for the purpose of this study, we will use the
user-based perspective for determination of WTP.
Payment vehicle (Out-of-pocket, tax, insurance)
The most common payment vehicles are direct out-of-pocket (OOP) payments, additional
tax payments, and private insurance premiums. The user-based perspective usually employs
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OOP payments whereas; the ex-ante perspective employs additional tax payments or increase in
insurance premiums as payment vehicle (Smith, Olsen, & Harris, 1999b). There is a lack of
consensus regarding the appropriate payment vehicle. Some argue (Birch, 1993) that insurance
premiums should be used whereas others argue (Donaldson et al, 1995) for different vehicles
(Smith et al., 1999b). It is likely that appropriateness of payment vehicle for a particular
commodity will depend on the type of product, and different health care systems. For example,
insurance premiums may be appropriate for the USA but not for the United Kingdom where
increased taxation would be more appropriate. Similarly, insurance premiums may be the
appropriate vehicle for high technology items or expensive low probability items and OOP in the
form of increased co-payments for pharmaceuticals (Drummond et al, 1997). Smith, Olsen and
Harris (1999) (Smith et al., 1999b) recommend that OOP payment is most relevant if users are
asked, whereas taxation is most relevant if the general population is asked in ex-ante perspective.
For the purpose of our study, OOP payments will be the payment vehicle, as it is an appropriate
approach for WTP for pharmaceuticals using user-based perspective. We will not ask WTP as
OOP payments in increased co-payments since respondents may base their responses on their
current co-payment structure.
Questionnaire format/Survey method
The WTP questions can be presented in five formats: 1) open-ended; 2) bidding game; 3)
payment card; 4) discrete-choice and 5) discrete choice with follow-up (Smith, 2000).
1) Open-ended questions
The respondents are simply asked to report their maximum willingness-to-pay. This
format may produce unbiased estimates of WTP since the respondents are not prompted. Though
easy to construct, open-ended questions are too hypothetical, do not reflect the way people
behave in the market and may be cognitively challenging for respondents, as they are not used to
answering such questions (Donaldson, Shackley, & Abdalla, 1997). The WTP estimates may be
imprecise due to wide variance and many non-responses or protest responses (Johannesson,
1996).
2) Bidding game method
In the bidding game method, the respondents are provided with an initial WTP amount,
which they can either accept or reject. Depending on whether they accept or reject the amount, a
higher or lower bid, respectively is presented and the process is continued until the maximum
WTP is reached. The bidding game method has improved precision but it may introduce a
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starting point bias, in which the respondents’ answers may be biased by the initial amounts
presented in the bidding game. There is no consistency in the published health care literature
about the presence of starting point bias in the bidding game method of eliciting WTP. Health
care studies specifically conducted to test for starting point bias did not show evidence of its
presence (O'Brien & Viramontes, 1994; O'Brien et al., 1998).
3) Payment card method
Payment cards have a specified range of values and the respondents are asked to indicate
which amounts they will definitely not pay, which amounts they will definitely pay and what is
the maximum amount they would pay for the health intervention. The payment card approach
was developed by Mitchell and Carson (Mitchell & Carson, 1981) and is believed to simulate
real-life situations by allowing the individuals to “shop around” for a value that they would most
pay (Donaldson, Thomas, & Torgerson, 1997). Donaldson and colleagues (Donaldson et al.,
1997) showed that compared to the open-ended format, the payment card method yields higher
response rates to WTP questions, more consistent mean and median values, and a stronger
association between WTP and ability to pay.
The payment card method may be susceptible to range bias i.e. the range of amounts
presented may influence the WTP responses (Neumann & Johannesson, 1994; Ryan, Scott, &
Donaldson, 2004). Midpoint or centering bias may also be a potential bias in WTP estimates
using payment card method. Midpoint bias is said to occur when the respondents have a tendency
to state the midpoint of the range as their WTP (Ryan, 2004). Studies have shown conflicting
results about the presence of range and centering bias with Neumann and colleagues (1994)
reporting its presence whereas a study by Ryan and colleagues (2004) did not find significant
range or centering bias in their study. Another study conducted to test for range and centering
bias used four versions of payment card with different ranges and center values and did not find
the existence of these biases (Rowe, Schulze, & Brefle, 1996).
4) Discrete choice (DC) method
The DC method also referred to as the referendum method is the recommended format by
the US National Oceanic and Atmospheric Administration Panel on contingent evaluation
(NOAA) (National Oceanic and Atmostpheric Administration, 1993). Each respondent is
provided with a single WTP amount, which they either accept or reject. Thus, each respondent
provides limited information about his or her WTP, which may be either equal, or above or
below the presented amounts. Different bids are presented to different subsamples, and then
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statistical methods are used to determine the societal WTP. The DC method can be modified by
introducing single bid-up or double bid-up following the initial amount. In the single bid-up
method, based on the acceptance or rejection of the initial WTP amount, the respondent is
provided with a higher or a lower bid amount. In the double bid-up method, the iterations are
truncated after providing two follow-up bids. Though the DC method avoids starting point and
range bias, the single-bid up and double-up versions of the method are susceptible to these biases.
This is because the single bid-up amount and the double bid-up amounts will be based on the
starting value used in the method. Also, the DC method is highly inefficient as large sample size
is required to identify the distribution of values with a degree of accuracy.
2.7: Willingness-To-Pay (WTP) Studies in CINV Literature
To date, only one study measuring the monetary value of improved emesis control has
been published. Following phase II randomized clinical trials establishing efficacy of NK-1
receptor antagonists, Dranitsaris et al (2001) undertook a multinational study (countries included
were Canada, Italy, Greece and Spain) to measure the maximum amount that cancer patients
would be willing to pay for reducing their risk of CINV following cisplatin-based chemotherapy.
Willingness-to-pay for various scenarios of absolute risk reduction of acute and delayed emesis
was assessed using the CV approach and the user-based perspective. The respondents were
presented with background information on CINV and the current treatments for emesis followed
by the various clinical scenarios for eliciting WTP. A payment card method was used to avoid
starting point bias and the first value given by the respondent was recorded as the WTP estimate.
Sociodemographic information such as age, marital status, education, family income, religious
affiliation and clinical characteristics such as diagnosis, history of previous chemotherapy,
previous emesis and treatment location were collected.
Results showed that cancer patients from Canada, Italy and Spain were willing to pay
$US46, $US34, and $US63 per day compared to $US8 for patients from Greece for 20% risk
reduction in acute emesis (baseline risk was 30%). For 30% risk reduction in delayed emesis
(baseline risk was 40%), Canadian, Italian and Spanish cancer patients were willing to pay
$US41, $US31, and $US50 daily for four days compared to US$9 for Greek patients.
Multivariate analyses adjusting for sociodemographic variables and previous history of emesis
showed that significant differences in patient value between countries still remained. For acute
and delayed emesis, family income was the only other significant variable predicting maximum
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WTP. The results also bring to light the cultural or geographical differences in the mean WTP
for improved control of emesis.
WTP for improved emesis control due to the addition of aprepitant to the standard
regimen for prevention of CINV due to highly emetogenic chemotherapy and use of palonosetron
instead of the other 5-HT3RA for prevention of CINV due to ME chemotherapy has not been
conducted in the United States. The NK-1 receptor antagonist, aprepitant is recommended for a
period of 3 days whereas the study provided a scenario with hypothetical antiemetic benefit and
duration of regimen.
To our knowledge, there are no studies that have conducted comprehensive economic
evaluation of the new antiemetic regimens for prevention of CINV following HE and ME
chemotherapy. No study has evaluated the cost-effectiveness of an antiemetic regimen with
aprepitant compared to the standard regimen of 5-HT3RA and dexamethasone, and regimen
recommended by ASCO and clinical practice. Lastly, due to the acute nature of CINV, a costbenefit analysis using monetary value of improved emetic control would be appropriate for
resource allocation decisions. The next chapter provides the objectives for the two phases of the
study and outlines the detailed methodology employed in order to achieve the study objectives.
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CHAPTER THREE

METHODOLOGY
The study was conducted in two phases. Phase I involved constructing two decision
analytic models to determine the incremental costs and benefits of alternative antiemetic
regimens for prevention of chemotherapy-induced nausea and vomiting (CINV) following 1)
highly emetogenic (HE) and 2) moderately emetogenic (ME) chemotherapy. Phase II involved
conducting face to face interviews to determine the maximum amount that patients with cancer
were willing to pay for improved emesis control provided by new antiemetic regimens. The
monetary value of the benefits of the new antiemetic regimens were used in cost-benefit analyses
(CBA) to estimate the net benefits provided by the new regimens.
3.1: Phase I - Development of Decision Analytical Model
It is expensive and time consuming to conduct clinical trials to compare an intervention
to all its relevant alternatives. In spite of that, the critical data obtained from clinical trials along
with other evidence is required to optimize the use of healthcare interventions. Thus, there is a
tradeoff between obtaining evidence of effects of alternative healthcare interventions and the cost
of obtaining such evidence. Decision models represent the sequence of chance events and
decisions over time. These models are one of the ways to synthesize evidence from different
sources in an attempt to form decisions about optimal health care interventions (Mandelblatt et
al., 1996).
Two decision analytical models were constructed to identify the relevant costs and
consequences of alternative antiemetic regimens for prevention of CINV following
administration of HE and ME chemotherapy. For the purpose of this study, HE chemotherapy
includes only cisplatin-based chemotherapy, which causes acute emesis in 99% of cancer patients
receiving it. The ME chemotherapy includes agents, which results in acute emesis in 30-90% of
patients and are listed in Table 2-3.
The cost-effectiveness analyses (CEA) were conducted from two different perspectives,
namely societal and third-party payer. The use of multiple perspectives is to make the study
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results relevant to different groups of stakeholders. The societal perspective is the broadest
perspective and includes the costs and benefits of the health care intervention, irrespective of who
incurs it. The CEA conducted from societal perspective includes both direct and indirect costs
associated with the intervention. It is also the recommended approach for CEA by the Panel on
Cost-effectiveness in Health and Medicine, U.S. Public Health Service (Gold, Siegel, Russell, &
Weinstein, 1996). CEA conducted from the societal perspective also helps in decision making
for allocation of resources from a public policy framework. Conducting CEA from the societal
perspective does not preclude us from conducting analyses from other perspectives of interest to
specific groups. Groups such as hospitals and payers are interested in making decisions about
coverage of effective but costly health care interventions by taking into account the costs and
benefits that are relevant to their setting. Thus, CEA conducted from the narrower third-party
payer perspective will assist the relevant groups in formulary decision-making for alternative
antiemetic regimens. The CEA conducted from the payer’s perspective include only the direct
costs related to the intervention incurred by the payer.
Intervention and Alternative Strategies
The rationale for choosing the alternatives for the decision models were explained in
Chapter 1. The choice of the antiemetic intervention strategies was based on recommendations
following the introduction of new antiemetic agents, regimens employed in clinical trials of the
new antiemetics, previous guidelines and commonly used regimens in clinical practice.
Alternative Strategies for Prevention of CINV Following HE Chemotherapy
Table 3-1 describes the prophylactic antiemetic strategies in terms of dosage,
formulations and duration of therapy for prevention of CINV following administration of HE
chemotherapy.
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Table 3-1: Antiemetic Strategies for Prevention of Chemotherapy-Induced Nausea and
Vomiting following Highly Emetogenic Chemotherapy

Strategies
Regimen A
(Aprepitant)

Acute Phase (Day 1)

Delayed Phase (Days 2-4)

Oral Aprepitant 125 mg

Oral Aprepitant 80 mg (Days 2-3)

Oral Dexamethasone 12 mg

Oral Dexamethasone 8 mg (Days 2-4)

IV Ondansetron 32 mg
Regimen B (Only
dexamethasone)

Oral Dexamethasone 20 mg

Regimen C
(Metoclopramide
combination)

IV Dexamethasone 20 mg

Regimen D
(Ondansetron
combination)

IV Dexamethasone 20 mg

Oral Dexamethasone 8 mg BID (Days 2-4)

IV Ondansetron 32 mg
IM Dexamethasone 8 mg BID (Days 2-3) and
4 mg BID (Day 4)

IV Ondansetron 8 mg

Oral Metoclopramide 20 mg QID (Days 2-4)

IM Dexamethasone 8 mg BID (Days 2-3) and
4mg BID (Day 4)

IV Ondansetron 8 mg

Oral Ondansetron 8 mg BID (Days 2-4)
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Addition of aprepitant to the standard regimen, regimen A in Table 3-1, has been
recommended by the Multinational Association of Supportive Cancer Care (MASCC) as the
regimen of choice for prevention of acute and delayed emesis following cisplatin-based HE
chemotherapy (MASCC, 2004). Regimen B has been employed as the comparator antiemetic
strategy in clinical trials of aprepitant (Hesketh et al., 2003; Poli-Bigelli et al., 2003). The other
comparators, regimens C and D are based on previous guidelines published by the American
Society of Clinical Oncology (ASCO), which recommended the use of combination therapy of
dexamethasone with either metoclopramide or a 5-HT3RA for prevention of delayed emesis
(Gralla et al., 1999).
The combination therapy of dexamethasone and a 5-HT3RA has been extensively used in
clinical practice for management of delayed emesis (DURTO, 2003), even though there is not
sufficient evidence to suggest that it has higher efficacy as compared to the dexamethasone and
metoclopramide combination. Thus, it is important to compare the two combination strategies
for prevention of delayed emesis since metoclopramide, in large doses is associated with side
effects in large doses whereas 5-HT3RAs are more expensive compared to metoclopramide.
Thus, based on published guidelines and clinical practice, we will compare the MASCC
recommended regimen to the standard regimen used in clinical trials, the regimen recommended
by ASCO, and a widely used regimen in clinical practice.
Alternative Strategies for Prevention of CINV Following ME Chemotherapy
Table 3-2 describes the prophylactic antiemetic strategies in terms of dosages,
formulations and duration of therapy for prevention of CINV following administration of ME
chemotherapy. Regimen 1 is IV administration of a single dose of palonosetron before
chemotherapy and regimen 2 is a single IV dose of an older 5-HT3RA which has been employed
as the comparator in clinical trials of palonosetron. The NCCN recommendations include a 5HT3RA and dexamethasone combination for prevention of acute emesis due to ME
chemotherapy and either dexamethasone or a 5-HT3RA for prevention of delayed emesis. The
antiemetic strategy regimen 3 reflects the NCCN 2005 guidelines. The 1999 ASCO guidelines
recommend a combination of a 5-HT3RA and dexamethasone for prevention of delayed emesis
and this is included as regimen 4 in the model.
Randomized controlled clinical trials have shown that the older 5-HT3RAs (ondansetron,
dolasetron and granisetron) are equivalent in their efficacy, and their oral dosage forms are also
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equivalent to their intravenous forms. A majority of the randomized clinical trials conducted for
establishing the efficacy of aprepitant and palonosetron have used ondansetron as the comparator.
Thus, for the purpose of this study, ondansetron will be representative of the 5-HT3 RA class of
drugs.
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Table 3-2: Antiemetic Strategies for Prevention of Chemotherapy-Induced Nausea and
Vomiting following Moderately Emetogenic Chemotherapy

Strategies

Acute Phase (Day 1)

Delayed Phase (Days 2-5)

Regimen 1
(Only Palonosetron)

IV Palonosetron 0.25 mg

-

Regimen 2

IV Ondansetron 32 mg

-

Regimen 3
(2005 NCCN)

IV Ondansetron 8 mg

Oral Dexamethasone 8mg
BID (Days 2-5)

Regimen 4
(1999 ASCO)

IV Ondansetron 8 mg

IV Dexamethasone 8 mg

IV Dexamethasone 8 mg

Oral Dexamethasone 8mg
BID (Days 2-5)
Oral Ondansetron 8mg BID
(Days 2-5)
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Model Structure and Simulation
The decision analytical models for antiemetic regimens for prevention of CINV
following HE and ME chemotherapy for a single cycle are described in Figure 3-1. The models
were developed using TreeAge Pro software (TreeAge Software, Inc., 2005). The first branch
point on the decision tree is a decision node indicating a choice of prophylactic antiemetic
regimens for prevention of CINV. Subsequently, the decision model is identical for all the
treatment alternatives. After receiving chemotherapy and a prophylactic regimen for the acute
phase, patients can either experience acute emesis or no acute emesis.
No Acute Emesis Arm:
For patients who do not experience acute emesis, these patients may or may not receive
rescue medications for control of nausea in the acute phase. In both cases, patients could
experience delayed emesis or no delayed emesis. The incidence of delayed emesis is assumed to
be dependent on the prophylactic antiemetic regimen received in the acute phase and the CINV
control obtained in the acute phase. The control of delayed CINV is assumed to be independent
of the receipt of rescue medications in the acute phase. Patients who do not experience any
delayed emesis may or may not receive rescue medications to control for delayed nausea.
Following this, patients may or may not experience the side effects due to the antiemetic
regimens. For the base-case analysis of both decision models, it was assumed that the proportion
of adverse events is the same for all the alternative antiemetic regimens. If patients experience
delayed emesis they may or may not receive rescue medications. In both instances, patients
could either receive outpatient care for uncontrolled emesis or may not require further care.
Acute Emesis Arm:
For patients who do experience acute emesis, they can either receive or not receive rescue
medications. Subsequently, these patients may or may not require outpatient care for
uncontrolled emesis. Following this, patients may or may not experience delayed emesis and
subsequently, the model is identical to those who had no acute emesis.
Most clinical studies conducted to determine the efficacy of antiemetic agents for
prevention of CINV following HE chemotherapy pertain to cisplatin-naïve adult patients
receiving their first cycle of single day cisplatin-based HE chemotherapy. Therefore, a
hypothetical cohort of 10,000 cisplatin-naïve cancer patients over the age of 18 who are
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scheduled to receive their first cycle of single day, outpatient, cisplatin-based chemotherapy
regimen was considered for the HE decision analytical model. Based on the mean age of the
population in the aprepitant clinical trials the mean age of the hypothetical cohort was assumed to
be 55 years. Similarly for the ME decision model the hypothetical cohort was chosen such that
its underlying characteristics were similar to the population in the clinical trials conducted for
determining the efficacy of antiemetic agents following ME chemotherapy. Therefore, for the
ME decision model, a hypothetical cohort of 10,000 chemotherapy-naïve patients over the age of
18 who are scheduled to receive their first cycle of single day, outpatient, ME chemotherapy such
as, any dose of carboplatin, epirubcin, cyclophosphamide < 1,500mg/m2, doxorubicin > 25
mg/m2, or cisplatin <50 mg/m2 was considered. The mean age of the cohort was 55 years.
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Figure 3-1: Structure of the Decision Analytical Model for Determining Cost-Effectiveness
of Prophylactic Antiemetic Regimens

66

METHODOLOGY

Reema Mody

Time Horizon of Analysis
Chemotherapy is usually administered to cancer patients for four to six cycles. Economic
evaluation of antiemetic regimens for prevention of CINV should be conducted for multiple
cycles of chemotherapy to capture all the relevant costs and benefits. Thus, ideally, the model
should represent four to six cycles of chemotherapy to capture the costs and outcomes
comprehensively. However, randomized controlled clinical trials for multiple cycles of
chemotherapy have only been conducted for the new regimen and the standard antiemetic
regimen. Due to lack of clinical efficacy data for multiple cycles for the other alternatives, the
decision analytical model was constructed to represent only one cycle of chemotherapy. The
time horizon of the model was five days to coincide with the actual time for which patients
experience CINV during one cycle of chemotherapy.
For both HE and ME chemotherapy models, the primary outcome measures are the cost
per completely controlled patient at the end of the five-day period. Completely controlled is
defined as no episodes of emesis and no use of rescue medications in both acute and delayed
phases. For the societal perspective, the total costs included the direct costs associated with
prevention and treatment of CINV and indirect costs due to lost work productivity due to
uncontrolled CINV. The CEA conducted from the third-party payer’s perspective included only
the direct costs associated with prevention and treatment of CINV.
Data for the Decision Models
The following section describes in detail data that were used to populate the model. The
probabilities of various events and associated treatment costs were the two types of data required
to populate the models. Probabilities of various events in the decision models can be obtained
through direct observation, review of the published literature or expert opinion. A
comprehensive review of the literature was conducted to get relevant probabilities of various
events in the decision model. For probabilities not available from published literature, expert
opinion was used. The expert opinion was obtained by conducting structured interviews with a
panel of oncologists and oncology nurses.
Probabilities for HE Decision Model
Efficacy of Alternative Prophylactic Regimens

67

METHODOLOGY

Reema Mody

The efficacy data represents the probability of achieving complete control of acute and
delayed emesis following the administration of the four prophylactic antiemetic regimens. The
base case estimates for acute and delayed efficacy of the alternative regimens are shown in Table
3-3. The table also includes the ranges of estimates that were used to conduct sensitivity
analyses.
The efficacy data for regimens A and B were based on the published results of two multicenter, randomized, double blind placebo controlled phase III trials (Hesketh et al., 2003; PoliBigelli et al., 2003). In both trials, patients were randomized to receive either the standard
regimen or the three-drug combination containing aprepitant. The studies were conducted in
cisplatin-naïve patients above 18 years of age who were scheduled to receive their first cycle of
chemotherapy including ≥ 50mg/m2 of cisplatin. The studies were used to determine the
probability of no acute emesis, no delayed emesis among those with no acute emesis and no
delayed emesis among those with acute emesis. Since the distribution of the study population
based on demographic characteristics was different for the two studies, the averages of the
probabilities obtained were used as base case estimates. For conducting sensitivity analyses, the
higher of the two estimates obtained from the two studies was used as the upper limit of the range
for the probability of no acute emesis. The lower limit of the range was set at the efficacy of the
standard regimen (74.2%) which includes the lower estimate obtained from the clinical trials and
also enable us to determine the robustness of the results if the benefit of the aprepitant regimen is
same as the standard regimen in the acute phase. The ranges for probabilities of no delayed
emesis given no acute emesis and no delayed emesis given acute emesis were based on the
individual estimates obtained from the two clinical trials.
The antiemetic drugs used for prophylaxis of acute emesis are same in regimens C and D.
The efficacy of the regimen for control of acute emesis was obtained from three randomized
controlled clinical trials (IGAR, 1995b, 1997, 1998a) and one observational study (IGAR,
2000a). The base case estimate of no acute emesis for regimens C and D was estimated to be
79.9%, calculated as the average of the individual estimates obtained from the four studies.
Similar to the range for regimen A, the upper limit was the highest estimate obtained from the
studies and the lower limit was set to be equal to the base case estimate of regimen B.
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The efficacy of regimen C in controlling delayed emesis was based on the published
results of two studies, one observational study and one multi-center, randomized double-blind
trial (IGAR, 1997, 2000a). The proportion of patients who do not have delayed emesis given that
they have control of acute emesis was calculated to be 73.55% and given that they have acute
emesis was 14.40%. The efficacy of regimen D in controlling delayed emesis was based on a
randomized, double blind trial conducted by the Italian Group for Antiemetic Research (IGAR,
1997).
Receiving Rescue Medications for Breakthrough Emesis
The base case probabilities for receiving rescue medications for breakthrough emesis and
the ranges used for sensitivity analyses are presented in Table 3-4. For regimens A and B, the
probability of receiving rescue medications following no acute emesis, acute emesis, no delayed
emesis and delayed emesis were obtained from calculations conducted using published data from
two randomized clinical trials of aprepitant (Hesketh et al., 2003; Poli-Bigelli et al., 2003). In
these two clinical trials, rescue medications were given for any degree of nausea or vomiting due
to chemotherapy. The receipt of rescue medications in the delayed phase was assumed to be
dependent on the prophylactic antiemetic regimen received for the delayed phase. The receipt of
rescue medications was assumed to be independent of the level of control of acute emesis or on
the receipt of rescue medications in the acute phase.
The clinical trials conducted to study the efficacy of regimens C and D (IGAR, 1995b,
1997, 1998a) stipulated the use of rescue medications only for patients with three or more
episodes of emesis whereas, the protocol of clinical trials for aprepitant and the standard regimen
stipulated that patients with any degree of nausea or vomiting could receive rescue medications
(Hesketh et al., 2003; Poli-Bigelli et al., 2003). Thus, for regimens C and D, the probability of
receiving rescue medications in the acute phase following no acute emesis and acute emesis is
assumed to be equal to that for regimen B. This assumption was made since the antiemetic drugs
for the acute phase are the same for the three regimens except for the difference in the dose of
ondansetron. The difference in the dose of ondansetron will not have an impact on the incidence
of emesis or use of rescue mediation since studies have shown that IV 8 mg offers similar acute
antiemetic efficacy as compared to IV 32 mg. In a randomized, double-blind clinical trial
conducted to determine the efficacy of regimens C and D for delayed emesis, rescue medications
were given for patients experiencing three or more emetic episodes in the delayed phase (IGAR
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1997). Due to lack of relevant and appropriate information in the included clinical trials, the
average of the corresponding estimates for regimens A and B were used.
For those who experience acute or delayed emesis, the probability of receiving rescue
medications was ranged from the lower limits obtained from the individual study estimates and
the higher limits were set at 100%, i.e. all patients in the cohort who experience emesis will
receive rescue medications. The lower limit of the range for sensitivity analyses for the
parameters: probability of receiving rescue medications given no acute emesis and no delayed
emesis were set at zero and the higher limit was set at the higher of the estimates obtained from
the included studies.
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Table 3-3: Base-Case Estimates and Sensitivity Analysis Ranges of Efficacy of Prophylactic Antiemetic Regimens for Acute and
Delayed Phase – For HE Model
Parameter

Baseline Estimate

Lower limit

Upper limit

References

Regimen A

0.870

0.742

0.900

1, 2

Regimen B

0.742

0.690

0.793

1, 2

Regimen C

0.799

0.742

0.832

3, 4, 5, 6

Regimen D

0.799

0.742

0.832

3, 4, 5, 6

Regimen A

0.830

0.793

0.866

1, 2

Regimen B

0.670

0.646

0.694

1, 2

Regimen C

0.736

0.733

0.738

4, 5

Regimen D

0.715

0.572

0.858

5

Regimen A

0.317

0.308

0.326

1, 2

Regimen B

0.154

0.122

0.185

1, 2

Regimen C

0.144

0.088

0.200

4, 5

Regimen D

0.286

0.228

0.343

5

No Acute Emesis

No Delayed Emesis Given No Acute Emesis

No Delayed Emesis Given Acute Emesis

References: 1. (P. J. Hesketh et al., 2003); 2. (Poli-Bigelli et al., 2003); 3. (IGAR, 1995b); 4. (IGAR, 2000a)
5. (IGAR, 1997); 6. (IGAR, 1998a)
Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4); Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4); Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral
Ondansetron 8 mg BID (Days 2-4)
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Table 3-4: Base-Case Estimates and Sensitivity Analysis Ranges for Receiving Rescue Medications for Uncontrolled CINV – For HE
Model
Parameter

Baseline Estimate

Lower limit

Upper limit

References

In the acute phase given no acute emesis
Regimen A

0.012

0.000

0.015

1, 2

Regimen B

0.012

0.000

0.015

1, 2

Regimen C

0.012

0.000

0.015

Assumed*

0.012

0.000

0.015

Assumed*

Regimen A

0.338

0.175

1.000

1, 2

Regimen B

0.394

0.304

1.000

1, 2

Regimen C

0.394

0.304

1.000

Assumed*

0.394

0.304

1.000

Assumed*

Regimen A

0.050

0.000

0.055

1, 2

Regimen B

0.028

0.000

0.035

1, 2

Regimen C

0.039

0.000

0.045

Assumed**

0.039

0.000

0.045

Assumed**

Regimen A

0.576

0.454

1.000

1, 2

Regimen B

0.531

0.477

1.000

1, 2

Regimen C

0.553

0.465

1.000

Assumed**

Regimen D

0.553

0.465

1.000

Assumed**

Regimen D
In the acute phase given acute emesis

Regimen D
In the delayed phase given no delayed emesis

Regimen D
In the delayed phase given delayed emesis

* Assumed based on the estimates for Regimen B as the acute phase antiemetics are same for the two regimens
** Assumed to be the average of estimates of regimen A and B.
References: 1. (P. J. Hesketh et al., 2003); 2. (Poli-Bigelli et al., 2003)
Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4); Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
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Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4); Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral
Ondansetron 8 mg BID (Days 2-4)
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Adverse Events due to Prophylactic Antiemetic Regimens
For the base-case model, it was assumed that the probability of experiencing adverse
events is similar between the four regimens. The probability of adverse effects due to regimen C
was modeled to conduct a scenario analysis. Thus for scenario analysis, only the adverse events
due to metoclopramide for regimen C were modeled and the adverse events due to the other three
regimens were assumed to be similar. The serious adverse reactions associated with the use of
metoclopramide are parkinsonism and/or other extrapyramidal reactions. These consist often of a
feeling of restlessness, facial spasms, involuntary movements and in some cases, muscular
twitching. Schnell and colleagues reported that five percent of patients receiving
metoclopramide will experience extrapyramidal symptoms (EPS) (Schnell, 2003). Based on their
database, Bleiberg and colleagues reported that 2.6% of patients had EPS due to metoclopramide
(Bleiberg, Autier, & Michaux, 1994). The average of the two estimates was used as the
probability of experiencing EPS in patients receiving regimen C. Extrapyramidal reactions have
been successfully controlled by antiparkinson and antihistamine/anticholinergic agents such as
25-50 mg of diphenhydramine hydrochloride. It was assumed that all patients experiencing EPS
will require treatment with diphenhydramine hydrochloride.
Probability of Outpatient Physician Visit due to Uncontrolled Emesis
The probability of uncontrolled emesis resulting in an outpatient physician visit or
inpatient hospitalization is very low. But since it involves a substantial amount of healthcare
resource utilization, the costs need to be modeled to provide an accurate representation of
management of CINV. The probability of requiring an outpatient visit for receiving intravenous
saline infusion and rescue medications was based on a structured interview conducted among an
expert panel consisting of three oncologists and three oncology nurses. The survey used for the
interview is included as Appendix I. Based on the responses obtained from the survey, the
probability of outpatient visits in the acute phase is extremely rare and 0.01 was used as the base
case probability. For sensitivity analysis, the probability was ranged from zero to 3% based on
the survey responses. Ihbe-Heffinger and colleagues (Ihbe-Heffinger et al., 2004) conducted a
study among German cancer centers and reported that 2.5% were hospitalized for dehydration
due to uncontrolled severe nausea and vomiting. Our survey respondents reported that
approximately 5% of patients may require additional care due to severe nausea and vomiting in
the delayed phase. Based on these estimates, the baseline probability of requiring outpatient
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physician visit for uncontrolled delayed emesis was estimated to be 3.5% and was ranged from
2%-5% for sensitivity analyses.
Probabilities for ME Decision Model
Efficacy of Alternative Prophylactic Regimens
The efficacy data represents the probability of achieving complete control of acute and
delayed emesis following administration of the four prophylactic antiemetic regimens. The base
case estimates for acute and delayed efficacy of the alternative regimens are shown in Table 3-5.
The table also includes the ranges that were used to conduct sensitivity analyses.
The efficacy data for regimens 1 and 2 were based on the published results of a multicenter, randomized, double blind, phase III trial conducted to study the antiemetic efficacy of
palonosetron in patients receiving moderately emetogenic chemotherapy (Gralla et al., 2003). In
this clinical trial, patients were randomized to receive either the standard regimen of a single IV
dose of ondansetron 32 mg or a single IV dose of palonosetron 0.25 mg. The study results were
used to determine the probabilities of no acute emesis, no delayed emesis among those with no
acute emesis, and no delayed emesis among those with acute emesis. The ranges for sensitivity
analysis of probabilities of no acute emesis and no delayed emesis among those with no acute
emesis were set at ±20% of the baseline probability estimates. If the probability exceeds 1.00,
the upper limit was reduced. The sensitivity analysis range for the probability of no delayed
emesis among those with acute emesis was ranged from 0.0 to 0.30. The upper limit of 0.30 was
chosen to test the robustness of the results if the probability was as high as the base case estimate
of regimen 3.
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Table 3-5: Base-Case Estimates and Sensitvity Analysis Ranges of Efficacy of Prophylactic Antiemetic Regimens for Acute and
Delayed Phase – For ME Model
Parameter

Baseline Estimate

Lower limit

Upper limit

References

Regimen 1

0.850

0.680

0.900

1

Regimen 2

0.720

0.576

0.864

1

Regimen 3

0.892

0.714

0.900

2, 3, 4, 5

Regimen 4

0.892

0.714

0.900

2, 3, 4, 5

Regimen 1

0.924

0.739

0.950

1

Regimen 2

0.812

0.649

0.950

1

Regimen 3

0.855

0.684

0.950

2, 4

Regimen 4

0.952

0.762

1.000

2

Regimen 1

0.133

0.000

0.300

1

Regimen 2

0.107

0.000

0.300

1

Regimen 3

0.300

0.000

0.568

2, 4

Regimen 4

0.568

0.300

0.682

2

No Acute Emesis

No Delayed Emesis Given No Acute Emesis

No Delayed Emesis Given Acute Emesis

References: 1. (R. Gralla et al., 2003); 2. (IGAR, 2004); 3. (Kaizer et al., 1994); 4. (IGAR, 2000c); 5. (Warr et al., 2005)
Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)

76

METHODOLOGY

Reema Mody

The antiemetic drugs used for prophylaxis of acute emesis are the same in regimens 3
and 4. The IGAR conducted a dexamethasone dose-finding study among patients receiving
moderately emetogenic chemotherapy (IGAR, 2004). One of the study arms employed a
combination of 8mg IV ondansetron and 8 mg IV dexamethasone as the prophylactic acute
antiemetic regimen. The results for this study arm were used as the baseline estimates for the
probability of no acute emesis for regimens 3 and 4. The range for sensitivity analyses were
set at ±20% of the baseline probability estimates. This range included the individual
estimates obtained from the results of three randomized controlled clinical trials that employ
the same regimen with different dosing schedules (IGAR, 2000c; Kaizer et al., 1994; Warr et
al., 2005)
The efficacy of regimen 3 in controlling delayed emesis was based on the published
results of two randomized clinical trials (IGAR, 2000c, 2004). The results obtained from one
study arm of a randomized clinical trial (IGAR, 2004) were used as baseline estimates for the
probability of no delayed emesis given no acute emesis and probability of no delayed emesis
given acute emesis for regimen 3. The range for sensitivity analysis was set at ±20% of the
baseline probability estimates, which included the individual estimates obtained from the two
studies for the probability of no delayed emesis given no acute emesis. For the probability of
no delayed emesis given acute emesis the lower limit was set at 0.00 and the baseline
estimate of regimen 4 was set as the upper limit. This range included the individual estimates
obtained from the two randomized clinical trials. The efficacy of regimen 4 in controlling
delayed emesis was based on a randomized, double blind trial conducted by the Italian Group
for Antiemetic Research (IGAR, 2000c). The range for the sensitivity analyses was set at ±
20% of the baseline estimates.
Receiving Rescue Medications for Breakthrough Emesis
The base case probabilities for receiving rescue medications for breakthrough emesis
and the ranges used for sensitivity analyses for the ME model are presented in Table 3-6.
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Table 3-6: Base-Case Estimates and Sensitivity Analyses Ranges for Receiving Rescue Medications for Uncontrolled CINV – For
ME Model
Parameter

Baseline Estimate

Lower limit

Upper limit

References

In the acute phase given no acute emesis
Regimen 1

0.047

0.000

0.104

1

Regimen 2

0.047

0.000

0.104

1

Regimen 3

0.104

0.000

0.125

2

0.104

0.000

0.125

2

Regimen 1

0.300

0.240

1.000

Assumed

Regimen 2

0.300

0.240

1.000

Assumed

Regimen 3

0.523

0.300

1.000

2

0.523

0.300

1.000

2

Regimen 1

0.074

0.000

0.100

1

Regimen 2

0.097

0.000

0.120

1

Regimen 3

0.085

0.000

0.120

Assumed*

0.085

0.000

0.120

Assumed*

Regimen 1

0.500

0.400

1.000

1

Regimen 2

0.472

0.378

1.000

1

Regimen 3

0.486

0.389

1.000

Assumed*

Regimen 4

0.486

0.389

1.000

Assumed*

Regimen 4
In the acute phase given acute emesis

Regimen 4
In the delayed phase given no delayed emesis

Regimen 4
In the delayed phase given delayed emesis

* Assumed to be the average of estimates of regimen 1 and 2. References: 1. (R. Gralla et al., 2003); 2. (Warr et al., 2005)
Regimen 1: IV Palonosetron 0.25mg; Regimen 2: IV Ondansetron 32mg; Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID
(Days 2-5); Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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For regimens 1 and 2, the probability of receiving rescue medications following no acute
emesis, no delayed emesis, and delayed emesis were obtained from calculations conducted using
published data from a randomized clinical trial of palonosetron (Gralla et al., 2003). The receipt
of rescue medications following acute emesis was assumed to be 0.30 for regimens 1 and 2.
For regimens 3 and 4, the probability of receiving rescue medications in the acute phase
following no acute emesis and following acute emesis, was assumed to be equal because it was
the same acute phase antiemetic regimen. This probability was obtained from a randomized
controlled trial (Warr et al., 2005). Due to lack of relevant data in the published literature, the
average of the probability estimates of regimens 1 and 2 were used as baseline estimates for
receiving rescue medications in the delayed phase following no delayed emesis and delayed
emesis.
For those patients who experience acute or delayed emesis, the probability of receiving
rescue medications was ranged from the lower limits calculated as -20% of baseline and the
upper limits were set at 1.00, i.e. all patients in the cohort who experience emesis will receive
rescue meds. The lower limit of the range for sensitivity analyses for the parameters: probability
of receiving rescue medications given no acute emesis and no delayed emesis were set at zero
and the higher limit was set at +20% of the baseline estimates.
Adverse Events due to Prophylactic Antiemetic Regimens
The 5HT3RAs including palonosetron have been found to have a favorable side effect
profile as compared to some of the older antiemetic agents such as metoclopramide. A
randomized double-blind controlled clinical trial conducted to determine the efficacy and safety
of palonosetron compared to ondansetron, found no significant differences in the proportion of
treatment-related adverse events in the two groups (Gralla et al., 2003). The prophylactic
antiemetic regimens used for prevention of CINV in the ME model were comprised of similar
individual antiemetics and thus it was assumed that the probability of experiencing adverse
events is similar between the four regimens. Thus, adverse events were not modeled for the ME
model.
Probability of Outpatient Physician Visit due to Uncontrolled Emesis
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The probability of uncontrolled emesis resulting in an outpatient physician visit or
inpatient hospitalization is very low. However, because it involves a substantial amount of
healthcare resource utilization, the costs need to be modeled to provide an accurate representation
of management of CINV. There is no reason to believe that the probability of outpatient
physician visits due to uncontrolled emesis will be dependent on the type of chemotherapy
received. The probability is more likely to depend only on the level of uncontrolled emesis
experienced by the patients. Thus, for this study, it is assumed that the probability of receiving
outpatient physician visits is similar to those for the HE model and also similar for all treatment
strategies.
Cost Estimates for the Decision Models
Direct Costs
The direct costs for the model included the costs of prophylactic antiemetic regimens,
drug administration, rescue medications for managing breakthrough emesis, outpatient care for
uncontrolled emesis and treating adverse events of antiemetic regimens.
Costs of Prophylactic Antiemetic Regimens
The drug costs for prophylactic antiemetic regimens, rescue medications and medications
to treat side effects were obtained from the Drug Topics Red Book (Red Book, 2005). The Red
Book lists the average wholesale price (AWP) for virtually every medicine prescribed. For drugs
which are available in generic forms, the average of the highest and lowest prices was used as the
drug cost. The unit costs for the various antiemetic agents and rescue medications are provided
in Table 3-7.
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Table 3-7: Unit Costs for Individual Antiemetic Drugs Used in the Decision Models
Base case
cost

Upper limit

Lower Limit

Aprepitant 125 mg

$108.77

$87.02

$130.52

Aprepitant 80 mg

$100.12

$80.10

$120.14

IV Ondansetron 32 mg

$206.41

$165.13

$247.69

IV Ondansetron 8 mg

$51.28

$41.02

$61.54

Oral Ondansetron 8 mg

$36.72

$29.38

$44.06

IV Dexamethasone 20 mg

$4.04

$1.31

$6.60

Oral Dexamethasone 4 mg

$1.57

$0.67

$2.33

IM/IV Dexamethasone 8 mg

$4.15

$1.34

$4.66

Oral Metoclopramide 20 mg

$1.43

$0.55

$3.22

$340.20

$272.16

$408.24

Oral Prochlorperazine 10 mg

$0.82

$0.58

$1.07

Oral Promethazine 25 mg

$0.52

$0.45

$0.59

Oral Lorazepam 1mg

$1.01

$0.57

$1.32

Drug
Prophylactic Antiemetic Drugs

IV Palonosetron 0.25mg
Rescue Medications
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For antiemetic drugs that were administered as infusion, administration costs were added
to the treatment costs. The administration costs were based on the G codes published by
Medicare for reimbursement (Department of Health and Human Services, 2004). The
reimbursement values for drug administration are appropriate for CEA conducted from the
payer’s perspective but not for the societal perspective. For the societal perspective, the actual
costs incurred for administering the antiemetic drugs should be used for the analysis. However, in
most cases the actual costs are not publicly available and the reimbursed charges are most
commonly employed. Thus, the Medicare reimbursement values have been used in this study for
CEA conducted from the societal perspective. The base case value is ranged between ± 20% to
conduct sensitivity analyses. The cost of prophylactic antiemetic regimens, administration costs
and the total treatment costs for the various strategies are shown in Tables 3-8 and 3-9.
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Table 3-8: Cost of Prophylactic Antiemetic Regimens Used in the Decision Analysis Model For HE Model
Costs

Regimen A

Regimen B

Regimen C

Regimen D

Prophylactic
antiemetic drugs

$530.00 (±20%)

$233.10 (±20%)

$93.23 (±20%)

$296.39(±20%)

Administration

$58.95 (±20%)

$58.95 (±20%)

$86.67 (±20%)

$86.67 (±20%)

Total Regimen

$588.50 (±20%)

$292.05 (±20%)

$179.90 (±20%)

$383.06 (±20%)
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Table 3-9: Cost of Prophylactic Antiemetic Regimens Used in the Decision Analysis Model For ME Model
Costs

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Prophylactic
antiemetic drugs

$340.20 (±20%)

$206.41 (±20%)

$67.99 (±20%)

$361.75 (±20%)

Administration

$58.95 (±20%)

$58.95 (±20%)

$86.67 (±20%)

$86.67 (±20%)

Total Regimen

$399.15 (±20%)

$265.36 (±20%)

$154.66 (±20%)

$448.42 (±20%)
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Costs of Managing Breakthrough Emesis
The rescue medications prescribed for breakthrough emesis were based on the 2005
NCCN guidelines. In previous economic evaluations it was assumed that patients will
experience on average two emetic episodes during a 24-hour time period and thus two doses of
rescue medications will be provided each day (Johnson & Bosanquet, 1995; Kwong &
Parasuraman, 1999). The base case analysis in this study was conducted assuming that patients
are prescribed prochlorperazine (Compazine) twice a day for one day for breakthrough emesis
during the acute phase and four times a day for two days during the delayed phase. The costs and
benefits were calculated for two scenarios where the drugs used for managing breakthrough
emesis in delayed phase were changed to a 5-HT3RA for regimens B and C. This is because the
prophylactic regimen for delayed phase does not include a 5-HT3RA and it may be preferred
instead of prochlorperazine for managing breakthrough emesis.
Based on unstructured interviews with oncology nurses at the cancer center it was found
that nurses conduct follow-up phone calls with patients to inquire about side effects of
chemotherapy. It was assumed that all patients who received rescue medications during the
delayed phase would spend a minimum of 15 minutes on the phone with the nurse to relate CINV
events. The hourly wage rate for registered nurses was multiplied with the time taken on the
phone to calculate the personnel costs associated with managing breakthrough emesis. The costs
for managing breakthrough emesis are presented in Table 3-10.
For patients that require additional care for extreme CINV event, it was assumed that the
patient will come for an outpatient visit and will require intravenous infusion of saline and rescue
antiemetic medications. It was assumed that the probability of requiring additional outpatient care
does not differ based on the prophylactic antiemetic regimen received.
Indirect Costs Associated with Management of CINV
Indirect costs associated with CINV were included to capture the impact of potential
savings associated with control of CINV with each treatment. O’Brien and colleagues (O'Brien et
al., 1993) conducted a study in five Canadian cancer centers to determine the costs associated
with CINV. The study reported a total loss of 198 hours of paid employment, 409 hours of
unpaid employment, and 186 hours of caregiver time among 72 patients who experienced emesis.
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Based on this study, we assumed that the patient’s average time away from paid or unpaid work
was 11.00 hours (the total of time away from employment – 793 divided by 72 patients). The
time away from work due to uncontrolled CINV was valued using the adult average wage rate
obtained from the Bureau of Labor Statistics (US Department of Labor, 2005). The base case
estimate was varied between 2.75 hours (estimated using only loss of paid employment) and 24
hours (3 days) of lost employment for conducting sensitivity analyses.
For the CEA conducted from the payer perspective, direct total cost included the cost of
the total regimen, cost associated with managing breakthrough emesis, cost of outpatient care for
uncontrolled emesis and cost of treating adverse events of antiemetic agents. The indirect costs
were added to the direct total costs for CEA conducted from the societal perspective.
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Table 3-10: Costs of Managing Breakthrough Emesis
Resources

Unit Costs

Upper Limit

Lower Limit

$0.82

$0.58

$1.07

$26.61/hour

$21.29/hour

$31.93/hour

$0.99

$0.79

$1.19

Rescue Medications
Oral Prochlorperazine 10 mg
Total Personnel costs (For delayed phase)
Average Salary – Registered Nurse
Total Cost of Outpatient Visit
Saline Infusion 1000cc

$48.98

$39.18

$58.78

st

$64.8

$51.84

$77.76

nd

$41.38

$33.10

$49.66

Physician Outpatient Visit
Administration cost for saline (1 hr)
Administration cost for saline (2 hr)
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Model Assumptions and Rationale
1. In clinical practice, agents such as lorazepam, prochlorperazine or promethazine are
prescribed in combination with the prophylactic antiemetic regimens included in the decision
models for prevention of CINV. It was assumed that the effectiveness, toxicity and cost of
these additional drugs will be consistent across the alternative treatment strategies and thus
have not been included in the model.
2. Lindley and colleagues have reported the level of compliance with three-single drug
antiemetic regimens in patients receiving moderately high to highly emetogenic
chemotherapy (Lindley et al., 2005). The study results showed no significant differences in
the level of compliance among patients receiving prochlorperazine (83%), dexamethasone
(85%) and ondansetron (80%). Currently, there is a lack of information on the level of
compliance with combination antiemetic regimens and whether it differs based on the type of
chemotherapy received by the patients. For this study, it was assumed that patients have
100% compliance with the antiemetic regimens in the acute and delayed phase. Thus, any
incidence of emesis in the acute or delayed phase was not due to non-compliance but a result
of lack of efficacy by the prophylactic antiemetic regimen.
3. The incidence of delayed emesis is known to be dependent on the level of control in the acute
emesis and the prophylactic antiemetic regimens prescribed (IGAR, 1994; Schnell, 2003).
The incidence of delayed emesis was assumed to be independent of the receipt of rescue
medications or additional outpatient care in the acute phase. The receipt of rescue
medications or outpatient care in the delayed phase is assumed to be dependent only on the
incidence of emesis in the delayed phase and independent of the type of prophylactic
antiemetic regimen received. The probability of receipt of rescue medications and outpatient
care for each regimen is varied in sensitivity analyses to test the robustness of the study
results.
4. Ideally, failures (patients who experience emesis/nausea/emesis and nausea) should be
assessed by the average number of emetic episodes per patient per treatment. Since all
clinical trials do not provide the average number of emetic episodes experienced per patient
explicitly, it is assumed that patients experience two emetic episodes on average in each 24
hours. It was also assumed that two doses of rescue medications will be required in 24 hours
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for all the treatment arms (Johnson & Bosanquet, 1995; Kwong & Parasuraman, 1999). For
uncontrolled delayed emesis, it was assumed that patients receive rescue medications for two
days. The estimates of number of doses of rescue medication and number of days were
varied in sensitivity analyses to test the robustness of the CEA results.
5. It was assumed that patients will either receive or not receive rescue medications for control
of emesis or nausea and were assumed to have achieved control of emesis/nausea/both
emesis and nausea if subsequent outpatient care is not required.
6. Only costs due to lost productivity during the delayed phase were included in the model as
the indirect costs. The workday lost during the acute phase is not included in the indirect cost
estimates as it is incurred by all patients irrespective of the treatment received.
7. The costs incurred by patients in hiring additional help for child care, home care or caregiver
costs were not included in the model. The out-of-pocket costs for managing nausea and
vomiting which may include cleaning costs, laundering soiled clothes were not included in
the model. These costs will be based on the number of emetic episodes experienced by the
patients and in our model, this was assumed to be similar for all treatment strategies. Thus,
increasing the costs by the same amounts in all the treatment arms would not affect the ICER
calculations.
8. Patients may use over the counter medications for treating nausea and vomiting and it is
assumed that the usage will be similar in all the treatment arms. Since the costs and benefits
associated with these medications are assumed to be the same in all arms, their inclusion will
not affect the ICER calculations and are not included in the model.
9. For the HE model, only the side effects due to metoclopramide were modeled. It was
assumed that the adverse events in the other regimens due to the individual antiemetics will
be similar. Thus incorporating the costs for treating adverse events by the same amounts in
all the treatment arms will not affect the ICER calculations.
Base-case Cost Effectiveness Analysis
Decision models can be evaluated using either cohort simulation or first-order simulation
model. In the first-order Monte Carlo simulation, a large number of patients are followed

89

METHODOLOGY

Reema Mody

through the model individually. A single patient is randomly selected and will randomly select a
path at each change node in the decision model based on the probability of each outcome. The
path followed by different patients will differ based on chance. Due to the process being
repeated for a large number of times, first-order Monte Carlo simulation models can be used to
estimate the sample mean and standard deviation associated with the costs and effects in each
arm of the model.
The base case analysis represents the average costs and effectiveness for a hypothetical
cohort of 10,000 patients. The baseline model was analyzed using a first-order Monte Carlo
simulation and this helps in determining the uncertainty associated with the derived costs and
outcomes. The average costs and effectiveness obtained were then used to calculate the
incremental cost-effectiveness ratio (ICER) for each treatment strategy. The ICER for a treatment
strategy is calculated as the additional cost per completely controlled patient relative to the next
most costly option. These analyses were performed for both HE and ME models from the payer
and the societal perspective.
Sensitivity Analyses
Sensitivity analysis is a means of assessing the extent to which the incremental costs and
incremental effectiveness of the alternative regimens are affected by parameter uncertainty and
model assumptions (Briggs, Sculpher, & Buxton, 1994). There are multiple methods which can
be used to conduct sensitivity analysis: one-way, two-way, multi-way, threshold analysis and
probabilistic sensitivity analyses (Briggs et al., 1994). In this study, one way sensitivity analyses
were conducted, in which each critical study parameter was varied over a plausible range to
evaluate key assumptions and test the robustness of the model.
Although, one-way sensitivity analyses are easy to understand, incremental costs and
effectiveness do not depend on single parameters. Probabilistic sensitivity analysis is a method
by which all parameters can be varied simultaneously to understand the overall impact on
incremental costs and effectiveness (Agro et al., 1997; Briggs, Goeree, Blackhouse, & O'Brien,
2002). Probabilistic sensitivity analysis (second-order Monte Carlo simulation) was conducted to
assess the impact of simultaneous variations in the distribution of important variables around
their point estimates. In second-order Monte Carlo simulation each parameter with a specified
range is associated with a distribution function and repeated samples are drawn at random from
these distributions to determine empirical distribution of cost-effectiveness ratio for each
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treatment strategy (Shaw & Zachry, 2002). The simulation can be run to generate hundreds of
scenarios of different combinations of input variables and generate the output values for a
strategy. Probabilistic sensitivity analysis provides superior information since it uses
distributions of input values instead of just a single mean value.
3.2: Phase II: Willingness-to-Pay and Cost-Benefit Analyses
The objectives of phase II are 2.1) to determine the monetary value placed on improved
emesis control due to addition of aprepitant to the standard regimen following administration of
HE chemotherapy using WTP method, 2.2) to determine the monetary value placed on improved
emesis control with the introduction of palonosetron instead of the standard regimen following
administration of ME chemotherapy using WTP method, 2.3) to determine the association
between maximum WTP for improved emesis control following HE chemotherapy and
respondents’ demographic and clinical characteristics, 2.4) to determine the association between
maximum WTP for improved emesis control following ME chemotherapy and respondents’
demographic and clinical characteristics, 2.5) to determine the net benefit of addition of
aprepitant to the standard antiemetic regimen for prevention of CINV due to HE chemotherapy
and 2.6) to determine the net benefit of palonosetron as the antiemetic drug for prevention of
CINV due to ME chemotherapy. In order to achieve the Phase II objectives, primary data will be
collected using a survey. The study population, survey instrument, data collection process and
the statistical techniques for Phase II are described below.
WTP Elicitation Using Contingent Valuation (CV) Method
WTP is based on the premise that the maximum amount of money an individual is
willing to pay for a commodity is an indicator of the utility or satisfaction to them of that
commodity. The contingent valuation (CV) method was used to assess consumers’ WTP for a
program. It is a direct measurement of WTP using a survey-based approach to elicit monetary (in
this case, dollar) values by presenting hypothetical scenarios about the healthcare intervention
under evaluation. The following section describes the methodology employed for measuring
patients’ WTP for 1) improved emesis control due to addition of aprepitant (new drug) to the
antiemetic regimen (5HT3 RA + dexamethasone) following HE chemotherapy – Scenario 1 and
2) improved emesis control due to the new drug palonosetron compared to the antiemetic
regimen (5HT3 RA + dexamethasone) following ME chemotherapy – Scenario 2. The main
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purpose of determining the WTP is to use the monetary valuation of benefits of antiemetic
regimen for conducting CBA of the emerging antiemetic regimens for preventing CINV
following HE and ME chemotherapy from a payer perspective.
The CV method was used to value the benefits offered by the two antiemetic agents. For
the purpose of this study, WTP was determined from the ex-post/user-based perspective. The
multiple uncertainties and use of compound probabilities involved in the ex-ante perspective can
pose a substantial cognitive burden for the respondents. Also, patients who are experiencing the
condition are considered to be the best candidates to provide the value of benefits provided by the
health interventions. For the purpose of this study, out-of-pocket payment was chosen as the
payment vehicle, as it is an appropriate approach for estimating WTP for pharmaceuticals using
the user-based perspective. A payment card format was employed to determine the maximum
WTP for improved emesis control for the two scenarios, HE chemotherapy and ME
chemotherapy. WTP can be asked in the various formats (explained in chapter 2) but each
method is susceptible to a number of potential biases. Range bias in payment scale format has
been assessed but it was not found to be a significant factor (Ryan et al., 2004). Since the
payment card method provides a format where the consumer can “shop around” for a value that
they would most likely pay which is close to a realistic scenario, it was the format of choice in
this study.
Study Population, Sample selection and Sample Size Estimation
Study Population
Population is an aggregation of study elements. In most cases, it is practically impossible
to survey the entire population. The survey sample is a subset of the population that is used to
gain information about the entire population. For the user-based perspective, the survey sample
can be drawn either from cancer patients or from the general population who are provided with
hypothetical scenarios where respondents are asked to assume that they have cancer.
The population for Phase II of this study was cancer patients recruited from the Mary
Babb Randolph Cancer Center (MBRCC) in Morgantown, WV. Patient preferences may be
preferred when an analysis is designed to evaluate alternative interventions for the same
condition and is not primarily intended for resource allocation decisions over a wide range of
illness. A patient population is appropriate for this study, since the purpose of our study is to
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assess the most efficient way to create health given a defined condition, i.e. CINV and a selection
of treatment choices, i.e. antiemetic regimens.
Sample Selection
Patients with cancer who were 18 years or older in age and receiving their first or
subsequent cycle of chemotherapy, or who have received chemotherapy in the past three months
in an outpatient setting were eligible to participate in the study. Eligible participants should be
able to understand and speak English. Also, based on the discretion of the oncologist or the
oncology nurses, patients with cognitive impairment were excluded from the study.
Sample Size Estimation
The sample size for the study was based on the number of patients required to detect a
minimum mean difference in willingness to pay of $30 for both the scenarios. The population
standard deviation required for sample size calculation was obtained from a pilot study conducted
among 20 patients. The details of the pilot study are discussed later. The sample size required
for the study was determined using the PASS 6.0 software. By accepting α = 0.05 (i.e., the
probability of type I error is 5%), β = 0.15 (i.e., 85% detection power), standard deviation =
$100.00, and a minimum difference in maximum WTP between the alternative regimens for
Scenario 1 and Scenario 2 = $30, the estimated sample size required for the study would be 100
patients.
Recruitment Procedures and Data Collection
Approval for the survey instrument and the script for recruitment of participants were
sought from the Institutional Review Board of West Virginia University. The oncologist or the
oncology nurse approached eligible participants and explained the purpose of the study. The
primary researcher described the study in detail and verbal consent was obtained, if patients were
interested in participating in the study. The script for approaching and recruitment of patients for
the study is attached as Appendix II.
Data collection can be done by face-to-face interviews, self-administered surveys, mail
surveys or telephone interviews. In this study, data were collected by conducting face-to-face
interviews with the patients when they come to the cancer center for regular check-ups, or for
receiving chemotherapy. There is agreement in the literature that face-to-face interviewing is the
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most preferred and reliable method for WTP elicitation (National Oceanic and Atmostpheric
Administration, 1993);(Mitchell & Carson, 1989). Face-to-face interviewing allows for
presenting the maximum amount of information, provides an opportunity for respondents to
consider their response and for reducing the potential for hypothetical bias (Smith et al, 1999b;
(Olsen & Smith, 2001). On completion of the interview, the participants were presented with a
West Virginia University souvenir mug as a token of appreciation for their time and effort. Data
was collected over a period of four months from mid-January to mid-May, 2005.
WTP Instrument Development
The WTP survey was developed by obtaining information from the published literature
and a multidisciplinary team of oncologists, a clinical pharmacist, health services researchers and
a health economist. Two versions of the survey were used, differing only in the order of
presentation of the two hypothetical scenarios. In Version A, the HE chemotherapy scenario was
presented first, followed by the ME chemotherapy scenario, whereas in Version B, the order was
reversed. Participants were alternately assigned to the two versions of the survey. The survey
has five sections and is presented as Appendix III. The global approach was used to construct the
scenarios for WTP elicitation.
The first section of the survey attempted to standardize the knowledge base of
participants by presenting information on chemotherapy, description of nausea and vomiting, risk
of emesis following chemotherapy, and standard treatment used to prevent emesis. Section two of
the survey was designed to collect information about clinical characteristics, such as type of
cancer, prior experience with chemotherapy, prior experience of nausea and vomiting due to
chemotherapy, severity of nausea experienced and number of emetic episodes during acute and
delayed phases.
Patients were told at the beginning of the session that the scenarios presented were
hypothetical and did not relate to their own personal situation. Sections three and four of the
survey include the description of the two clinical scenarios and all the relevant information about
the antiemetic regimens. The two scenarios differ in the type of chemotherapy received by the
patients, and prophylactic antiemetic regimens compared. The actual names of the new drugs or
the standard treatment were not used for scenario descriptions. In scenario 1, patients were asked
to imagine that they are receiving HE chemotherapy which causes acute emesis in greater than
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99% of patients and delayed emesis in greater than 75% of patients. This was followed by the
description of the standard antiemetic regimen and the new regimen (standard regimen with
aprepitant) for prevention of CINV following HE chemotherapy. In Scenario 2, patients were
asked to imagine that they are receiving ME chemotherapy which causes acute emesis in 30-90%
of patients and delayed emesis in 55% of patients. This was followed by the description of the
standard antiemetic regimen and the new regimen (palonosetron) for prevention of CINV
following ME chemotherapy.
After information about each scenario was presented, respondents were asked whether
they prefer the new regimen compared to the standard regimen for each scenario and the reasons
for their preferred choice. This was followed by eliciting information about how important they
considered the acute and delayed risk reduction due to the new regimens on a scale of 0 to 10,
where 0 is not at all important and 10 is very important. Respondents were asked to imagine that
the new antiemetic regimens will not be covered by their drug insurance plans. They were asked
to indicate the maximum amount that they would be willing to pay out-of-pocket for improved
emesis control (reduction in acute emesis from 30% to 17% and delayed emesis from 55% to
37%) due to addition of a three-day regimen of aprepitant to the standard regimen in scenario 1.
Similarly, respondents were asked to indicate the maximum amount that they would be WTP out
of pocket for improved emesis control (reduction in delayed emesis from 45% to 33%) for a
single day treatment with palonosetron instead of the standard regimen. The maximum WTP was
determined using the payment card method. The payment card had a range of WTP amounts that
were obtained by conducting a pilot survey of the instrument in 20 patients.
Many people are not willing to forgo any money for health gains because either they are
opposed to paying for health or they oppose the suggestion of paying out of pocket or increase in
taxes or insurance premiums. The protest is typically expressed as zero responses but sometimes
may be excessively high amounts. For respondents who provided $0 as the maximum WTP, it is
important to determine whether it is “genuine” valuation of the benefits of the intervention or a
“protest” zero. A follow-up question was asked to respondents who provided $0 as WTP to
determine if it was a protest zero or a genuine zero. Respondents were also asked to record the
level of difficulty they had in understanding the hypothetical scenarios and to provide a
maximum WTP amount. The time taken to complete the interview was also recorded.
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Section 5, the last section of the survey was designed to obtain demographic information
such as age, gender, education, marital status, employment status, number of members in the
household, annual income before taxes, and insurance status.
Instrument Validation
Questionnaire Validity
The survey was reviewed by a multidisciplinary team of an oncologist, a clinical
pharmacist and health outcomes researchers to assess its content validity. The qualitative
feedback obtained from the team regarding the relevance of questions, clarity of questions and
response options were was used to modify the survey. Based on the feedback, the efficacies of
the regimens described in the hypothetical scenarios were presented using pie charts. The
modified survey was then used to conduct a pilot study. The construct validity of the final survey
was assessed by testing the positive relationship between income levels and WTP amounts,
which is discussed in the data analysis section.
Pilot Study
A pilot study was used to determine the range for the payment card method and to
establish the time taken to complete the survey. The other goals of the pilot study were to assess
the respondents’ level of understanding of the scenarios and WTP questions. The study was
conducted among 20 cancer patients who were receiving chemotherapy or had received in the
past three months. In the pilot study, the patients were presented with open-ended question to
elicit their maximum WTP for the improved emesis control due to the new antiemetic regimen.
A range for the payment card for the final survey was created from the responses of the pilot
survey.
Data Handling and Data Analysis
The principal investigator was responsible for obtaining, organizing, analyzing and
maintaining the data. The first two objectives (2.1 and 2.2) of Phase II of the study are to
determine the maximum amount that patients with cancer are WTP for improved emesis control
for both scenarios. The actual amount marked on the payment card range was considered as the
maximum WTP amount. Summary WTP is usually presented as the mean and/or median.
Though, the mean is sensitive to the shape of the distribution and less robust than the median, it
is theoretically the correct measure of benefits for conducting a CBA. It is recommended that
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mean WTP along with the range of values should be presented as a summary welfare measure in
WTP studies (Smith, Olsen, & Harris, 1999c). In this study, WTP estimates for scenario 1 and
scenario 2 have been presented as means and medians. The average WTP estimates for the entire
sample, sample excluding all zeroes and sample excluding only the protest zeroes are reported.
Demographic and clinical characteristics of the sample are presented as means, medians or
proportions. Appropriate statistical tests were conducted to determine the differences in mean
WTP amount based on demographic and clinical characteristics.
Objectives 2.3 and 2.4 involve determining the association between WTP for improved
emetic control and patients’ demographic and clinical characteristics for both scenarios. Based
on the manner in which the WTP data is treated, different regression models can be employed to
study the association between WTP and respondent characteristics. Some researchers consider
the WTP data obtained from payment card method as censored data and the use of OLS models
for censored dependent variable violates the assumption that the error term is normally
distributed (Cameron & Huppert, 1989; Donaldson, Jones, Mapp, & Olsen, 1998). To overcome
the problems with OLS models, researchers have explored the use of grouped data regression
models to determine association of WTP with respondent characteristics (Donaldson et al., 1998).
Another method is to consider the maximum WTP amount indicated on the payment scale as a
continuous variable and use it as a dependent variable for ordinary least squares (OLS) regression
models.
Usually, studies employing payment card for WTP elicitation instructs the respondent to
circle an amount in the range provided that is closet to their maximum WTP amount. In this
case, the maximum WTP amounts are restricted by the ranges provided and grouped regression
models should be used for analyses. However, in this study, the respondents were instructed to
specify the exact WTP amount if the amount they wish to circle was not shown in the payment
card range. Thus, the maximum WTP amounts are not restricted by the limited range provided
and can be considered as continuous variable and OLS models can be used to determine the
association of WTP and respondent characteristics. A number of studies employing payment
card method have used OLS regression model for the purpose of determining the association
between WTP and annual household income level (Davey et al., 1998; Dranitsaris, 1997;
Dranitsaris et al., 2001a; O'Brien, Novosel, Torrance, & Streiner, 1995). Also, in practice, OLS
may provide a robust estimator of the mean WTP (Donaldson et al., 1998).
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If the observed WTP amount indicated on the payment scale has a skewed distribution,
regression analyses with logarithmic of WTP as dependent variable will be performed.
Multivariable regression models were performed for the sample with positive WTP values. All
statistical analyses were conducted in SPSS Version 13.0.
Cost-Benefit Analyses of Antiemetic Regimens
The last two objectives (2.5 and 2.6) of Phase II involve conducting CBA for determining
the net benefit of using the new regimens instead of the standard regimens for prevention of
CINV following HE and ME chemotherapy. The CBA were conducted from the payer
perspective.
Calculation of Net Benefit
Cost benefit analysis is an economic evaluation method where the costs and benefits of
the health care intervention are valued in monetary terms. The analytic time period of the CBA
model is one chemotherapy cycle and a payer perspective will be undertaken. WTP amounts
were used as monetary measures of improved emesis control, i.e. incremental benefits of the new
antiemetic regimens over the standard regimens for prevention of CINV following HE and ME
chemotherapy. The cost parameters for the cost-benefit model were calculated as the incremental
cost of the new antiemetic regimen compared to the standard regimen. Costs from a payer
perspective will include the acquisition cost of prophylactic antiemetic regimens. The net benefit
of the intervention is calculated as the difference of incremental costs and benefits of the new
antiemetic regimen compared to the standard regimen.
Net Benefit = Incremental benefits (valued as WTP) – Incremental costs
Sensitivity Analysis
One-way sensitivity analyses were conducted to test the robustness of the study results.
The average WTP amounts were varied between the ±95% confidence limits of the WTP
estimates. The impact of changes in the incremental costs of the antiemetic regimens on the net
benefit was also studied.
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CHAPTER FOUR

RESULTS

4.1: Results for Phase I
Phase I of the study involved constructing decision models to outline the costs and
benefits associated with prophylactic antiemetic regimens for prevention of chemotherapyinduced nausea and vomiting (CINV) following highly emetogenic (HE) and moderately
emetogenic (ME) chemotherapy. This section presents the results on total costs, total
effectiveness and incremental cost-effectiveness ratios (ICER) of the different antiemetic
regimens incorporated in the decision model.
For Highly Emetogenic Chemotherapy Decision Model – Base Case Analysis
Base Case Analysis Results – Without Side Effects of Regimens
A decision model was constructed to evaluate the total costs and benefits of four
prophylactic antiemetic regimens for prevention of CINV due to HE chemotherapy (Refer Table
3-1). A hypothetical cohort of 10,000 cancer patients receiving HE chemotherapy was evaluated
using first-order Monte Carlo simulation. The base case analysis was conducted based on the
assumption that the probability of side effects due to regimen C is zero. The analysis was also
performed for the decision model where the probability of side effects for regimen C was
modeled and the results are reported later in the chapter. The costs from the payer’s perspective
include only the direct costs whereas both direct and indirect costs are included in the societal
perspective.
The base case results for the costs, effectiveness, direct cost of achieving one patient with
complete protection from emesis and the ICER for each of the four antiemetic regimens from the
payer perspective are reported in Table 4-1.
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Table 4-1: Base Case Results from Payer Perspective using Monte Carlo Simulation of 10,000 Patients with Cancer Receiving
Highly Emetogenic Chemotherapy – Side Effects Not Modeled
Side Effects Not Modeled

Treatment Strategy
Direct Costs
Mean (SD)

Effectiveness
Mean (SD)

Cost of achieving one
patient with complete
control of emesis

Incremental cost effectiveness
ratio/patient with complete control
of emesis

Regimen C (Metoclopramide)

$187.18 ($33.37)

0.555 (0.497)

$337.26

-

Regimen B (Standard)

$300.53 ($36.69)

0.478 (0.499)

$628.72

Dominateda

Regimen D (Ondansetron)

$389.97 ($32.29)

0.539 (0.498)

$723.51

Dominateda

Regimen A (Aprepitant)

$593.45 ($27.02)

0.676 (0.468)

$877.88

$3,363.181/patient with complete
control of emesis

Payer Perspective

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
a

Dominated by regimen C
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Regimen C, which includes metoclopramide as one of the antiemetic agents in the
delayed phase, was the least expensive ($187.18 per patient for a period of 5 days) and regimen
A (regimen with aprepitant) was the most expensive antiemetic treatment ($593.45) from the
payer perspective. The direct costs of achieving one patient with complete protection from
emesis with regimen A was found to be $877.88 which was approximately 1.2 times the direct
cost of regimen D ($723.51) and approximately 2.6 times the total cost of regimen C ($337.26).
The ICER for each treatment strategy was calculated to determine the additional cost per patient
with complete control of emesis relative to the next costly option. Under the base-case
assumptions using the direct costs, regimen A provided more health benefits and was more costly
than regimen C, with a resulting ICER of $3,363.181 per patient with complete control of emesis.
Regimens B and D were less effective and more costly than the base comparator, regimen C, i.e.
regimens B and D are dominated by regimen C. The direct costs and effectiveness for the
antiemetic regimens are represented graphically in figure 4-1 where the X-axis represents the
effectiveness with respect to the probability of achieving patients with complete control of
emesis, and the Y-axis represents costs in dollars.
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Figure 4-1: Direct Costs and Effectiveness of Different Antiemetic Regimens for Patients
Receiving Highly Emetogenic Chemotherapy from Payer Pespective – No Side Effects
Modeled
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The base case results for the total costs, effectiveness, total cost for achieving one patient
with complete control of emesis and the ICER for each of the four antiemetic regimens from the
societal perspective are also reported in Table 4-2. These results are represented graphically in
figure 4-2. Similar to the results of the analysis from the payer perspective, regimen A was the
most expensive treatment regimen ($658.97) followed by regimen D ($494.84), regimen B
($431.56) and regimen C ($295.89). The total costs of achieving a patient with complete
protection from emesis with regimen A was found to be $963.41, which was approximately 1.8
times the total cost of the regimen C ($530.27). The ICER results show that the dominance
status of the antiemetic regimens remained the same as in the analysis from the payer’s
perspective. The ICER of regimen A (regimen with aprepitant) compared with regimen C was
$2,881 per patient with complete control of emesis. Regimens B and D had higher costs and
lower effectiveness compared to regimen C and were thus said to be dominated by regimen C.
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Table 4-2: Base Case Results from Societal Perspective using Monte Carlo Simulation of 10,000 Patients with Cancer Receiving
Highly Emetogenic Chemotherapy – Side Effects Not Modeled
Side Effects Not Modeled

Treatment Strategy
Societal Perspective

Total Costs Mean
(SD)

Effectiveness
Mean (SD)

Cost of achieving one
patient with complete
control of emesis

Incremental cost effectiveness
ratio/patient with complete control
of emesis

Regimen C (Metoclopramide)

$295.89 ($149.29)

0.558 (0.497)

$530.27

-

Regimen B (Standard)

$431.56 ($153.69)

0.478 (0.499)

$902.85

Dominateda

Regimen D (Ondansetron)

$494.84 ($148.27)

0.543 (0.498)

$911.31

Dominateda

Regimen A (Aprepitant)

$658.97 ($129.75)

0.684 (0.465)

$963.41

$2,881.605/patient with complete
control of emesis

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
a

Dominated by regimen C
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Figure 4-2: Total Costs and Effectiveness of Different Antiemetic Regimens for Patients
Receiving Highly Emetogenic Chemotherapy from Societal Perspective – No Side
Effects Modeled
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For Highly Emetogenic Chemotherapy Decision Model – Scenario Analysis
Impact of Side-Effects of Metoclopramide
In order to examine whether side effects due to metoclopramide affected the results of the
decision model, the probability of experiencing the side effects and the costs associated with it
were modeled. The mean costs, effectiveness, direct cost of achieving one patient with complete
control of emesis and the ICER for each of the four antiemetic regimens from the payer
perspective are reported in Table 4-3.
The mean direct costs were the highest for regimen A followed by regimens D, B and C.
The mean direct costs associated with regimen C were $187.65 and the effectiveness was 0.542.
The ICER results for the antiemetic regimens were sensitive to the changes, i.e. the inclusion of
probabilities and costs due to side effects associated with regimen C. Regimen B was more
costly and less effective as compared to regimen C and thus is said to be dominated by regimen
C. Regimen D had higher costs and higher effectiveness compared to regimen C. However,
regimen D also had a higher ICER compared to regimen A, which is more costly and more
effective strategy than regimen D. Based on this, regimen C can be ruled out from the ICER
calculations through extended dominance by a blend of regimen C and regimen A with a
coefficient of inequity between 0.5 and 0.962. The ICER of regimen A compared with regimen
C was $2,857.20 per patient with complete control of emesis. The results of this analysis from
the payer’s perspective are also presented in figure 4-3.
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Table 4-3: Base Case Results from Payer Perspective using Monte Carlo Simulation of 10,000 Patients with Cancer Receiving
Highly Emetogenic Chemotherapy – Side Effects Modeled
Treatment Strategy
Payer Perspective

Side Effects Modeled
Direct Costs
Mean (SD)

Effectiveness
Mean (SD)

Cost of achieving one
patient with complete
control of emesis

Incremental cost effectiveness
ratio/patient with complete
control of emesis

Regimen C (Metoclopramide)

$187.65 ($34.90)

0.542 (0.498)

$346.22

-

Regimen B (Standard)

$300.68 ($37.12)

0.478 (0.499)

$629.04

Dominated*

Regimen D (Ondansetron)

$390.50 ($34.36)

0.547 (0.498)

$713.89

Extended Dominance**

Regimen A (Aprepitant)

$593.66 ($28.11)

0.684 (0.465)

$867.92

$2,857.20 per patient with
complete control of emesis

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
*
**

Regimen B dominated by regimen C
Regimen D dominated by a blend of regimen C and regimen A with a coefficient of inequity between 0.50 and 0.962
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Figure 4-3: Direct Costs, Effectiveness of Different Antiemetic Regimens for Patients
Receiving Highly Emetogenic Chemotherapy from Payer Perspective – Side effects
modeled
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The mean costs, effectiveness, total cost of achieving one patient with complete control
of emesis and the ICER for each of the four antiemetic regimens from the societal perspective are
reported in Table 4-4. The mean total costs from the societal perspective were the highest for
regimen A followed by regimens D, B and C. The mean total costs associated with regimen C
were $659.30 and the effectiveness was 0.548. The ICER results for the antiemetic regimens
were sensitive to the changes, i.e. the inclusion of probability and costs due to side effects
associated with regimen C. Regimen B was more costly and less effective as compared to
regimen C and thus is said to be dominated by regimen C. Regimen D had higher costs and
higher effectiveness compared to regimen C but also had higher ICER compared to regimen A,
which is more costly and more effective strategy than regimen D. Based on this, regimen C can
be ruled out from the ICER calculations through extended dominance with a coefficient of
inequity between 0.453 and 0.999. The ICER for regimen A compared to regimen C was found
to be $2,731.09 per patient with complete control of emesis. The results of this analysis from the
societal perspective are also presented in figure 4-4.
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Table 4-4: Base Case Results from Societal Perspective using Monte Carlo Simulation of 10,000 Patients with Cancer Receiving
Highly Emetogenic Chemotherapy – Side Effects Modeled
Side Effects Modeled

Treatment Strategy
Societal Perspective

Total Costs Mean
(SD)

Effectiveness
Mean (SD)

Cost of achieving one
patient with complete
control of emesis

Incremental cost effectiveness
ratio/patient with complete
control of emesis

Regimen C (Metoclopramide)

$293.34 ($149.34)

0.548 (0.497)

$535.29

-

Regimen B (Standard)

$429.87 ($154.56)

0.482 (0.499)

$891.85

Dominated*

Regimen D (Ondansetron)

$493.43 ($148.25)

0.548 (0.498)

$900.42

Extended Dominance**

Regimen A (Aprepitant)

$659.30 ($129.91)

0.682 (0.465)

$966.72

$2,731.09 per patient with
complete control of emesis

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
*

**

Regimen B dominated by regimen C
Regimen D dominated by a blend of regimen C and regimen A with a coefficient of inequity between 0.453 and 0.999
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Figure 4-4: Total Costs, Effectiveness of Different Antiemetic Regimens for Patients
Receiving Highly Emetogenic Chemotherapy from Societal Perspective – Side effects
modeled
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Sensitivity Analyses for Highly Emetogenic Chemotherapy Model
The estimates for the input parameters, both costs and effectiveness were derived and
integrated from multiple sources. Thus, like any other economic model, the present model
contains some degree of uncertainty. Sensitivity analysis is a commonly used tool to deal with
uncertainty in the model input parameters. In one-way sensitivity analyses, one parameter at a
time is varied over a certain range and the ICERs are recalculated. A comparison between the
original ICER and those obtained from sensitivity analyses provide an indication of the stability
of the model to changes in the values of the parameter.
Effect of Changes in Control of Acute and Delayed Emesis
The efficacy parameters, probability of no acute emesis, probability of no delayed emesis
given no acute emesis and probability of no delayed emesis given acute emesis were varied over
a plausible range obtained from published literature. Table 4-5 presents the range for sensitivity
analysis and the direct costs and effectiveness from the payer’s perspective. Table 4-6 presents
the same results for the model from the societal perspective. The ICER for each regimen obtained
from sensitivity analyses are reported in Table 4-7.
The change in the proportion of patients having no acute emesis has a significant impact
on the effectiveness estimates for each regimen but a minor impact on the direct costs of each
regimen. Although the dominance status of each regimen remained the same as in the base case
analysis, the ICER of regimen A was extremely sensitive to the changes in the probability of no
acute emesis for regimen A. For example, for the societal perspective, lowering the probability
of no acute emesis of regimen A from 0.870 to 0.742 increased the ICER to $19,536.81 per
patient with complete control of emesis and conversely, increasing the probability of no acute
emesis of regimen A from 0.870 to 0.900 decreased the ICER to $2,521.81 per patient with
complete control of emesis. Similar impact on ICER of regimen A was obtained for analysis
conducted from payer perspective.
For the payer perspective, the changes in the probability of no delayed emesis given no
acute emesis had a significant impact on the effectiveness of the considered treatment regimens
but not on the costs. However, the same changes had a significant impact on both the
effectiveness and cost estimates of each regimen for the analysis conducted from the societal
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perspective. This is in part because in the societal perspective the indirect costs, which includes
the work days lost due to uncontrolled delayed emesis, are taken into consideration. Thus,
increasing the control of delayed emesis will result in lower work productivity losses and
decreasing the control of delayed emesis will result in greater work productivity losses. The
results in Table 4-7 show the ICER of each regimen for the higher and lower limits of the
probability of no delayed emesis given no acute emesis. For changes in the ranges for regimens
A, B and C, the dominance status of each regimen remains the same. However, the change in the
parameter estimates of regimen D has an impact on the dominance status of the considered
treatments. When the probability of no delayed emesis given no acute emesis for regimen D is
increased from 0.715 to 0.858, regimen D has higher costs and higher effectiveness compared to
regimen C, and thus is no longer dominated. Compared to regimen C, the ICER of regimen D is
$2,173.07 per patient with complete control of emesis under the payer perspective and $1,787.86
per patient with complete control of emesis under the societal perspective. The ICER of regimen
A compred to regimen D was $7.633.18 per patient with complete control of emesis from the
payer perspective and $1,787.86 per patient with complete control of emesis from the societal
perspective.
As indicated by the results, the effectiveness of each considered treatment was not
sensitive to the changes in the probability of no delayed emesis given acute emesis. The
robustness of the results is because effectiveness of each regimen is defined as no emesis in the
acute and delayed phase and no rescue medications in the acute and delayed phases. Thus, any
changes in the probability of no delayed emesis given acute emesis will not impact the
effectiveness of each regimen. The changes in the base estimate of the parameter had a very
slight impact on the costs of each regimen. The ICER results showed that the changes in the
probability neither had a significant impact on the dominance status of the regimens nor on the
ICER of regimen A.
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Table 4-5: One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from Payer
Perspective – Efficacy Parameters
DIRECT COSTS
Regimen A

Regimen B

EFFECTIVENESS

Regimen C

Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Parameter: Probability of No Acute Emesis
Base Case

$593.45

$300.53

$187.18

$389.97

0.676

0.478

0.555

0.539

Regimens

Range

Regimen A

0.742

$594.94

$300.71

$187.29

$390.26

0.578

0.477

0.558

0.542

0.900

$593.11

$300.71

$187.29

$390.26

0.701

0.477

0.558

0.542

0.690

$593.46

$301.31

$187.29

$390.26

0.678

0.444

0.558

0.542

0.793

$593.46

$300.12

$187.29

$390.26

0.678

0.510

0.558

0.542

0.742

$593.46

$300.71

$188.02

$390.84

0.678

0.477

0.518

0.504

0.832

$593.46

$300.71

$186.86

$390.84

0.678

0.477

0.581

0.565

0.742

$593.46

$300.71

$188.02

$390.84

0.678

0.477

0.518

0.504

0.832

$593.46

$300.71

$186.86

$390.84

0.678

0.477

0.581

0.565

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-5 (Continued): One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from
Payer Perspective– Efficacy Parameters
DIRECT COSTS
Regimen A

Regimen B

Regimen C

EFFECTIVENESS
Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Parameter: Probability of No Delayed Emesis Given No Acute Emesis
Base Case

$593.45

$300.53

$187.18

$389.97

0.676

0.478

0.555

0.539

Regimens

Range

Regimen A

0.793

$593.99

$300.71

$187.29

$390.26

0.647

0.477

0.558

0.542

0.866

$592.95

$300.71

$187.29

$390.26

0.707

0.477

0.558

0.542

0.646

$593.46

$300.99

$187.29

$390.26

0.678

0.460

0.558

0.542

0.694

$593.46

$300.42

$187.29

$390.26

0.678

0.484

0.558

0.542

0.733

$593.46

$300.71

$187.33

$390.26

0.678

0.478

0.556

0.542

0.738

$593.46

$300.71

$187.26

$390.26

0.678

0.478

0.560

0.542

0.572

$593.46

$300.71

$187.29

$392.10

0.678

0.477

0.558

0.434

0.858

$593.46

$300.71

$187.29

$388.41

0.678

0.477

0.558

0.651

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-5 (Continued): One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from
Payer Perspective – Efficacy Parameters
DIRECT COSTS
Regimen A

Regimen B

Regimen C

EFFECTIVENESS
Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Parameter: Probability of No Delayed Emesis Given Acute Emesis
Base Case

$593.45

$300.53

$187.18

$389.97

0.676

0.478

0.555

0.539

Regimen

Range

Regimen A

0.308

$593.48

$300.71

$187.29

$390.26

0.678

0.477

0.558

0.542

0.326

$593.44

$300.71

$187.29

$390.26

0.678

0.477

0.558

0.542

0.122

$593.46

$300.84

$187.29

$390.26

0.678

0.477

0.558

0.542

0.185

$593.46

$300.58

$187.29

$390.26

0.678

0.477

0.558

0.542

0.088

$593.46

$300.71

$187.47

$390.26

0.678

0.477

0.558

0.542

0.200

$593.46

$300.71

$187.12

$390.26

0.678

0.477

0.558

0.542

0.228

$593.46

$300.71

$187.29

$390.45

0.678

0.477

0.558

0.542

0.343

$593.46

$300.71

$187.29

$390.07

0.678

0.477

0.558

0.542

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-6: One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from Societal
Perspective – Efficacy Parameters
TOTAL COSTS
Regimen A

Regimen B

EFFECTIVENESS

Regimen C

Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Parameter: Probability of No Acute Emesis
Base Case

$658.97

$431.56

$295.89

$494.84

0.684

0.478

0.558

0.543

Regimens

Range

Regimen A

0.742

$680.49

$431.74

$295.64

$495.29

0.578

0.478

0.558

0.542

0.900

$655.72

$431.74

$295.64

$495.29

0.701

0.478

0.558

0.542

0.690

$660.43

$439.93

$295.64

$495.29

0.678

0.444

0.558

0.542

0.793

$660.43

$423.71

$295.64

$495.29

0.678

0.510

0.558

0.542

0.742

$660.43

$431.74

$305.92

$502.79

0.678

0.478

0.519

0.504

0.832

$660.43

$431.74

$289.69

$490.94

0.678

0.478

0.581

0.565

0.742

$660.43

$431.74

$305.92

$502.79

0.678

0.478

0.519

0.504

0.832

$660.43

$431.74

$289.69

$490.94

0.678

0.478

0.581

0.565

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-6 (Continued): One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from
Societal Perspective – Efficacy Parameters
TOTAL COSTS
Regimen A

Regimen B

Regimen C

EFFECTIVENESS
Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Probability of No Delayed Emesis Given No Acute Emesis
Base Case

$658.97

$431.56

$295.89

$494.84

0.684

0.478

0.558

0.543

Regimens

Range

Regimen A

0.793

$670.06

$431.74

$295.64

$495.29

0.648

0.478

0.558

0.542

0.866

$651.05

$431.74

$295.64

$495.29

0.707

0.478

0.558

0.542

0.646

$660.43

$437.06

$295.64

$495.27

0.678

0.460

0.558

0.542

0.694

$660.43

$426.41

$295.64

$495.27

0.678

0.494

0.558

0.542

0.733

$660.43

$431.74

$296.36

$495.29

0.678

0.478

0.556

0.542

0.738

$660.43

$431.74

$295.17

$495.29

0.678

0.478

0.560

0.542

0.572

$660.43

$431.74

$295.64

$529.46

0.678

0.478

0.558

0.434

0.858

$660.43

$431.74

$295.64

$461.11

0.678

0.478

0.558

0.651

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-6 (Continued): One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from
Societal Perspective – Efficacy Parameters
TOTAL COSTS
Regimen A

Regimen B

EFFECTIVENESS

Regimen C

Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Probability of No Delayed Emesis Given Acute Emesis
Base Case

$658.97

$431.56

$295.89

$494.84

0.684

0.478

0.558

0.543

Regimens

Range

Regimen A

0.308

$660.78

$431.74

$295.64

$495.29

0.678

0.477

0.558

0.542

0.326

$660.08

$431.74

$295.64

$495.29

0.678

0.477

0.558

0.542

0.122

$660.43

$434.20

$295.64

$495.29

0.678

0.477

0.558

0.542

0.185

$660.43

$429.35

$295.64

$495.29

0.678

0.477

0.558

0.542

0.088

$660.43

$431.74

$299.01

$495.29

0.678

0.477

0.558

0.542

0.200

$660.43

$431.74

$292.28

$495.29

0.678

0.477

0.558

0.542

0.228

$660.43

$431.74

$295.64

$498.77

0.678

0.477

0.558

0.542

0.343

$660.43

$431.74

$295.64

$491.86

0.678

0.477

0.558

0.542

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-7: One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from Payer
and Societal Perspective – ICERs for Efficacy Parameters
ICER per patient with complete control of
emesis – Payer Perspective
Regimen A

ICER per patient with complete control of emesis –
Societal Perspective

Regimen B

Regimen D

Regimen A

Regimen B

Regimen D

$3,363.181

Dominateda

Dominateda

$2,881.605

Dominateda

Dominateda

Probability of No Acute Emesis
Base Case
Regimens

Range

Regimen A

0.742

$20,694.99

Dominateda

Dominateda

$19,536.81

Dominateda

Dominateda

0.900

$2,842.19

Dominateda

Dominateda

$2,521.81

Dominateda

Dominateda

0.690

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.793

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.742

$2,545.98

Dominateda

Dominateda

$2,226.10

Dominateda

Dominateda

0.832

$4,219.81

Dominateda

Dominateda

$3,847.59

Dominateda

Dominateda

0.742

$2,545.98

Dominateda

Dominateda

$2,226.10

Dominateda

Dominateda

0.832

$4,219.81

Dominateda

Dominateda

$3,847.59

Dominateda

Dominateda

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4);
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4);
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4);
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
All treatments are compared to Regimen C
a
Dominated by regimen C
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Table 4-7 (Continued): One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from
Payer and Societal Perspective – ICERs for Efficacy Parameters
Parameters/Range

Base Case

ICER per patient with complete control of
emesis – Payer Perspective

ICER per patient with complete control of emesis –
Societal Perspective

Regimen A

Regimen B

Regimen D

Regimen A

Regimen B

Regimen D

$3,363.181

Dominateda

Dominateda

$2,881.605

Dominateda

Dominateda

Probability of No Delayed Emesis Given No Acute Emesis
Regimen A

Regimen B

Regimen C

Regimen D

0.793

$4,559.31

Dominateda

Dominateda

$4,197.39

Dominateda

Dominateda

0.866

$2,726.00

Dominateda

Dominateda

$2,388.31

Dominateda

Dominateda

0.646

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.694

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.733

$3,337.42

Dominateda

Dominateda

$2,991.71

Dominateda

Dominateda

0.738

$3,445.34

Dominateda

Dominateda

$3,098.10

Dominateda

Dominateda

0.572

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.858

$7,633.18

Dominateda

$2,173.08

$7,419.57

Dominateda

$1,787.86

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
All treatments are compared to Regimen C
a
Dominated by regimen C
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Table 4-7 (Continued): One Way Sensitivity Analyses Results for Highly Emetogenic Chemotherapy Model with No Side Effects from
Payer and Societal Perspective – ICERs for Efficacy Parameters
Parameters/Range

Base Case

ICER per patient with complete control of
emesis – Payer Perspective

ICER per patient with complete control of emesis –
Societal Perspective

Regimen A

Regimen B

Regimen D

Regimen A

Regimen B

Regimen D

$3,363.181

Dominateda

Dominated

$2,881.605

Dominateda

Dominateda

Probability of No Delayed Emesis Given Acute Emesis
Regimen A

Regimen B

Regimen C

Regimen D

0.308

$3,401.51

Dominateda

Dominateda

$3,057.66

Dominateda

Dominateda

0.326

$3,401.19

Dominateda

Dominateda

$3,051.80

Dominateda

Dominateda

0.122

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.185

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.088

$3,399.83

Dominateda

Dominateda

$3,026.54

Dominateda

Dominateda

0.200

$3,402.87

Dominateda

Dominateda

$3,082.92

Dominateda

Dominateda

0.228

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.343

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
All treatments are compared to Regimen C
a
Dominated by regimen C
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Effect of Changes in the Receipt of Rescue Medications
The parameters, probability of receiving rescue medications in the acute phase given no
acute emesis and given acute emesis and probability of receiving rescue medications in the
delayed phase given no delayed emesis and given delayed emesis were varied over a plausible
range shown in Chapter 3, Table 3-6. Table 4-8 presents the range for each parameter for each
regimen and the direct costs and effectiveness estimates from the payer’s perspective. Table 4-9
presents the results from the societal perspective. The ICER for each regimen obtained from
sensitivity analyses are reported in Table 4-10.
As evident from Tables 4-8 and 4-9, the changes in the probability of receiving rescue
medications in the acute phase given no acute emesis for each regimen had an impact on the
effectiveness results for that regimen but no significant impact on the costs. The dominance
status of each considered treatment remained the same as in base case but resulted in changes in
the ICERs of regimen A. Decreasing the proportion of patients receiving rescue medications for
no acute emesis for regimen A to zero resulted in an ICER of $3,181.86 per patient with
complete control of emesis from payer’s perspective and $2,857.60 from the societal perspective.
Conversely, for other regimens, decreasing the proportion of patients receiving rescue
medications for no acute emesis to zero resulted in an increased ICER for regimen A.
The costs, effectiveness and ICER results were not sensitive to changes in the
probabilities of receipt of rescue medications in the acute phase given acute emesis and receipt of
rescue medications in the delayed phase given delayed emesis. From the payer and societal
perspectives, the costs, effectiveness and ICER results for the alternative regimens were sensitive
to the changes in the probability of receipt of rescue medications in the delayed phase given no
delayed emesis. Decreasing the probability of receipt of rescue medications in the delayed phase
given no delayed emesis for regimen A resulted in decreasing the ICER to $2,615.75 and
$2,348.85, for the payer and societal perspective respectively. Increasing the probability of
receipt of rescue medications in the delayed phase given no delayed emesis for regimen A
resulted in increasing the ICER to $3,506.52 and $3,149.23 for the payer and societal
perspective, respectively. The changes in this probability for regimen D resulted in a change in
the dominance status of the antiemetic regimens. When the probability of receiving rescue
medications for regimen D was set at zero, the ICER from societal perspective for regimen A
increased to $3,054.73 and regimen D was ruled out by extended dominance status (Table 4-10).
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Effect of Changes in the Receipt of Outpatient Care
The impact of changes in the probability of receiving outpatient care during the acute
phase and delayed phase, either with no rescue medications or with rescue medications, on direct
costs, total costs, effectiveness and ICERs are presented in Tables 4-8, 4-9 and 4-10. The results
show that the baseline estimates were not sensitive to the changes in the probability of receipt of
outpatient care during either the acute or delayed phase. The dominance status of the antiemetic
regimens remained the same, from the payer and societal perspectives, as in the base-case
analysis.
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Table 4-8: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Receipt of Rescue
Medications
DIRECT COSTS
Regimen A

Regimen B

Regimen C

EFFECTIVENESS
Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given No Acute Emesis
Base Case

$593.45

$300.53

$187.18

$389.97

0.676

0.478

0.555

0.539

Regimens

Range

Regimen A

0.000

$593.44

$300.71

$187.29

$390.26

0.686

0.477

0.558

0.542

0.015

$593.47

$300.71

$187.29

$390.26

0.676

0.477

0.558

0.542

0.000

$593.46

$300.69

$187.29

$390.26

0.678

0.483

0.558

0.542

0.015

$593.46

$300.71

$187.29

$390.26

0.678

0.476

0.558

0.542

0.000

$593.46

$300.71

$187.27

$390.24

0.678

0.477

0.565

0.549

0.015

$593.46

$300.71

$187.29

$390.26

0.678

0.477

0.557

0.541

0.000

$593.46

$300.71

$187.27

$390.24

0.678

0.477

0.565

0.549

0.015

$593.46

$300.71

$187.29

$390.26

0.678

0.477

0.557

0.541

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-8 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Receipt of
Rescue Medications
DIRECT COSTS
Regimen A

Regimen B

Regimen C

EFFECTIVENESS
Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Parameter: Probability of Receipt of Rescue Medications in the Acute Phase Given Acute Emesis
Base Case

$593.45

$300.53

$187.18

$389.97

0.676

0.478

0.555

0.539

Regimens

Range

Regimen A

0.175

$593.43

$300.71

$187.29

$390.26

0.678

0.477

0.558

0.542

1.000

$593.60

$300.71

$187.29

$390.26

0.678

0.477

0.558

0.542

0.304

$593.46

$300.67

$187.29

$390.26

0.678

0.477

0.558

0.542

1.000

$593.46

$300.96

$187.29

$390.26

0.678

0.477

0.558

0.542

0.304

$593.46

$300.71

$187.26

$390.23

0.678

0.477

0.558

0.542

1.000

$593.46

$300.71

$187.49

$390.46

0.678

0.477

0.558

0.542

0.304

$593.46

$300.71

$187.29

$390.26

0.678

0.477

0.558

0.542

1.000

$593.46

$300.71

$187.29

$390.26

0.678

0.477

0.558

0.542

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-8 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Receipt of
Rescue Medications
Parameters/Range

DIRECT COSTS
Regimen A

Regimen B

Regimen C

EFFECTIVENESS
Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Parameter: Probability of Receipt of Rescue Medications in the Delayed Phase Given No Delayed Emesis
Base Case

$593.45

$300.53

$187.18

$389.97

0.676

0.478

0.555

0.539

Regimens

Range

Regimen A

0.000

$592.96

$300.71

$187.29

$390.26

0.713

0.477

0.558

0.542

0.055

$593.51

$300.71

$187.29

$390.26

0.674

0.477

0.558

0.542

0.000

$594.46

$300.51

$187.29

$390.26

0.678

0.491

0.558

0.542

0.035

$594.46

$300.76

$187.29

$390.26

0.678

0.474

0.558

0.542

0.000

$593.46

$300.71

$186.97

$390.26

0.678

0.477

0.581

0.542

0.045

$593.46

$300.71

$187.34

$390.26

0.678

0.477

0.555

0.542

0.000

$593.46

$300.71

$187.29

$389.93

0.678

0.477

0.558

0.564

0.045

$593.46

$300.71

$187.29

$390.31

0.678

0.477

0.558

0.539

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-8 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Receipt of
Rescue Medications
DIRECT COSTS
Regimen A

Regimen B

Regimen C

EFFECTIVENESS
Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Parameter: Probability of Receipt of Rescue Medications in the Delayed Phase Given Delayed Emesis
Base Case

$593.45

$300.53

$187.18

$389.97

0.676

0.478

0.555

0.539

Regimens

Range

Regimen A

0.454

$593.08

$300.71

$187.29

$390.26

0.678

0.477

0.558

0.542

1.000

$594.79

$300.71

$187.29

$390.26

0.678

0.477

0.558

0.542

0.477

$593.46

$300.38

$187.29

$390.26

0.678

0.477

0.558

0.542

1.000

$593.46

$303.58

$187.29

$390.26

0.678

0.477

0.558

0.542

0.465

$593.46

$300.71

$186.84

$390.26

0.678

0.477

0.558

0.542

1.000

$593.46

$300.71

$189.55

$390.26

0.678

0.477

0.558

0.542

0.465

$593.46

$300.71

$187.29

$389.83

0.678

0.477

0.558

0.542

1.000

$593.46

$300.71

$187.29

$392.45

0.678

0.477

0.558

0.542

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)

128

RESULTS

Reema Mody

Table 4-8 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Receipt of
Outpatient Care
DIRECT COSTS

Base Case

EFFECTIVENESS

Regimen A

Regimen B

Regimen C

Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

$593.45

$300.53

$187.18

$389.97

0.676

0.478

0.555

0.539

Parameter: Probability of Receipt of Outpatient Care During Acute Phase Given:
No Rescue
Medications

Rescue
Medications

0.000

$593.23

$300.29

$186.96

$389.93

0.678

0.477

0.558

0.542

0.030

$593.92

$301.54

$187.94

$390.91

0.678

0.477

0.558

0.542

0.000

$593.34

$300.44

$187.08

$390.05

0.678

0.477

0.558

0.542

0.030

$593.70

$301.25

$$187.71

$390.68

0.678

0.477

0.558

0.542

Parameter: Probability of Receipt of Outpatient Care During Delayed Phase Given:
No Rescue
Medications

Rescue
Medications

0.02

$593.06

$299.84

$186.60

$389.59

0.678

0.477

0.558

0.542

0.05

$593.86

$301.58

$187.97

$390.92

0.678

0.477

0.558

0.542

0.02

$592.91

$$299.72

$186.44

$389.43

0.678

0.477

0.558

0.542

0.05

$594.00

$301.69

$188.14

$391.08

0.678

0.477

0.558

0.542

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4);
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4);
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4);
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-9: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Receipt of Rescue
Medications
TOTAL COSTS
Regimen A

Regimen B

Regimen C

EFFECTIVENESS
Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given No Acute Emesis
Base Case

$658.97

$431.56

$295.89

$494.84

0.684

0.478

0.558

0.543

Regimens

Range

Regimen A

0.000

$660.41

$431.74

$295.64

$495.29

0.686

0.477

0.558

0.542

0.015

$660.41

$431.74

$295.64

$495.29

0.676

0.477

0.558

0.542

0.000

$660.43

$431.72

$295.64

$495.29

0.678

0.483

0.558

0.542

0.015

$660.43

$431.74

$295.64

$495.29

0.678

0.476

0.558

0.542

0.000

$660.43

$431.74

$295.63

$495.27

0.678

0.477

0.565

0.549

0.015

$660.43

$431.74

$295.65

$495.29

0.678

0.477

0.557

0.541

0.000

$660.43

$431.74

$295.63

$495.27

0.678

0.477

0.565

0.549

0.015

$660.43

$431.74

$295.65

$495.29

0.678

0.477

0.557

0.541

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-9 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Receipt of
Rescue Medications
TOTAL COSTS
Regimen A

Regimen B

Regimen C

EFFECTIVENESS
Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Parameter: Probability of Receipt of Rescue Medications in the Acute Phase Given Acute Emesis
Base Case

$658.97

$431.56

$295.89

$494.84

0.684

0.478

0.558

0.543

Regimens

Range

Regimen A

0.175

$660.39

$431.74

$295.64

$495.29

0.678

0.477

0.558

0.542

1.000

$660.57

$431.74

$295.64

$495.29

0.678

0.477

0.558

0.542

0.304

$660.43

$431.70

$295.64

$495.29

0.678

0.477

0.558

0.542

1.000

$660.43

$431.99

$295.64

$495.29

0.678

0.477

0.558

0.542

0.304

$660.43

$431.74

$295.61

$495.26

0.678

0.477

0.558

0.542

1.000

$660.43

$431.74

$295.84

$495.49

0.678

0.477

0.558

0.542

0.304

$660.43

$431.74

$295.64

$495.29

0.678

0.477

0.558

0.542

1.000

$660.43

$431.74

$295.64

$495.29

0.678

0.477

0.558

0.542

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-9 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Receipt of
Rescue Medications
TOTAL COSTS
Regimen A

Regimen B

Regimen C

EFFECTIVENESS
Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Parameter: Probability of Receipt of Rescue Medications in the Delayed Phase Given No Delayed Emesis
Base Case

$658.97

$431.56

$295.89

$494.84

0.684

0.478

0.558

0.543

Regimens

Range

Regimen A

0.000

$659.92

$431.74

$295.64

$495.29

0.713

0.477

0.558

0.542

0.055

$660.48

$431.74

$295.64

$495.29

0.674

0.477

0.558

0.542

0.000

$660.43

$431.54

$295.64

$495.29

0.678

0.491

0.558

0.542

0.035

$660.43

$431.79

$295.64

$495.29

0.678

0.474

0.558

0.542

0.000

$660.43

$431.74

$295.33

$495.29

0.678

0.477

0.581

0.542

0.045

$660.43

$431.74

$295.69

$495.29

0.678

0.477

0.555

0.542

0.000

$660.43

$431.74

$295.64

$494.96

0.678

0.477

0.558

0.564

0.045

$660.43

$431.74

$295.64

$495.34

0.678

0.477

0.558

0.539

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-9 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Receipt of
Rescue Medications
TOTAL COSTS
Regimen A

Regimen B

Regimen C

EFFECTIVENESS
Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

Parameter: Probability of Receipt of Rescue Medications in the Delayed Phase Given Delayed Emesis
Base Case

$658.97

$431.56

$295.89

$494.84

0.684

0.478

0.558

0.543

Regimens

Range

Regimen A

0.454

$660.04

$431.74

$295.64

$495.29

0.678

0.477

0.558

0.542

1.000

$661.75

$431.74

$295.64

$495.29

0.678

0.477

0.558

0.542

0.477

$660.43

$431.41

$295.64

$495.29

0.678

0.477

0.558

0.542

1.000

$660.43

$434.61

$295.64

$495.29

0.678

0.477

0.558

0.542

0.465

$660.43

$431.74

$295.20

$495.29

0.678

0.477

0.558

0.542

1.000

$660.43

$431.74

$297.91

$495.29

0.678

0.477

0.558

0.542

0.465

$660.43

$431.74

$295.64

$494.85

0.678

0.477

0.558

0.542

1.000

$660.43

$431.74

$295.64

$497.48

0.678

0.477

0.558

0.542

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-9 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Receipt of
Outpatient Care
TOTAL COSTS

Base Case

EFFECTIVENESS

Regimen A

Regimen B

Regimen C

Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

$658.97

$431.56

$295.89

$494.84

0.684

0.478

0.558

0.543

Parameter: Probability of Receipt of Outpatient Care During Acute Phase Given:
No Rescue
Medications

Rescue
Medications

0.000

$660.20

$431.32

$295.32

$494.96

0.678

0.477

0.558

0.542

0.030

$660.89

$432.57

$296.30

$495.94

0.678

0.477

0.558

0.542

0.000

$660.31

$431.46

$295.43

$495.06

0.678

0.477

0.558

0.542

0.030

$660.66

$432.28

$296.07

$495.71

0.678

0.477

0.558

0.542

Probability of Receipt of Outpatient Care During Delayed Phase Given:
No Rescue
Medications

Rescue
Medications

0.02

$660.02

$430.87

$294.96

$494.62

0.678

0.477

0.558

0.542

0.05

$660.83

$432.61

$296.33

$495.95

0.678

0.477

0.558

0.542

0.02

$659.88

$430.75

$294.79

$494.46

0.678

0.477

0.558

0.542

0.05

$660.97

$432.72

$296.49

$496.11

0.678

0.477

0.558

0.542

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4);
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4);
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4);
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-10: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective – ICERs
for Receipt of Rescue Medications
ICER per patient with complete control of
emesis – Payer Perspective
Regimen A

Regimen B

Regimen D

ICER per patient with complete control of emesis –
Societal Perspective
Regimen A

Regimen B

Regimen D

Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given No Acute Emesis
Base Case

$3,363.181

Dominateda

Dominateda

$2,881.605

Dominateda

Dominateda

Regimens

Range

Regimen A

0.000

$3,181.86

Dominateda

Dominateda

$2,857.60

Dominateda

Dominateda

0.015

$3,461.03

Dominateda

Dominateda

$3,108.34

Dominateda

Dominateda

0.000

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.015

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.000

$3,606.28

Dominateda

Dominateda

$3,238.79

Dominateda

Dominateda

0.015

$3,353.70

Dominateda

Dominateda

$3,011.94

Dominateda

Dominateda

0.000

$3,606.28

Dominateda

Dominateda

$3,238.79

Dominateda

Dominateda

0.015

$3,353.70

Dominateda

Dominateda

$3,011.94

Dominateda

Dominateda

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
a
Dominated by regimen C
All treatments are compared to Regimen C
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Table 4-10 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective –
ICERs for Receipt of Rescue Medications
ICER per patient with complete control of
emesis – Payer Perspective
Regimen A

Regimen B

Regimen D

ICER per patient with complete control of emesis –
Societal Perspective
Regimen A

Regimen B

Regimen D

Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given Acute Emesis
Base Case

$3,363.181

Dominateda

Dominateda

$2,881.605

Dominateda

Dominateda

Regimens

Range

Regimen A

0.175

$3,401.06

Dominateda

Dominateda

$3,054.44

Dominateda

Dominateda

1.000

$3,402.54

Dominateda

Dominateda

$3,055.92

Dominateda

Dominateda

0.304

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

1.000

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.304

$3,401.60

Dominateda

Dominateda

$3,054.98

Dominateda

Dominateda

1.000

$3,399.68

Dominateda

Dominateda

$3,053.05

Dominateda

Dominateda

0.304

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

1.000

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4);
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4);
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
a
Dominated by regimen C
All treatments are compared to Regimen C
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Table 4-10 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective –
ICERs for Receipt of Rescue Medications
ICER per patient with complete control of
emesis – Payer Perspective
Regimen A

Regimen B

Regimen D

ICER per patient with complete control of emesis –
Societal Perspective
Regimen A

Regimen B

Regimen D

Parameter: Probability of Receiving Rescue Medications In the Delayed Phase Given No Delayed Emesis
Base Case

$3,363.181

Dominateda

Dominateda

$2,881.605

Dominateda

Dominateda

Regimens

Range

Regimen A

0.000

$2,615.75

Dominateda

Dominateda

$2,348.85

Dominateda

Dominateda

0.055

$3,506.52

Dominateda

Dominateda

$3,149.23

Dominateda

Dominateda

0.000

$3.401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.035

$3.401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.000

$4,201.21

Dominateda

Dominateda

$3,733.41

Dominateda

Dominateda

0.045

$3,304.48

Dominateda

Dominateda

$2,967.69

Dominateda

Dominateda

0.000

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Extended Dominanceb

0.045

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4); Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4);
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4); Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral
Ondansetron 8 mg BID (Days 2-4)
All treatments are compared to Regimen C
a
Dominated by regimen C
b
Regimen D is dominated by a blend of regimens C and A
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Table 4-10 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective –
ICERs for Receipt of Rescue Medications
ICER per patient with complete control of
emesis – Payer Perspective
Regimen A

Regimen B

Regimen D

ICER per patient with complete control of emesis –
Societal Perspective
Regimen A

Regimen B

Regimen D

Parameter: Probability of Receiving Rescue Medications In the Delayed Phase Given Delayed Emesis
$3,363.181

Base Case

Dominateda

Dominateda

$2,881.605

Dominateda

Dominateda
Dominateda

Regimens

Range

Regimen A

0.454

$3,398.15

Dominateda

Dominateda

$3,051.53

Dominateda

Dominateda

1.000

$3,412.47

Dominateda

Dominateda

$3,065.85

Dominateda

Dominateda

0.477

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

1.000

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

0.465

$3,405.09

Dominateda

Dominateda

$3,058.46

Dominateda

Dominateda

1.000

$3,382.39

Dominateda

Dominateda

$3,035.77

Dominateda

Dominateda

0.465

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

1.000

$3,401.35

Dominateda

Dominateda

$3,054.73

Dominateda

Dominateda

Regimen B

Regimen C

Regimen D

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4)
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4)
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
All treatments are compared to Regimen C
a
Dominated by regimen C
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Table 4-10 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective –
ICERs for Receipt of Outpatient Care

Base Case

ICER per patient with complete control of
emesis – Payer Perspective

ICER per patient with complete control of
emesis – Societal Perspective

Regimen A

Regimen B

Regimen D

Regimen A

Regimen B

Regimen D

$3,363.181

Dominateda

Dominateda

$2,881.605

Dominateda

Dominateda

Parameter: Probability of Receipt of Outpatient Care During Acute Phase Given:
No Rescue Medications

Rescue Medications

0.000

$3,402.15

Dominateda

Dominateda

$3,055.53

Dominateda

Dominateda

0.030

$3,399.75

Dominateda

Dominateda

$3,053.13

Dominateda

Dominateda

0.000

$3,402.14

Dominateda

Dominateda

$3,055.52

Dominateda

Dominateda

0.030

$3,399.77

Dominateda

Dominateda

$3,053.15

Dominateda

Dominateda

Parameter: Probability of Receipt of Outpatient Care During Delayed Phase Given:
No Rescue Medications

Rescue Medications

0.02

$3,403.73

Dominateda

Dominateda

$3,057.11

Dominateda

Dominateda

0.05

$3,398.97

Dominateda

Dominateda

$3,052.35

Dominateda

Dominateda

0.02

$3,403.89

Dominateda

Dominateda

$3,057.27

Dominateda

Dominateda

0.05

$3,398.82

Dominateda

Dominateda

$3,052.20

Dominateda

Dominateda

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4);
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4);
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4);
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4).
All treatments are compared to Regimen C
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Effect of Changes in Cost and Utilization Parameters
The impact of changes in the cost of antiemetic drugs and antiemetic regimens, infusion
costs, and number of days for which rescue medications were received, on costs and
effectiveness are reported in Tables 4-11 and 4-12. The impacts of changes in the parameters on
the ICER of each treatment regimen are presented in Table 4-13. The total costs of the
prophylactic antiemetic regimens were varied between plus 20% and minus 20% of the base-case
estimates.
The variations in the costs did not change the dominance status of the individual
antiemetic regimens. Increasing the total cost of regimen A by 20% increases the ICER for
regimen A to $4,386.99 per patient with complete control of emesis from a payer perspective,
and to $2,415.71 per patient with complete control of emesis from a societal perspective. For
analysis conducted from payer perspective, a 20% increase in the cost of aprepitant increased the
ICER of regimen A by approximately $555 per patient with complete control of emesis, while a
20% decrease in the cost of aprepitant decreased the ICER of the regimen by approximately by
$480 per patient with complete control of emesis. The dominance status of each considered
regimen remained the same as in the base-case analysis. The results were not sensitive to the
changes in the cost of intravenous ondansetron, infusion costs and the number of days for which
rescue medications given during the delayed phase.
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Table 4-11: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Cost Parameters
DIRECT COSTS

Base Case

EFFECTIVENESS

Regimen A

Regimen B

Regimen C

Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

$593.45

$300.53

$187.18

$389.97

0.676

0.478

0.555

0.539

Parameter: Total Prophylactic Antiemetic Regimen Costs
Regimen

Range

Regimen A

$470.80

$475.76

$300.71

$187.29

$390.26

0.678

0.477

0.558

0.542

$760.20

$652.31

$300.71

$187.29

$390.26

0.678

0.477

0.558

0.542

$233.64

$593.46

$242.30

$187.29

$390.26

0.678

0.477

0.558

0.542

$350.46

$593.46

$359.12

$187.29

$390.26

0.678

0.477

0.558

0.542

$143.92

$593.46

$300.71

$151.31

$390.26

0.678

0.477

0.558

0.542

$215.88

$593.46

$300.71

$223.27

$390.26

0.678

0.477

0.558

0.542

$306.45

$593.46

$300.71

$187.29

$313.65

0.678

0.477

0.558

0.542

$459.67

$593.46

$300.71

$187.29

$466.87

0.678

0.477

0.558

0.542

Regimen B

Regimen C

Regimen D

Parameter: Cost of Aprepitant
Aprepitant

$247.22

$531.70

$300.71

$187.29

$390.26

0.678

0.477

0.558

0.542

$370.80

$655.30

$300.71

$187.29

$390.26

0.678

0.477

0.558

0.542

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4); Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4); Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral
Ondansetron 8 mg BID (Days 2-4)
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Table 4-11 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Cost
Parameters
DIRECT COSTS

Base Case

EFFECTIVENESS

Regimen A

Regimen B

Regimen C

Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

$593.45

$300.53

$187.18

$389.97

0.676

0.478

0.555

0.539

Parameter: Cost of IV Ondansetron
Ondansetron

$165.13

$552.08

$259.23

$176.87

$379.84

0.678

0.477

0.558

0.542

$247.69

$634.84

$342.18

$197.71

$400.67

0.678

0.477

0.558

0.542

$47.16

$581.56

$288.70

$175.32

$378.29

0.678

0.477

0.558

0.542

$70.74

$605.36

$312.72

$199.26

$402.22

0.678

0.477

0.558

0.542

$22.18

$593.46

$300.71

$181.75

$384.72

0.678

0.477

0.558

0.542

$33.26

$593.46

$300.71

$192.83

$395.80

0.678

0.477

0.558

0.542

Parameter: Infusion Costs
First Drug

Second Drug

Parameter: Number of Days of Receiving Rescue Medications During Delayed Phase
No. of Days

1 day

$592.89

$299.85

$186.51

$389.50

0.678

0.477

0.558

0.542

3 days

$594.03

$301.57

$188.06

$391.01

0.678

0.477

0.558

0.542

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4);
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4);
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-12: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Cost Parameters
TOTAL COSTS

Base Case

EFFECTIVENESS

Regimen A

Regimen B

Regimen C

Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

$658.97

$431.56

$295.89

$494.84

0.684

0.478

0.558

0.543

Parameter: Total Prophylactic Antiemetic Regimen Costs
Regimen

Range

Regimen A

$470.80

$542.73

$431.74

$295.64

$495.29

0.678

0.477

0.558

0.542

$760.20

$778.13

$431.74

$295.64

$495.29

0.678

0.477

0.558

0.542

$233.64

$660.43

$373.33

$295.64

$495.29

0.678

0.477

0.558

0.542

$350.46

$660.43

$490.15

$295.64

$495.29

0.678

0.477

0.558

0.542

$143.92

$660.43

$431.74

$259.66

$495.29

0.678

0.477

0.558

0.542

$215.88

$660.43

$431.74

$331.62

$495.29

0.678

0.477

0.558

0.542

$306.45

$660.43

$431.74

$295.64

$418.68

0.678

0.477

0.558

0.542

$459.67

$660.43

$431.74

$295.64

$571.90

0.678

0.477

0.558

0.542

Regimen B

Regimen C

Regimen D

Parameter: Cost of Aprepitant
Aprepitant

$247.22

$598.60

$431.74

$295.64

$495.29

0.678

0.477

0.558

0.542

$370.80

$722.20

$431.74

$295.64

$495.29

0.678

0.477

0.558

0.542

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4); Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4); Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral
Ondansetron 8 mg BID (Days 2-4)
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Table 4-12 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Cost
Parameters
TOTAL COSTS

Base Case

EFFECTIVENESS

Regimen A

Regimen B

Regimen C

Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

$658.97

$431.56

$295.89

$494.84

0.684

0.478

0.558

0.543

Parameter: Cost of IV Ondansetron
Ondansetron

$165.13

$619.05

$390.26

$285.23

$484.87

0.678

0.477

0.558

0.542

$247.69

$701.80

$473.21

$306.06

$505.70

0.678

0.477

0.558

0.542

$47.16

$648.52

$419.72

$283.67

$483.32

0.678

0.477

0.558

0.542

$70.74

$672.33

$443.75

$307.62

$507.25

0.678

0.477

0.558

0.542

$22.18

$660.43

$431.74

$290.10

$489.75

0.678

0.477

0.558

0.542

$33.26

$660.43

$431.74

$301.18

$500.83

0.678

0.477

0.558

0.542

Parameter: Infusion Costs
First Drug

Second Drug

Parameter: Number of Days of Receiving Rescue Medications During Delayed Phase
No. of Days

1 day

$659.85

$430.88

$294.87

$494.53

0.678

0.477

0.558

0.542

3 days

$661.00

$432.59

$296.42

$496.04

0.678

0.477

0.558

0.542

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4);
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4);
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
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Table 4-13: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective – ICERs
for Cost Parameters
ICER per patient with complete control of
emesis – Payer Perspective

Base Case

ICER per patient with complete control of emesis –
Societal Perspective

Regimen A

Regimen B

Regimen D

Regimen A

Regimen B

Regimen D

$3,363.181

Dominateda

Dominateda

$2,881.605

Dominateda

Dominated

Parameter: Total Prophylactic Antiemetic Regimen Costs
Regimen

Range

Regimen A

$470.80

$2,415.71

Dominateda

Dominateda

$2,069.09

Dominateda

Dominateda

$760.20

$4,386.99

Dominateda

Dominateda

$4,040.37

Dominateda

Dominateda

$233.64

$3,401.35

Dominateda

Dominateda

$3,054,73

Dominateda

Dominateda

$350.46

$3,401.35

Dominateda

Dominateda

$3,054,73

Dominateda

Dominateda

$143.92

$,3702.65

Dominateda

Dominateda

$3,356.03

Dominateda

Dominateda

$215.88

$3,100.05

Dominateda

Dominateda

$2,753.43

Dominateda

Dominateda

$306.45

$3,401.35

Dominateda

Dominateda

$3,054,73

Dominateda

Dominateda

$459.67

$3,401.35

Dominateda

Dominateda

$3,054,73

Dominateda

Dominateda

Regimen B

Regimen C

Regimen D

Parameter: Cost of Aprepitant
Aprepitant

$247.22

$2,883.91

Dominateda

Dominateda

$2,537.29

Dominateda

Dominateda

$370.80

$3,918.79

Dominateda

Dominateda

$3,572.17

Dominateda

Dominateda

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4); Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4);
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4); Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral
Ondansetron 8 mg BID (Days 2-4)
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Table 4-13 (Continued): One Way Sensitivity Analyses Results For HE Model with No Side Effects from Payer and Societal Perspective –
ICERs for Cost Parameters
Parameters/Range

Base Case

ICER – Payer Perspective

ICER – Societal Perspective

Regimen A

Regimen B

Regimen D

Regimen A

Regimen B

Regimen D

$3,363.181

Dominated

Dominated

$2,881.605

Dominated

Dominated

Parameter: Cost of IV Ondansetron
Ondansetron

$165.13

$3,142.09

Dominated

Dominated

$2,795.47

Dominated

Dominated

$247.69

$3,660.62

Dominated

Dominated

$3,314.00

Dominated

Dominated

$47.16

$3,401.93

Dominated

Dominated

$3,055.31

Dominated

Dominated

$70.74

$3,400.78

Dominated

Dominated

$3,054.16

Dominated

Dominated

$22.18

$3,447.74

Dominated

Dominated

$3,101.12

Dominated

Dominated

$33.26

$3,354.96

Dominated

Dominated

$3,008.34

Dominated

Dominated

Parameter: Infusion Costs
First Drug

Second Drug

Parameter: Number of Days of Receiving Rescue Medications During Delayed Phase
No. of Days

1 day

$3,403.04

Dominated

Dominated

$3,056.42

Dominated

Dominated

3 days

$3,399.66

Dominated

Dominated

$3,053.04

Dominated

Dominated

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4); Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4); Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral
Ondansetron 8 mg BID (Days 2-4)
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Effect of Changes in Rescue Medications for Breakthrough Emesis
The delayed phase antiemetic drugs for regimens B and C did not include a 5-HT3RA for
the base-case analysis. In the event of breakthrough emesis during the delayed phase, the base
case analysis modeled the receipt of agents other than 5-HT3RAs as rescue medications. A
scenario analysis was conducted whereby the rescue medications for regimen B and regimen C
included two doses of ondansetron 8 mg for two days in addition to the other rescue medications.
The results obtained for this scenario are reported in Table 4-14.
The addition of 5-HT3RA to rescue medications for regimen B increased the direct and
total costs associated with regimen B, but did not have any impact on the dominance status or
ICER of any other antiemetic regimens. The addition of 5-HT3RA to rescue medications for
regimen C increased the costs associated with regimen C and thus lead to a decrease in the ICER
for regimen A to $3,043.64 and $2,698.79, from the payer and societal perspectives, respectively.
Effect of Changes in Indirect Costs Associated with CINV and its Treatment
The impact of variation in the average hourly wages on total costs, effectiveness and
ICER of each antiemetic regimen from the societal perspective are presented in Table 4-15.
Decreasing the average hourly wage by 20% resulted in an increase in the ICER of regimen A to
$3,199.74 per patient with complete control of emesis, while increasing the average wage by
20% had little impact on the ICER of regimen A. There are uncertainties regarding the amount
of lost productivity associated with delayed CINV. Thus, the number of hours of lost
productivity were varied between 2.75 hours to 24 hours (equivalent to 3 work-days) to study its
impact on the ICER of the antiemetic regimens. The results reported in Table 4-15 show that a
decrease in the lost work hours to 2.75 increases the ICER to $3,314.70 per patient with complete
control of emesis, while increasing the lost work hours to 24 hours decreases the ICER to
$2,645.09.
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Table 4-14: Change in the Antiemetic Regimen for Breakthrough Emesis for Highly Emetogenic Chemotherapy Model
Parameter: Change in Rescue Medications in Delayed Phase for Regimen B
Regimen
Regimen C

Effectiveness

Direct Costs

ICER per patient with
complete control of emesis

Total Costs

ICER per patient with
complete control of emesis

0.564

$187.05

-

$294.19

-

a

Regimen B

0.484

$336.20

Dominated

$465.93

Dominateda

Regimen D

0.549

$389.99

Dominateda

$494.93

Dominateda

Regimen A

0.684

$593.25

$3,368.16

$659.37

$2,995.73

Parameter: Change in Rescue Medications in Delayed Phase for Regimen C
Regimen

Effectiveness

Direct Costs

ICER per patient with
complete control of emesis

Total Costs

ICER per patient with
complete control of emesis

Regimen C

0.564

$222.00

-

$328.78

-

Regimen B

0.484

$300.95

Dominateda

$431.20

Dominateda

Regimen D

0.549

$390.67

Dominateda

$494.89

Dominateda

Regimen A

0.684

$593.63

$3,043.64

$659.08

$2,689.79

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4);
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4);
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
All treatment regimens compared to regimen C
a
Dominated by regimen C
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Table 4-15: Change in the Indirect Costs Associated with CINV and its Treatment for Highly Emetogenic Chemotherapy Model
Total Costs

Base Case

ICER per patient with complete control of emesis

Regimen A

Regimen B

Regimen C

Regimen D

Regimen A

Regimen B

Regimen C

Regimen D

$658.97

$431.56

$295.89

$494.84

$2,881.605

Dominateda

-

Dominateda

Parameter: Average Wage Per Hour
Range
Average Wage

$14.96

$632.41

$376.92

$250.31

$451.35

$3,199.74

Dominateda

-

Dominateda

$30.48

$672.82

$455.99

$315.70

$514.72

$2,990.58

Dominateda

-

Dominateda

Number of Hours of Lost Productivity
Range
No. of Hours

2.75 hrs

$610.20

$333.47

$214.38

$416.51

$3,314.70

Dominateda

-

Dominateda

24 hrs

$739.56

$586.59

$423.70

$619.41

$2,645.09

Dominateda

-

Dominateda

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4);
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4);
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
All treatment regimens compared to regimen C
a
Dominated by regimen C
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Probabilistic Sensitivity Analysis for Highly Emetogenic Chemotherapy Model
Although, one-way sensitivity analyses are easy to understand, incremental costs and
effectiveness do not depend on single parameters and the overall variability in the decision model
cannot be captured completely. Probabilistic sensitivity analysis using second-order Monte Carlo
simulation provides a method to simultaneously vary all the parameters to investigate the overall
impact on ICERs. All costs and probabilities were given ranges and a triangular distribution was
specified for each of the variable. Triangular distribution uses the lowest, highest and the most
likely value of any parameter.
The results of the probabilistic sensitivity analysis from the payer and societal
perspectives are presented in Table 4-16. Although the dominance status of the antiemetic
regimens remained the same as in the base-case analysis, the ICER for regimen A increased to
$3,923.51 per patient with complete protection from emesis from the payer perspective and
increased to $3,524.75 per patient with complete protection from emesis from the societal
perspective.
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Table 4-16: Probabilistic Sensitivity Analysis for Costs, Effectiveness and Incremental Cost Effectiveness Ratios for Antiemetic
Regimens for Prevention of CINV in Patients Receiving Highly Emetogenic Chemotherapy from a Payer Perspective

Side Effects Not Modeled

Treatment Strategy
Direct Costs
Mean (SD)

Effectiveness
Mean (SD)

Cost of achieveing one patient
with complete control of emesis

Incremental cost
effectiveness ratio/patient
with complete control of
emesis

Regimen C (Metoclopramide)

$187.65 ($10.38)

0.561 (0.015)

$334.64

-

Regimen B (Standard)

$301.01 ($18.51)

0.482 (0.016)

$624.59

Dominateda

Regimen D (Ondansetron)

$386.74 ($18.83)

0.545 (0.047

$709.67

Dominateda

Regimen A (Aprepitant)

$594.28 ($25.91)

0.664 (0.031)

$894.47

$3,923.51

Payer Perspective

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4);
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4);
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
All treatment regimens compared to regimen C
a
Dominated by regimen C
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Table 4-17: Probabilistic Sensitivity Analysis for Costs, Effectiveness and Incremental Cost Effectiveness Ratios for Antiemetic
Regimens for Prevention of CINV in Patients Receiving Highly Emetogenic Chemotherapy from a Societal Perspective

Side Effects Not Modeled

Treatment Strategy
Total Costs Mean
(SD)

Effectiveness
Mean (SD)

Cost of achieveing one patient
with complete control of emesis

Incremental cost
effectiveness ratio/patient
with complete control of
emesis

Regimen C (Metoclopramide)

$303.68 ($44.67)

0.560 (0.015)

$541.89

-

Regimen B (Standard)

$439.64 ($54.89)

0.482 (0.016)

$912.00

Dominateda

Regimen D (Ondansetron)

$499.28 ($48.73)

0.544 (0.046)

$917.67

Dominateda

Regimen A (Aprepitant)

$669.57 ($38.98)

0.664 (0.031)

$1,008.05

$3,524.75

Societal Perspective

Regimen A: Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg
(Days 2-4);
Regimen B: Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)
Regimen C: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4);
Regimen D: IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID
(Days 2-4)
All treatment regimens compared to regimen C
a
Dominated by regimen C
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For Moderately Emetogenic Chemotherapy Decision Model – Base Case Analysis
Base Case Analysis Results
A decision model was constructed to evaluate the total costs and benefits of four
prophylactic antiemetic regimens for prevention of CINV due to ME chemotherapy (Refer to
Table 3-2). A hypothetical cohort of 10,000 cancer patients receiving ME chemotherapy was
evaluated using first-order Monte Carlo simulation. The base case results for the costs,
effectiveness, cost of achieving one patient with complete protection from emesis and the ICER
for each of the four antiemetic regimens from the payer perspective are reported in Table 4-18.
The results showed that regimen 3 was the least expensive while regimen 4 was the most
costly prophylactic antiemetic regimen for prevention of CINV following ME chemotherapy. It
was also evident from the results that the effectiveness estimates were equivalent for regimens 1
(regimen which includes palonosetron) and 4 (ASCO 1999 guidelines). The direct cost of
achieving one patient with complete control of emesis with the regimen including palonosetron
was approximately three times that of regimen 3. Under the base case assumptions, from the
payer perspective, the ICER for regimen 1 over regimen 3 was $3,582.48 per patient with
complete control of emesis. Regimen 2, with lower effectiveness and higher costs was
dominated by regimen 3. The direct costs and effectiveness for the antiemetic regimens from the
payer perspective are represented graphically in Figure 4-5.
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Table 4-18: Base Case Results from Payer Perspective using Monte Carlo Simulation of 10,000 Patients with Cancer Receiving
Moderately Emetogenic Chemotherapy

Treatment Strategy

Direct Costs Mean
(SD)

Effectiveness
Mean (SD)

Cost of achieveing one
patient with complete
control of emesis

Incremental cost effectiveness
ratio/patient with complete
control of emesis

Regimen 3 (NCCN)

$159.12 ($23.91)

0.627 (0.484)

$253.74

-

Regimen 2 (Only Ondansetron)

$273.08 ($34.63)

0.502 (0.500)

$544.09

Dominated*

Regimen 1 (Palonosetron)

$403.45 ($24.55)

0.695 (0.460)

$580.25

$3,582.48

Regimen 4 (ASCO)

$451.30 ($17.41)

0.699 (0.459)

$646.09

$14,953.27

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg;
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
*
Regimen 2 was dominated by Regimen 3
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Figure 4-5: Direct Costs, Effectiveness of Different Antiemetic Regimens for Patients
Receiving Moderately Emetogenic Chemotherapy

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral
Ondansetron 4mg BID (Days 2-5)
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The base case results for the costs, effectiveness, cost of achieving one patient with
complete protection from emesis and the ICER for each of the four antiemetic regimens from the
societal perspective are reported in Table 4-19. The total costs and effectiveness for the
antiemetic regimens from the societal perspective are represented graphically in Figure 4-6.
Similar to the results from the payer perspective, regimen 2 was dominated by regimen 3. The
mean costs for achieving one patient with complete control of emesis for each antiemetic
regimen were higher compared to those obtained from the payer’s perspective. The mean costs
for achieving one patient with complete antiemetic protection for regimen 2 was higher ($752.03)
as compared to regimen 1 ($655.65). From the societal perspective, the ICER for regimen 1
compared to regimen 3 was $3,549.02 per patient with complete control of emesis and for
regimen 4 compared to regimen 1 was $6,499.87.
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Table 4-19: Base Case Results from Payer Perspective using Monte Carlo Simulation of 10,000 Patients with Cancer Receiving
Moderately Emetogenic Chemotherapy

Treatment Strategy

Total Costs
Mean (SD)

Effectiveness
Mean (SD)

Cost of achieveing one
patient with complete
control of emesis

Incremental cost effectiveness
ratio/patient with complete
control of emesis

Regimen 3 (NCCN)

$216.31 ($122.24)

0.630 (0.483)

$343.35

-

Regimen 2 (Only Ondansetron)

$381.05 ($149.06)

0.507 (0.500)

$752.03

Dominated*

Regimen 1 (Palonosetron)

$457.64 ($120.53)

0.698 (0.459)

$655.65

$3,549.02

Regimen 4 (ASCO)

$475.84 ($85.69)

0.701 (0.458)

$679.00

$6,499.87

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg;
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
*
Regimen 2 was dominated by Regimen 3
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Figure 4-6: Total Costs, Effectiveness of Different Antiemetic Regimens for Patients
Receiving Moderately Emetogenic Chemotherapy

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral
Ondansetron 4mg BID (Days 2-5)
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Sensitivity Analyses for Moderately Emetogenic Chemotherapy Model
Effect of Changes in Control of Acute and Delayed Emesis
The efficacy parameters, probability of no acute emesis, probability of no delayed emesis
given no acute emesis and probability of no delayed emesis given acute emesis were varied over
a plausible range obtained from published literature. Table 4-20 presents the range for sensitivity
analysis and the direct costs and effectiveness from the payer’s perspective. Table 4-21 presents
the same results for the model from societal perspective. The ICER for each regimen obtained
from sensitivity analyses are reported in Table 4-22.
The change in the probability of no acute emesis for regimen 1 had a significant impact
on the costs, effectiveness and ICER of antiemetic regimens from the payer and societal
perspectives. Decreasing the probability from 0.850 to 0.680 resulted in the regimen with
palonosetron being dominated by regimen 3. Additionally, the ICER for regimen 4 was
calculated in comparison to regimen 3, the only non-dominated option. This result was similar to
the ICER of regimen 4 over regimen 3, calculated for base-case estimates (value not shown in the
table). Conversely, increasing the probability of no acute emesis for regimen 1 from 0.850 to
0.900 changes the dominance status, with regimen 4 being dominated by regimen 3. The results
were also sensitive to the variations in the probability of no acute emesis for regimens 3 and 4.
The changes in the probability of no delayed emesis given no acute emesis have a similar
impact on the base-case results. Decreasing the probability for regimen 1 results in it being
dominated by other regimens and increasing the probability, results in regimen 4 being
dominated. Similarly, decreasing the probability for regimens 3 and 4 translates into higher costs
and higher effectiveness of regimen 1, while increasing the probability of regimens 3 and 4
results in elimination of regimen 1 from ICER calculations based on dominance and extended
dominance.
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Table 4-20: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Efficacy
Parameters
DIRECT COSTS
Regimen 1

Regimen 2

EFFECTIVENESS

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of No Acute Emesis
Base Case

$403.45

$273.08

$159.12

$451.30

0.695

0.502

0.627

0.699

Regimen

Range

Regimen 1

0.680

$406.13

$273.10

$159.33

$451.39

0.554

0.503

0.625

0.696

0.900

$402.84

$273.10

$159.33

$451.39

0.734

0.503

0.625

0.696

0.576

$403.59

$275.00

$159.33

$451.39

0.693

0.402

0.625

0.696

0.864

$403.59

$271.20

$159.33

$451.39

0.693

0.604

0.625

0.696

0.714

$403.59

$273.10

$161.37

$452.99

0.693

0.503

0.500

0.557

0.900

$403.59

$273.10

$159.23

$451.32

0.693

0.503

0.631

0.702

0.714

$403.59

$273.10

$161.37

$452.99

0.693

0.503

0.500

0.557

0.900

$403.59

$273.10

$159.23

$451.32

0.693

0.503

0.631

0.702

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-20 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Efficacy
Parameters
Parameters/Range

DIRECT COSTS
Regimen 1

Regimen 2

Regimen 3

EFFECTIVENESS
Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of No Delayed Emesis Given No Acute Emesis
Base Case

$403.45

$273.08

$159.12

$451.30

0.695

0.502

0.627

0.699

Regimen

Range

Regimen 1

0.739

$405.95

$273.10

$159.33

$451.39

0.554

0.503

0.625

0.696

0.950

$403.26

$273.10

$159.33

$451.39

0.713

0.503

0.625

0.696

0.649

$403.59

$274.78

$159.33

$451.39

0.693

0.402

0.625

0.696

0.950

$403.59

$271.69

$159.33

$451.39

0.693

0.589

0.625

0.696

0.684

$403.59

$273.10

$161.56

$451.39

0.693

0.503

0.500

0.696

0.950

$403.59

$273.10

$158.09

$451.39

0.693

0.503

0.694

0.696

0.762

$403.59

$273.10

$159.33

$453.88

0.693

0.503

0.625

0.557

1.000

$403.59

$273.10

$159.33

$450.77

0.693

0.503

0.625

0.731

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-20 (Continued): One Way Sensitivity Analyses Results For ME Model with No Side Effects from Payer Perspective– Efficacy
Parameters
Parameters/Range

DIRECT COSTS
Regimen 1

Regimen 2

EFFECTIVENESS

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Probability of No Delayed Emesis Given Acute Emesis
Base Case

$403.45

$273.08

$159.12

$451.30

0.695

0.502

0.627

0.699

Regimen

Range

Regimen 1

0.000

$403.89

$273.10

$159.33

$451.39

0.693

0.503

0.625

0.696

0.300

$403.21

$273.10

$159.33

$451.39

0.693

0.503

0.625

0.696

0.000

$403.59

$273.53

$159.33

$451.39

0.693

0.503

0.625

0.696

0.300

$403.59

$272.33

$159.33

$451.39

0.693

0.503

0.625

0.696

0.000

$403.59

$273.10

$159.80

$451.39

0.693

0.503

0.625

0.696

0.568

$403.59

$273.10

$158.90

$451.39

0.693

0.503

0.625

0.696

0.300

$403.59

$273.10

$159.33

$451.82

0.693

0.503

0.625

0.696

0.682

$403.59

$273.10

$159.33

$451.21

0.693

0.503

0.625

0.696

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-21: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Efficacy
Parameters
TOTAL COSTS
Regimen 1

Regimen 2

EFFECTIVENESS

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of No Acute Emesis
Base Case

$457.64

$381.05

$216.31

$475.84

0.698

0.500

0.630

0.701

Regimen

Range

Regimen 1

0.680

$499.24

$382.14

$217.31

$476.71

0.554

0.503

0.625

0.696

0.900

$446.72

$382.14

$217.31

$476.71

0.734

0.503

0.625

0.696

0.576

$458.66

$412.76

$217.31

$476.71

0.693

0.402

0.625

0.696

0.864

$458.66

$351.52

$217.31

$476.71

0.693

0.604

0.625

0.696

0.714

$458.66

$382.14

$247.31

$497.65

0.693

0.503

0.500

0.557

0.900

$458.66

$382.14

$215.96

$475.77

0.693

0.503

0.631

0.702

0.714

$458.66

$382.14

$247.31

$497.65

0.693

0.503

0.500

0.557

0.900

$458.66

$382.14

$215.96

$475.77

0.693

0.503

0.631

0.702

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-21 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Efficacy
Parameters
TOTAL COSTS
Regimen 1

Regimen 2

Regimen 3

EFFECTIVENESS
Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of No Delayed Emesis Given No Acute Emesis
Base Case

$457.64

$381.05

$216.31

$475.84

0.698

0.500

0.630

0.701

Regimen

Range

Regimen 1

0.739

$505.51

$382.14

$217.31

$476.71

0.554

0.503

0.625

0.696

0.950

$452.08

$382.14

$217.31

$476.71

0.713

0.503

0.625

0.696

0.649

$458.66

$417.02

$217.31

$476.71

0.693

0.402

0.625

0.696

0.950

$458.66

$352.61

$217.31

$476.71

0.693

0.589

0.625

0.696

0.684

$458.66

$382.14

$262.70

$476.71

0.693

0.503

0.500

0.696

0.950

$458.66

$382.14

$192.09

$476.71

0.693

0.503

0.694

0.696

0.762

$458.66

$382.14

$217.31

$527.14

0.693

0.503

0.625

0.557

1.000

$458.66

$382.14

$217.31

$463.97

0.693

0.503

0.625

0.731

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-21 (Continued): One Way Sensitivity Analyses Results For ME Model with No Side Effects from Societal Perspective– Efficacy
Parameters
TOTAL COSTS
Regimen 1

Regimen 2

Regimen 3

EFFECTIVENESS
Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of No Delayed Emesis Given Acute Emesis
Base Case

$457.64

$381.05

$216.31

$475.84

0.698

0.500

0.630

0.701

Regimen

Range

Regimen 1

0.000

$464.60

$382.14

$217.31

$476.71

0.693

0.503

0.625

0.696

0.300

$451.20

$382.14

$217.31

$476.71

0.693

0.503

0.625

0.696

0.000

$458.66

$391.04

$217.31

$476.71

0.693

0.503

0.625

0.696

0.300

$458.66

$366.08

$217.31

$476.71

0.693

0.503

0.625

0.696

0.000

$458.66

$382.14

$226.95

$476.71

0.693

0.503

0.625

0.696

0.568

$458.66

$382.14

$208.70

$476.71

0.693

0.503

0.625

0.696

0.300

$458.66

$382.14

$217.31

$485.32

0.693

0.503

0.625

0.696

0.682

$458.66

$382.14

$217.31

$473.04

0.693

0.503

0.625

0.696

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-22: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective – ICERs
for Efficacy Parameters
ICER per patient with complete control of emesis – Payer
Perspective
Regimen 1

Regimen 2

ICER per patient with complete control of emesis – Societal
Perspective

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of No Acute Emesis
Base Case

$3,582.48

Dominateda

-

$14,953.27

$3,549.02

Dominateda

-

$6,499.87

Regimen

Range

Regimen 1

0.680

Dominateda

Dominateda

-

$4,118.70

Dominateda

Dominateda

-

$3,658.01

0.900

$2,237.88

Dominateda

-

Dominateda

$2,108.29

Dominateda

-

Dominateda

0.576

$3,589.75

Dominateda

-

$16,655.68

$3,546.97

Dominateda

-

$6,292.08

0.864

$3,589.75

Dominateda

-

$16,665.68

$3,546.97

Dominateda

-

$6,292.08

0.714

$1,256.47

Extended Dominanceb

-

Dominateda

$1,096.38

Extended
Dominanceb

-

Dominateda

0.900

$3,913.53

Dominateda

-

$5,239.52

Extended
Dominancec

Dominateda

-

$3,631.19

0.714

$1,256.47

Extended Dominanceb

-

Dominateda

$3,634.32

Dominateda

-

$4,220.16

$3,437.29

a

-

$8,893.67

Regimen 2

Regimen 3

Regimen 4

0.900

$3,913.53

a

Dominated

$5,239.52

-

Dominated

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens compared to regimen 3
a
Dominated by regimen 3; b Dominated by a blend of regimen 3 and regimen 1; c Dominated by a blend of regimen 3 and 4
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Table 4-22 (Continued): One Way Sensitivity Analyses Results For HE Model with No Side Effects from Payer and Societal Perspective –
ICERs for Efficacy Parameters
ICER per patient with complete control of emesis – Payer
Perspective
Regimen 1

Regimen 2

Regimen 3

ICER per patient with complete control of emesis – Societal
Perspective

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Probability of No Delayed Emesis Given No Acute Emesis
$3,582.48

Dominateda

-

$14,953.27

$3,549.02

Dominateda

-

$6,499.87

0.739

Dominateda

Dominateda

-

$4,118.70

Dominateda

Dominateda

-

$3,658.01

0.950

$2,786.28

Dominateda

-

Dominateda

$2,681.61

Dominateda

-

Dominateda

0.649

$3,589.75

Dominateda

-

$16,665.68

$3,546.97

Dominateda

-

$6,292.08

0.950

$3,589.75

Dominateda

-

$16,665.68

$3,546.97

Dominateda

-

$6,292.08

0.684

$1,253.66

Extended
Dominanceb

-

$16,665.68

$1,015.05

Extended
Dominanceb

-

$6,292.08

0.950

Dominateda

Dominateda

-

$200,606.36

Dominateda

Dominateda

-

$194,660.47

a

a

a

Base Case
Regimen
Regimen 1

Regimen 2

Regimen 3

Regimen 4

Range

0.762

$3,589.75

Dominated

-

Dominated

$3,546.97

Dominated

-

Dominateda

1.000

Extended
Dominancec

Dominateda

-

$2,749.35

Extended
Dominancec

Dominateda

-

$2,326.89

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens compared to regimen 3
a
Dominated by regimen 3; b Dominated by a blend of regimen 3 and regimen 1; c Dominated by a blend of regimen 3 and 4
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Table 4-22 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective –
ICERs for Efficacy Parameters
ICER – Payer Perspective
Regimen 1

Regimen 2

Regimen 3

ICER – Societal Perspective
Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of No Delayed Emesis Given Acute Emesis
Base Case

$3,582.48

Dominateda

-

$14,953.27

$3,549.02

Dominateda

-

$6,499.87

Regimen

Range

Regimen 1

0.000

$3,594.15

Dominateda

-

$16,561.40

$3,634.32

Dominateda

-

$4,220.16

0.300

$3,584.23

Dominateda

-

$16,796.61

$3,437.29

Dominateda

-

$8,893.67

0.000

$3,589.75

Dominateda

-

$16,665.68

$3,546.97

Dominateda

-

$6,292.08

$3,589.75

a

$3,546.97

a

-

$6,292.08

a

-

$6,292.08

a

-

$6,292.08

a

-

$9,294.71

a

-

$5,014.84

Regimen 2

0.300
Regimen 3

0.000
0.568

Regimen 4

0.300
0.682

$,3582.77
$3,595.99
$3,589.75
$3,589.75

Dominated

a

Dominated

a

Dominated

a

Dominated

a

Dominated

-

$16,665.68
$16,665.68
$16,665.68
$16,813.59
$16,602.76

$3,405.27
$3,673.55
$3,546.97
$3,546.97

Dominated
Dominated
Dominated
Dominated

Dominated

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens are compared to regimen 3
a
Dominated by regimen 3
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Effect of Changes in the Receipt of Rescue Medications
The results of sensitivity analysis on the probability of receipt of rescue medications
during acute and delayed phase are reported in Table 4-23 from the payer perspective and in
Table 4-24 from the societal perspective. The ICER results are presented in Table 4-25. The
results were not sensitive to changes in the probability of receiving rescue medications in the
acute phase given acute emesis, and the probability of receiving rescue medications in the
delayed phase given delayed emesis. The probabilities of receiving rescue medications in the
acute phase given no acute emesis and in the delayed phase given no delayed emesis have a
significant impact on the model results. For regimen 1, increasing the probability of receiving
rescue medications in the acute phase given no acute emesis, and for regimens 3 and 4,
decreasing the same probability resulted in a change in the dominance status of the various
antiemetic regimens (Refer to Table 4-25). Similar changes were observed due to the variations
in the probability of receiving rescue medications in the delayed phase given no delayed emesis
for regimens 1, 3 and 4.
Effect of Changes in the Receipt of Outpatient Care
The results of sensitivity analysis on the probability of receipt of outpatient care during
the acute and delayed phase from the payer perspective are reported in Tables 4-23 and 4-24.
The ICER results are presented in Table 4-25. The base-case results were not sensitive to changes
in the probability of receiving outpatient care either in the acute phase or the delayed phase. The
dominance status of the antiemetic regimens remained the same as the base case results; from the
payer and societal perspectives.
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Table 4-23: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Receipt of Rescue
Medications
DIRECT COSTS
Regimen 1

Regimen 2

Regimen 3

EFFECTIVENESS
Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Probability of Receiving Rescue Medications In the Acute Phase Given No Acute Emesis
Base Case

$403.45

$273.08

$159.12

$451.30

0.695

0.502

0.627

0.699

Regimen

Range

Regimen 1

0.000

$403.42

$273.10

$159.33

$451.39

0.727

0.503

0.625

0.696

0.104

$403.69

$273.10

$159.33

$451.39

0.652

0.503

0.625

0.696

0.000

$403.59

$273.05

$159.33

$451.39

0.693

0.528

0.625

0.696

0.104

$403.59

$273.17

$159.33

$451.39

0.693

0.473

0.625

0.696

0.000

$403.59

$273.10

$159.17

$451.24

0.693

0.503

0.698

0.777

0.125

$403.59

$273.10

$159.36

$451.43

0.693

0.503

0.610

0.679

0.000

$403.59

$273.10

$159.17

$451.24

0.693

0.503

0.698

0.777

0.125

$403.59

$273.10

$159.36

$451.43

0.693

0.503

0.610

0.679

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-23 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Receipt of
Rescue Medications
DIRECT COSTS
Regimen 1

Regimen 2

Regimen 3

EFFECTIVENESS
Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given Acute Emesis
Base Case
Regimen

Range

$403.45

$273.08

$159.12

$451.30

0.695

0.502

0.627

0.699

Regimen 1

0.240

$403.57

$273.10

$159.33

$451.39

0.693

0.503

0.625

0.696

1.000

$403.76

$273.10

$159.33

$451.39

0.693

0.503

0.625

0.696

0.240

$403.59

$273.01

$159.33

$451.39

0.693

0.503

0.625

0.696

1.000

$403.59

$273.42

$159.33

$451.39

0.693

0.503

0.625

0.696

0.300

$403.59

$273.10

$159.29

$451.39

0.693

0.503

0.625

0.696

1.000

$403.59

$273.10

$159.41

$451.39

0.693

0.503

0.625

0.696

0.300

$403.59

$273.10

$159.33

$451.39

0.693

0.503

0.625

0.696

1.000

$403.59

$273.10

$159.33

$451.39

0.693

0.503

0.625

0.696

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-23 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Receipt of
Rescue Medications
DIRECT COSTS
Regimen 1

Regimen 2

Regimen 3

EFFECTIVENESS
Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of Receiving Rescue Medications In the Delayed Phase Given No Delayed Emesis
Base Case

$403.45

$273.08

$159.12

$451.30

0.695

0.502

0.627

0.699

Parameter

Range

Regimen 1

0.000

$402.80

$273.10

$159.33

$451.39

0.749

0.503

0.625

0.696

0.100

$403.87

$273.10

$159.33

$451.39

0.674

0.503

0.625

0.696

0.000

$403.59

$272.32

$159.33

$451.39

0.693

0.557

0.625

0.696

0.120

$403.59

$273.29

$159.33

$451.39

0.693

0.490

0.625

0.696

0.000

$403.59

$273.10

$158.43

$451.39

0.693

0.503

0.683

0.696

0.120

$403.59

$273.10

$159.69

$451.39

0.693

0.503

0.601

0.696

0.000

$403.59

$273.10

$159.33

$450.37

0.693

0.503

0.625

0.761

0.120

$403.59

$273.10

$159.33

$451.81

0.693

0.503

0.625

0.669

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-23 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Receipt of
Rescue Medications
DIRECT COSTS
Regimen 1

Regimen 2

Regimen 3

EFFECTIVENESS
Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of Receiving Rescue Medications In the Delayed Phase Given Delayed Emesis
Base Case

$403.45

$273.08

$159.12

$451.30

0.695

0.502

0.627

0.699

Regimen

Range

Regimen 1

0.400

$403.33

$273.10

$159.33

$451.39

0.693

0.503

0.625

0.696

1.000

$404.88

$273.10

$159.33

$451.39

0.693

0.503

0.625

0.696

0.378

$403.59

$272.62

$159.33

$451.39

0.693

0.503

0.625

0.696

1.000

$403.59

$275.79

$159.33

$451.39

0.693

0.503

0.625

0.696

0.389

$403.59

$273.10

$159.06

$451.39

0.693

0.503

0.625

0.696

1.000

$403.59

$273.10

$160.72

$451.39

0.693

0.503

0.625

0.696

0.389

$403.59

$273.10

$159.33

$451.28

0.693

0.503

0.625

0.696

1.000

$403.59

$273.10

$159.33

$452.00

0.693

0.503

0.625

0.696

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-23 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Receipt of
Outpatient Care
DIRECT COSTS

Base Case

EFFECTIVENESS

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

$403.45

$273.08

$159.12

$451.30

0.695

0.502

0.627

0.699

Parameter: Probability of Receipt of Outpatient Care During Acute Phase Given:
No Rescue
Medications

Rescue
Medications

0.000

$403.31

$272.58

$159.19

$451.26

0.693

0.503

0.625

0.696

0.030

$404.15

$274.15

$159.60

$451.67

0.693

0.503

0.625

0.696

0.000

$403.47

$272.88

$159.18

$451.24

0.693

0.503

0.625

0.696

0.030

$403.83

$273.55

$159.63

$451.70

0.693

0.503

0.625

0.696

Parameter: Probability of Receipt of Outpatient Care During Delayed Phase Given:
No Rescue
Medications

Rescue
Medications

0.02

$403.20

$272.28

$158.90

$451.21

0.693

0.503

0.625

0.696

0.05

$403.98

$273.92

$159.75

$451.58

0.693

0.503

0.625

0.696

0.02

$403.20

$272.37

$158.93

$451.22

0.693

0.503

0.625

0.696

0.05

$403.98

$273.83

$159.73

$451.57

0.693

0.503

0.625

0.696

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-24: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Receipt of Rescue
Medications
TOTAL COSTS
Regimen 1

Regimen 2

Regimen 3

EFFECTIVENESS
Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given No Acute Emesis
Base Case

$457.64

$381.05

$216.31

$475.84

0.698

0.500

0.630

0.701

Regimen

Range

Regimen 1

0.000

$458.59

$382.14

$217.31

$476.71

0.727

0.503

0.625

0.696

0.104

$458.74

$382.14

$217.31

$476.71

0.652

0.503

0.625

0.696

0.000

$458.66

$382.08

$217.31

$476.71

0.693

0.528

0.625

0.696

0.104

$458.66

$382.21

$217.31

$476.71

0.693

0.473

0.625

0.696

0.000

$458.66

$382.14

$217.16

$476.56

0.693

0.503

0.698

0.777

0.125

$458.66

$382.14

$217.34

$476.74

0.693

0.503

0.610

0.679

0.000

$458.66

$382.14

$217.16

$476.56

0.693

0.503

0.698

0.777

0.125

$458.66

$382.14

$217.34

$476.74

0.693

0.503

0.610

0.679

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-24 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Receipt of
Rescue Medications
TOTAL COSTS
Regimen 1

Regimen 2

Regimen 3

EFFECTIVENESS
Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given Acute Emesis
Base Case

$457.64

$381.05

$216.31

$475.84

0.698

0.500

0.630

0.701

Regimen

Range

Regimen 1

0.240

$458.64

$382.14

$217.31

$476.71

0.693

0.503

0.625

0.696

1.000

$458.83

$382.14

$217.31

$476.71

0.693

0.503

0.625

0.696

0.240

$458.66

$382.11

$217.31

$476.71

0.693

0.503

0.625

0.696

1.000

$458.66

$382.46

$217.31

$476.71

0.693

0.503

0.625

0.696

0.300

$458.66

$382.14

$217.27

$476.67

0.693

0.503

0.625

0.696

1.000

$458.66

$382.14

$217.39

$476.79

0.693

0.503

0.625

0.696

0.300

$458.66

$382.14

$217.39

$476.79

0.693

0.503

0.625

0.696

1.000

$458.66

$382.14

$217.39

$476.79

0.693

0.503

0.625

0.696

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)

176

RESULTS

Reema Mody

Table 4-24 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Receipt of
Rescue Medications
TOTAL COSTS
Regimen 1

Regimen 2

Regimen 3

EFFECTIVENESS
Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Probability of Receiving Rescue Medications In the Delayed Phase Given No Delayed Emesis
Base Case

$457.64

$381.05

$216.31

$475.84

0.698

0.500

0.630

0.701

Regimen

Range

Regimen 1

0.000

$457.87

$382.14

$217.31

$476.71

0.749

0.503

0.625

0.696

0.100

$458.94

$382.14

$217.31

$476.71

0.674

0.503

0.625

0.696

0.000

$458.66

$381.35

$217.31

$476.71

0.693

0.557

0.625

0.696

0.120

$458.66

$382.33

$217.31

$476.71

0.693

0.490

0.625

0.696

0.000

$458.66

$382.14

$216.41

$476.71

0.693

0.503

0.683

0.696

0.120

$458.66

$382.14

$217.67

$476.71

0.693

0.503

0.601

0.696

0.000

$458.66

$382.14

$217.31

$475.68

0.693

0.503

0.625

0.761

0.120

$458.66

$382.14

$217.31

$477.13

0.693

0.503

0.625

0.669

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-24 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Receipt of
Rescue Medications
TOTAL COSTS
Regimen 1

Regimen 2

Regimen 3

EFFECTIVENESS
Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Probability of Receiving Rescue Medications In the Delayed Phase Given Delayed Emesis
Base Case

$457.64

$381.05

$216.31

$475.84

0.698

0.500

0.630

0.701

Regimen

Range

Regimen 1

0.400

$458.40

$382.14

$217.31

$476.71

0.693

0.503

0.625

0.696

1.000

$459.95

$382.14

$217.31

$476.71

0.693

0.503

0.625

0.696

0.378

$458.66

$381.66

$217.31

$476.71

0.693

0.503

0.625

0.696

1.000

$458.66

$384.83

$217.31

$476.71

0.693

0.503

0.625

0.696

0.389

$458.66

$382.14

$217.05

$476.71

0.693

0.503

0.625

0.696

1.000

$458.66

$382.14

$218.70

$476.71

0.693

0.503

0.625

0.696

0.389

$458.66

$382.14

$217.31

$476.59

0.693

0.503

0.625

0.696

1.000

$458.66

$382.14

$217.31

$477.32

0.693

0.503

0.625

0.696

Regimen 2

Regimen 3

Regimen 4

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-24 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Receipt of
Outpatient Care
TOTAL COSTS

Base Case

EFFECTIVENESS

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

$457.64

$381.05

$216.31

$475.84

0.698

0.500

0.630

0.701

Parameter: Probability of Receipt of Outpatient Care During Acute Phase Given:
No Rescue
Medications

Rescue
Medications

0.000

$458.38

$381.62

$217.17

$476.57

0.693

0.503

0.625

0.696

0.030

$459.22

$383.19

$217.58

$476.98

0.693

0.503

0.625

0.696

0.000

$458.54

$381.91

$217.16

$476.56

0.693

0.503

0.625

0.696

0.030

$458.90

$382.59

$217.61

$477.01

0.693

0.503

0.625

0.696

Probability of Receipt of Outpatient Care During Delayed Phase Given:
No Rescue
Medications

Rescue
Medications

0.02

$458.27

$381.32

$216.89

$476.52

0.693

0.503

0.625

0.696

0.05

$459.05

$382.96

$217.73

$476.89

0.693

0.503

0.625

0.696

0.02

$458.27

$381.41

$216.91

$476.53

0.693

0.503

0.625

0.696

0.05

$459.05

$382.87

$217.71

$476.88

0.693

0.503

0.625

0.696

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-25: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective – ICERs
for Receipt of Rescue Medications
ICER per patient with complete control of emesis – Payer
Perspective

Base Case

ICER per patient with complete control of emesis – Societal
Perspective

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

$3,582.48

Dominateda

-

$14,953.27

$3,549.02

Dominateda

-

$6,499.87

Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given No Acute Emesis
Regimen 1

Regimen 2

Regimen 3

Regimen 4

0.000

$2,388.78

Dominateda

-

Dominateda

$2,360.30

Dominateda

-

Dominated

0.104

Extended
Dominanceb

Dominateda

-

$4,118.69

Extended Dominanceb

Dominateda

-

$3,658.01

0.000

$3,589.75

Dominateda

-

$16,665.68

$3,546.97

Dominateda

-

$6,292.08

0.104

$3,589.75

Dominateda

-

$16,665.68

$3,546.97

Dominateda

0.000

Dominateda

Dominateda

-

$3,690.35

Dominateda

Dominateda

-

$3,277.58

0.125

$2,953.43

Dominateda

-

Dominateda

$2,918.23

Dominateda

-

Dominated

0.000

Dominateda

Dominateda

-

$3,690.35

Dominateda

Dominateda

-

$3,277.58

0.125

$2,953.43

Dominateda

-

Dominateda

$2,918.23

Dominateda

-

Dominated

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens were compared to regimen 3
a
Dominated by regimen 3
b
Dominated by a blend of regimen 3 and regimen 4

180

$6,292.08

RESULTS

Reema Mody

Table 4-25 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective –
ICERs for Receipt of Rescue Medications
ICER per patient with complete control of emesis –
Payer Perspective
Regimen 1

Regimen 2

Regimen 3

ICER per patient with complete control of emesis – Societal
Perspective

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Probability of Receiving Rescue Medications In the Acute Phase Given Acute Emesis
Base Case

$3,582.48

Dominateda

-

$14,953.27

$3,549.02

Dominateda

-

$6,499.87

Regimen

Range

Regimen 1

0.240

$3,589.54

Dominateda

-

$16,670.84

$3,546.75

Dominateda

-

$6,297.24

1.000

$3,592.29

Dominateda

-

$16,605.50

$3,549.51

Dominateda

-

$6,231.90

0.240

$3,589.75

Dominateda

-

$16,665.68

$3,546.97

Dominateda

-

$6,292.08

1.000

$3,589.75

Dominateda

-

$16,665.68

$3,546.97

Dominateda

-

$6,292.08

0.300

$3,590.34

Dominateda

-

$16,651.87

$3,547.55

Dominateda

-

$6,278.28

$3,588.51

a

$3,545.72

a

-

$6,321.61

a

Regimen 2

Regimen 3

1.000
Regimen 4

Dominated

a

-

$16,695.20

Dominated

0.300

$3,589.75

Dominated

-

$16,665.68

$3,546.97

Dominated

-

$6,292.08

1.000

$3,589.75

Dominateda

-

$16,665.68

$3,546.97

Dominateda

-

$6,292.08

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens were compared to regimen 3
a
Dominated by regimen 3
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Table 4-25 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective –
ICERs for Receipt of Rescue Medications
ICER per patient with complete control of emesis –
Payer Perspective
Regimen 1

Regimen 2

Regimen 3

ICER per patient with complete control of emesis – Societal
Perspective

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Probability of Receiving Rescue Medications In the Delayed Phase Given No Delayed Emesis
Base Case

$3,582.48

Dominateda

-

$14,953.27

$3,549.02

Dominateda

-

$6,499.87

Regimen

Range

Regimen A

0.000

$1,972.53

Dominateda

-

Dominateda

$1,948.94

Dominateda

-

Dominateda

0.100

Extended
Dominanceb

Dominateda

-

$4,118.70

Extended Dominanceb

Dominateda

-

$3,658.01

0.000

$3,589.75

Dominateda

-

$16,665.68

$3,546.97

Dominateda

-

$6,292.08

0.120

$3,589.75

Dominateda

-

$16,665.68

$3,546.97

Dominateda

-

$6,292.08

0.000

Extended
Dominanceb

Dominateda

-

$23,208.07

Extended Dominanceb

Dominateda

-

$20,620.16

0.120

$2,658.10

Dominateda

-

$16,665.68

$2,626.37

Dominateda

-

$6,292.08

a

-

$1,902.38

a

-

Dominateda

Regimen B

Regimen C

Regimen D

0.000
0.120

a

Dominated
$3,589.75

a

Dominated

a

Dominated

-

b

$2,412.92
Dominated

Extended Dominance
a

$,3546.97

Dominated

Dominated

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens were compared to regimen 3
a
Dominated by regimen 3
b
Dominated by a blend of regimens 3 and 4
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Table 4-25 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective –
ICERs for Receipt of Rescue Medications
ICER per patient with complete control of emesis –
Payer Perspective
Regimen 1

Regimen 2

Regimen 3

Regimen 4

ICER per patient with complete control of emesis – Societal
Perspective
Regimen 1

Regimen 2

Regimen 3

Regimen 4

Probability of Receiving Rescue Medications In the Delayed Phase Given Delayed Emesis
Base Case

$3,582.48

Dominated

-

$14,953.27

$3,549.02

Dominated

-

$6,499.87

Regimen

Range

Regimen A

0.400

$3,585.97

Dominated

-

$16,755.44

$3,543.19

Dominated

-

$6,381.85

1.000

$3,608.68

Dominated

-

$16,216.85

$3,565.89

Dominated

-

$5,843.26

0.378

$3,589.75

Dominated

-

$16,665.68

$3,546.97

Dominated

-

$6,292.08

1.000

$3,589.75

Dominated

-

$16,665.68

$3,546.97

Dominated

-

$6,292.08

0.389

$3,593.62

Dominated

-

$16,665.68

$3,550.83

Dominated

-

$6,292.08

1.000

$3,569.27

Dominated

-

$16,665.68

$3,526.49

Dominated

-

$6,292.08

0.389

$3,589.75

Dominated

-

$16,625.65

$3,546.97

Dominated

-

$6,252.06

1.000

$3,589.75

Dominated

-

$16,877.76

$3,546.97

Dominated

-

$6,504.16

Regimen B

Regimen C

Regimen D

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens were compared to regimen 3
a
Dominated by regimen 3
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Table 4-25 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective –
ICERs for Receipt of Outpatient Care
ICER per patient with complete control of emesis –
Payer Perspective

Base Case

ICER per patient with complete control of emesis – Societal
Perspective

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

$3,582.48

Dominateda

-

$14,953.27

$3,549.02

Dominateda

-

$6,499.87

Parameter: Probability of Receipt of Outpatient Care During Acute Phase Given:
No Rescue
Medications

Rescue
Medications

0.000

$3,587.65

Dominateda

-

$16,715.53

$3,544.87

Dominateda

-

$6,341.93

0.030

$3,593.96

Dominateda

-

$16,565.97

$3,551.17

Dominateda

-

$6,192.38

0.000

$3,590.21

Dominateda

-

$16,654.97

$3,547.42

Dominateda

-

$6,281.38

0.030

$3,588.85

Dominateda

-

$16,687.09

$3,546.07

Dominateda

-

$6,313.49

Parameter: Probability of Receipt of Outpatient Care During Delayed Phase Given:
No Rescue
Medications

Rescue
Medications

0.020

$3,590.23

Dominateda

-

$16,737.45

$3,546.73

Dominateda

-

$6,256.19

0.050

$3,589.28

Dominateda

-

$16,593.90

$3,546.73

Dominateda

-

$6,220.31

0.020

$3,589.89

Dominateda

-

$16,740.96

$3,547.10

Dominateda

-

$6,367.36

0.050

$3,589.62

Dominateda

-

$16,590.40

$3,546.83

Dominateda

-

$6,216.80

Regimen 1: IV Palonosetron 0.25mg; Regimen 2: IV Ondansetron 32mg, Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID
(Days 2-5); Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens were compared to regimen 3; a Dominated by regimen 3
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Effect of Changes in the Cost and Utilization Parameters
The impact of changes in the total cost of prophylactic antiemetic regimens, cost of
palonosetron, cost of ondansetron, infusion costs, and the number of days of receiving rescue
medications during the delayed phase from the payer and societal perspectives are reported in
Tables 4-26 and 4-27, respectively. The ICER results are presented in Table 4-28. The ICER
results showed that regimen 1 was dominated by regimen 3 for four conditions, 1) when the cost
of regimen 1 was increased by 20%, 2) decreasing the cost of regimen 4 by 20%, 3) increasing
the cost of palonosetron by 20%, and 4) decreasing the cost of ondansetron by 20%.
Effect of Changes in Rescue Medications for Breakthrough Emesis
The delayed phase antiemetic regimen for strategies 1, 2 and 3 did not include a 5HT3RA in the base-case analysis. In the event of breakthrough emesis in the delayed phase,
prochlorperazine was the rescue medication used for base-case analysis. The use of 5-HT3RA if
not used prophylactically, is recommended by some guidelines. A scenario analysis was
conducted in which rescue medications for regimens 1, 2 and 3 included two doses of
ondansetron 8 mg for two days in addition to the other rescue medications. The impact of
changes in rescue medications for breakthrough emesis during delayed phase on costs and ICERs
are reported in Table 4-29.
Addition of ondansetron as rescue medication in the delayed phase changed the
dominance status of the antiemetic regimens from the societal perspective. Regimen 1 was
dominated by regimen 4 and the ICER for regimen 4 over regimen 3 was $3,658.01 per patient
with complete control of emesis. The change in the rescue medications in the delayed phase for
regimen 2 did not change the dominance status and the ICER of the antiemetic regimens. The
results were sensitive to the changes made for regimen 3. Although the dominance status
remained same, the total costs for regimen 3 increased resulting in a decrease in the ICER of
regimen A.
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Table 4-26: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Cost Parameters
DIRECT COSTS

Base Case

EFFECTIVENESS

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

$403.45

$273.08

$159.12

$451.30

0.695

0.502

0.627

0.699

Parameter: Total Prophylactic Antiemetic Regimen Costs
Regimen

Range

Regimen 1

$319.31

$323.75

$273.10

$159.33

$451.39

0.693

0.503

0.625

0.696

$478.98

$483.42

$273.10

$159.33

$451.39

0.693

0.503

0.625

0.696

$212.29

$403.59

$220.03

$159.33

$451.39

0.693

0.503

0.625

0.696

$318.43

$403.59

$326.17

$159.33

$451.39

0.693

0.503

0.625

0.696

$123.73

$403.59

$273.10

$128.40

$451.39

0.693

0.503

0.625

0.696

$185.59

$403.59

$273.10

$190.26

$451.39

0.693

0.503

0.625

0.696

$358.74

$403.59

$273.10

$159.33

$361.71

0.693

0.503

0.625

0.696

$538.10

$403.59

$273.10

$159.33

$541.07

0.693

0.503

0.625

0.696

$272.16

$335.55

$273.10

$159.33

$451.39

0.693

0.503

0.625

0.696

$408.24

$471.63

$273.10

$159.33

$451.39

0.693

0.503

0.625

0.696

Regimen 2

Regimen 3

Regimen 4

Cost of Palonosetron
Palonosetron

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-26 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Cost
Parameters
DIRECT COSTS

Base Case

EFFECTIVENESS

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

$403.45

$273.08

$159.12

$451.30

0.695

0.502

0.627

0.699

Parameter: Cost of IV Ondansetron
Ondansetron

$165.13

$403.59

$231.70

$149.00

$382.40

0.693

0.503

0.625

0.696

$247.69

$403.70

$314.50

$169.70

$520.40

0.693

0.503

0.625

0.696

$47.16

$391.70

$261.12

$147.44

$439.55

0.693

0.503

0.625

0.696

$70.74

$415.48

$285.08

$171.21

$463.23

0.693

0.503

0.625

0.696

$22.18

$403.59

$273.10

$153.79

$445.85

0.693

0.503

0.625

0.696

$33.26

$403.59

$273.10

$273.10

$456.93

0.693

0.503

0.625

0.696

Parameter: Infusion Costs
First Drug

Second Drug

Parameter: Number of Days of Receiving Rescue Medications During Delayed Phase
No. of Days

1 day

$403.07

$272.31

$158.78

$450.99

0.693

0.503

0.625

0.696

3 days

$404.10

$273.89

$159.88

$451.79

0.693

0.503

0.625

0.696

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-27: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Cost Parameters
TOTAL COSTS

Base Case

EFFECTIVENESS

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

$457.64

$381.05

$216.31

$475.84

0.698

0.500

0.630

0.701

Parameter: Total Prophylactic Antiemetic Regimen Costs
Regimen

Range

Regimen 1

$319.31

$378.82

$382.14

$217.31

$476.71

0.693

0.503

0.625

0.696

$478.98

$538.49

$382.14

$217.31

$476.71

0.693

0.503

0.625

0.696

$212.29

$458.66

$329.07

$217.31

$476.71

0.693

0.503

0.625

0.696

$318.43

$458.66

$435.21

$217.31

$476.71

0.693

0.503

0.625

0.696

$123.73

$458.66

$382.14

$186.38

$476.71

0.693

0.503

0.625

0.696

$185.59

$458.66

$382.14

$248.24

$476.71

0.693

0.503

0.625

0.696

$358.74

$458.66

$382.14

$217.31

$387.03

0.693

0.503

0.625

0.696

$538.10

$458.66

$382.14

$217.31

$566.39

0.693

0.503

0.625

0.696

Regimen 2

Regimen 3

Regimen 4

Parameter: Cost of Palonosetron
Palonosetron

$272.16

$390.62

$382.14

$217.31

$476.71

0.693

0.503

0.625

0.696

$408.24

$526.70

$382.14

$217.31

$476.71

0.693

0.503

0.625

0.696

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-27 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Cost
Parameters
TOTAL COSTS

Base Case

EFFECTIVENESS

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

$457.64

$381.05

$216.31

$475.84

0.698

0.500

0.630

0.701

Parameter: Cost of IV Ondansetron
Ondansetron

$165.13

$458.66

$340.70

$207.00

$407.70

0.693

0.503

0.625

0.696

$247.69

$458.66

$423.60

$227.70

$545.70

0.693

0.503

0.625

0.696

$47.16

$446.77

$370.16

$205.42

$464.87

0.693

0.503

0.625

0.696

$70.74

$470.55

$394.12

$229.20

$488.55

0.693

0.503

0.625

0.696

$22.18

$458.66

$382.14

$211.77

$471.17

0.693

0.503

0.625

0.696

$33.26

$458.66

$382.14

$222.85

$482.25

0.693

0.503

0.625

0.696

Parameter: Infusion Costs
First Drug

Second Drug

Parameter: Number of Days of Receiving Rescue Medications During Delayed Phase
No. of Days

1 day

$458.14

$381.35

$216.76

$476.31

0.693

0.503

0.625

0.696

3 days

$459.17

$382.93

$217.86

$477.11

0.693

0.503

0.625

0.696

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
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Table 4-28: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective – ICERs
for Cost and Utilization Parameters
ICER per patient with complete control of emesis –
Payer Perspective
Regimen 1

Regimen 2

Regimen 3

ICER per patient with complete control of emesis – Societal
Perspective

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Parameter: Total Costs of Prophylactic Antiemetic Regimens
Base Case
Regimen

Range

Regimen 1

$319.31
$478.98

Regimen 2

Regimen 3

Regimen 4

$3,582.48

Dominated

-

$14,953.27

$3,549.02

Dominated a

-

$6,499.87

$2,416.40

Dominateda

-

$44,498.76

$2,373.61

Dominateda

-

$34,125.16

a

-

$3,658.01

a

a

Dominated

a

Dominated

a

-

$4,118.70

Dominated

a

Dominated

$212.29

$3,589.75

Dominated

-

$16,665.68

$3,546.97

Dominated

-

$6,292.08

$318.43

$3,589.75

Dominateda

-

$16,665.68

$3,546.97

Dominateda

-

$6,292.08

$123.73

$4,044.31

Dominateda

-

$16,665.68

$4,001.53

Dominateda

-

$6,292.08

$185.59

$3,135.20

Dominateda

-

$16,665.68

$3,092.41

Dominateda

-

$6,292.08

$358.74

Dominateda

Dominateda

-

$2,854.04

Dominated a

Dominateda

-

$2,393.36

$538.10

$3,589.75

Dominateda

-

$47,929.09

$3,546.97

Dominateda

-

$37,555.49

Parameter: Cost of Palonosetron
Palonosetron

$272.16

$2,589.81

Dominateda

-

$40,385.15

$2,547.03

Dominateda

-

$30,011.56

$408.24

Dominateda

Dominateda

-

$4,118.70

Dominated a

Dominateda

-

$3,658.01

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens were compared to regimen 3; a Dominated by regimen 3
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Table 4-28 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective –
ICERs for Cost and Utilization Parameters
Parameters/Range

Base Case

ICER per patient with complete control of emesis –
Payer Perspective

ICER per patient with complete control of emesis – Societal
Perspective

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

$3,582.48

Dominateda

-

$14,953.27

$3,549.02

Dominated a

-

$6,499.87

Dominateda

-

$3,291.22

Dominated

Dominateda

-

$2,830.54

a

Parameter: Cost of IV Ondansetron
Ondansetron

$165.13

Dominated

a

$247.69

$3,438.98

Dominated

-

$40,698.18

$3,396.19

Dominated

-

$30,324.58

$47.16

$,3589.74

Dominateda

-

$16,682.53

$3,546.96

Dominateda

-

$6,308.94

$70.74

$3,589.76

Dominateda

-

$16,648.82

$3,546.96

Dominateda

-

$6,275.22

$22.18

$3,671.17

Dominateda

-

$14,734.37

$3,628.39

Dominateda

-

$4,360.78

$33.26

$3,508.33

Dominateda

-

$18,596.98

$3,465.55

Dominateda

-

$8,233.38

Infusion Costs
First Drug

Second Drug

Parameter: Number of Days of Receiving Rescue Medications During Delayed Phase
No. of Days

1 day

$3,590.26

Dominateda

-

$16,706.68

$3,547.48

Dominateda

-

$6,333.08

3 days

$3,589.25

Dominateda

-

$16,624.68

$3,546.46

Dominateda

-

$6,251.08

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens were compared to regimen 3
a
Dominated by regimen 3
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Table 4-29: Change in the Antiemetic Regimen for Breakthrough Emesis
Change in Rescue Meds in Delayed Phase for Regimen 1
Regimen

Effectiveness

Direct Costs

ICER per patient with complete
control of emesis

Total Costs

ICER per patient with
complete control of emesis

Regimen 3

0.627

$159.33

-

$217.31

-

Regimen 2

0.502

$273.10

Dominated by regimen 3

$382.14

Dominated by regimen 3

Regimen 1

0.693

$425.60

$3,913.32

$480.68

Dominated by regimen 4

Regimen 4

0.696

$451.39

$8,990.44

$476.71

$3,658.01

Change in Rescue Meds in Delayed Phase for Regimen 2
Regimen

Effectiveness

Direct Costs

ICER per patient with complete
control of emesis

Total Costs

ICER per patient with
complete control of emesis

Regimen 3

0.627

$159.33

-

$182.80

-

Regimen 2

0.502

$306.96

Dominated by regimen 3

$273.10

Dominated by regimen 3

Regimen 1

0.693

$403.50

$3,589.75

$403.50

$3,244.54

Regimen 4

0.696

$451.39

$16,665.68

$451.39

$16,665.68

Change in Rescue Meds in Delayed Phase for Regimen 3
Regimen

Effectiveness

Direct Costs

ICER per patient with complete
control of emesis

Total Costs

ICER per patient with
complete control of emesis

Regimen 3

0.627

$182.80

-

$240.80

-

Regimen 2

0.502

$273.10

Dominated by regimen 3

$382.14

Dominated by regimen 3

Regimen 1

0.693

$403.50

$3,244.54

$458.56

$3,201.76

Regimen 4

0.696

$451.39

$16,665.68

$476.71

$6,292.08
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Effect of Changes in Indirect Costs Associated with CINV and its Treatment
The impact of variation in the average hourly wages on total costs, effectiveness, and
ICER for each antiemetic regimen from the societal perspective is presented in Table 4-30.
Decreasing the hourly wage by 20% resulted in an increase in the ICER of regimen 4 from
$6,499.87 to $10,631.89 per patient with complete control of emesis. Due to lack of sufficient
and reliable data regarding the amount of lost productivity associated with delayed CINV, it was
varied in sensitivity analysis to understand its impact on costs and ICERs. Decreasing the
number of hours of lost productivity to 2.75 hours increased the ICER of regimen 4 to
$14,072.28 per patient with complete control of emesis, while increasing the number of hours of
lost productivity to 24 hours (equivalent to 3 work-days) decreased the ICER of regimen 4 to
$3,113.57.
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Table 4-30: Change in the Indirect Costs Associated with CINV and its Treatment
TOTAL COSTS

Base Case

ICER per patient with complete control of emesis

Regimen 1

Regimen 2

Regimen 3

Regimen 4

Regimen 1

Regimen 2

Regimen 3

Regimen 4

$457.64

$381.05

$216.31

$475.84

$3,549.02

Dominated a

-

$6,499.87

Parameter: Average Wage Per Hour
Average Wage

$14.96

$435.62

$336.52

$193.05

$466.12

$3,564.87

Dominated a

-

$10,631.89

$30.48

$468.85

$402.32

$228.04

$481.39

$3,539.05

Dominated a

-

$4,372.24

Parameter: Number of Hours of Lost Productivity
No. of Hours

2.75 hrs

$417.36

$300.36

$173.82

$457.72

$3,579.06

Dominated a

-

$14,072.28

24 hrs

$523.74

$511.00

$285.83

$506.62

Dominateda

Dominated a

-

$3,113.57

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens were compared to regimen 3
a
Dominated by regimen 3
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Probabilistic Sensitivity Analysis for Moderately Emetogenic Chemotherapy Model
The results of probabilistic sensitivity analysis from the payer perspectives are shown in
Table 4-31. The results were very sensitive to the simultaneous variation in all the parameters.
From the payer perspective, regimen 2 was dominated by regimen 3 while regimen 1 was
excluded from the ICER calculations due to extended dominance. The ICER of regimen 4
compared to regimen 1 was $3,091.58 per patient with complete control of emesis and compared
to regimen 3 was calculated to be $5,370.87 per patient with complete control of emesis. The
results of probabilistic sensitivity analysis from the societal perspectives are shown in Table 432. The results for the societal perspective were similar to those for the payer perspective. From
the societal perspective, the ICER of regimen 4 compared to regimen 1 was $1,446.30 per patient
with complete control of emesis and compared to regimen 3 was $4,831.22 per patient with
complete control of emesis.
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Table 4-31: Probabilistic Sensitivity Analysis for Costs, Effectiveness and Incremental Cost Effectiveness Ratios for Antiemetic
Regimens for Prevention of CINV in Patients Receiving Highly Emetogenic Chemotherapy from a Payer Perspective

Payer Perspective

Treatment Strategy
Direct Costs
Mean (SD)

Effectiveness
Mean (SD)

Cost of achieveing one
patient with complete
control of emesis

Incremental cost effectiveness
ratio/patient with complete control
of emesis

Regimen 3

$179.21 (8.24)

0.596 (0.056)

$300.65

-

Regimen 2

$279.86 (17.72)

0.510 (0.060)

$549.04

Dominated*

Regimen 1

$411.05 (28.33)

0.631 (0.054)

$651.45

Extended Dominance**

Regimen 4

$471.24 (25.31)

0.651 (0.056)

$724.49

$3,091.58¶

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens were compared to regimen 3
*

Regimen 2 was dominated by regimen 3
Regimen 1 is dominated by a blend of regimen 3 and regimen 4 with a coefficient of inequity between 0.206 and 0.358
¶
ICER for regimen 4 compared to regimen 3 without excluding the extended dominance strategy
**
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Table 4-32: Probabilistic Sensitivity Analysis for Costs, Effectiveness and Incremental Cost Effectiveness Ratios for Antiemetic
Regimens for Prevention of CINV in Patients Receiving Highly Emetogenic Chemotherapy from a Societal Perspective

Societal Perspective

Treatment Strategy
Total Costs
Mean (SD)

Effectiveness
Mean (SD)

Cost of achieveing one
patient with complete control
of emesis

Incremental cost effectiveness
ratio/patient with complete
control of emesis

Regimen 3

$256.49 (35.31)

0.596 (0.056)

$430.01

-

Regimen 2

$394.30 (51.12)

0.510 (0.061)

$773.31

Dominated*

Regimen 1

$490.85 (44.84)

0.631 (0.054)

$777.30

Extended Dominancea

Regimen 4

$518.72 (34.82)

0.651 (0.056)

$797.10

$1,446.30¶

Regimen 1: IV Palonosetron 0.25mg;
Regimen 2: IV Ondansetron 32mg,
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
All regimens were compared to regimen 3
*
Regimen 2 was dominated by regimen 3
¶
ICER for regimen 4 compared to regimen 3 without excluding the extended dominance strategy
a
Regimen 1 is dominated by a blend of regimen 3 and regimen 4 with a coefficient of inequity between 0.106 and 0.355
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4.2: Results for Phase II
Phase II of this study involved face-to-face interviews of cancer patients to determine
their willingness-to-pay for improved emesis control due to two new antiemetic regimens for
prevention of CINV. The WTP amounts were then used as a measure of benefits to conduct costbenefit analyses of new antiemetic agents for prevention of CINV due to highly emetogenic and
moderately emetogenic chemotherapy agents.
A total of 124 patients with cancer were approached by nurses or oncologists for
participation in the study. Out of 124 patients, four patients refused to participate in the study. A
total of 120 patients agreed to participate in the study yielding a response rate of 96.8%. Of the
120 respondents, 59 respondents received version A and 61 received version B of the survey.
Demographic Characteristics of Study Participants
As shown in Table 4-33, the mean age of the study population was 56.5 years (SD = 12.0
years, range = 22 – 85 years). Sixty percent of the study population was female. More than 44%
of the study population had annual household income level below $30,000. Approximately 58%
of the respondents had one more member in their household and 13% of the respondents lived
alone. Approximately 39% of respondents had primary health care coverage through their or
their spouse’s employer. Almost 36% of the respondents had Medicare as their primary health
care insurer.
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Table 4-33: Demographic Characteristics of Respondents
Demographic Characteristics

N (Valid %)
Total N = 120

Age - Mean (SD)

56.5 (12.0)

Gender
Male

48 (40.0%)

Female

72 (60.0%)

Race
White

117 (97.5%)

African American

2 (1.7%)

Asian

1 (0.8%)

Education Level
Less than high school education

22 (18.3%)

Completed high school education

53 (44.2%)

More than high school education

45 (37.5%)

Marital Status
Married

93 (77.5%)

Not Married/Single/Divorced/Widowed

27 (22.5%)

Employment
Not working

88 (73.3%)

Working (Part-time or Full-time)

32 (26.7%)

Annual Household Income Level
≤$30,000

53 (44.2%)

$30,001 - $60,000

37 (30.8%)

>$60,000

30 (25.0%)

Type of Primary Insurance
Medicare

43 (35.8%)

Medicaid

15 (12.5%)

Employer-based

47 (39.2%)

No coverage

5 (4.2%)

a

10 (8.3%)

Other
a

Other type of insurance coverage included self coverage, VA, MAMSI
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Clinical Characteristics of Study Participants
Table 4-34 shows the clinical characteristics of all the respondents. With 28% of patients
diagnosed with breast cancer, it was the most prevalent type of cancer among the study
population followed by lung cancer (23.3% of respondents). Based on the algorithm for
classifying combination chemotherapy regimens as defined in Tables 2-3 and 2-4 in Chapter 2,
almost 57% of the respondents received highly emetogenic chemotherapy. Only 10% of all
respondents received cisplatin-based highly emetogenic chemotherapy. All study participants
had received prophylactic antiemetic regimens before chemotherapy for prevention of CINV
during the acute phase. A majority of the study respondents (54.2%) received a combination of a
5-HT3RA and corticosteroid before chemotherapy. With 16.7% of respondents, the combination
of Aloxi and a corticosteroid was the next most common antiemetic regimen prescribed. The
three-drug regimen of aprepitant (Emend®), 5-HT3RA and corticosteroid was prescribed to
approximately 8% of the patients. Ten percent of the patients received a single drug regimen of
5-HT3RA. The study results also showed that various other antiemetic combination regimens
such as Aloxi+Emend, Aloxi+Emend+corticosteroid, 5-HT3RA+Emend, Emend+corticosteroid
were prescribed during the acute phase for prevention of CINV.
Past CINV Experience of Study Participants
The past experiences of CINV of study respondents are reported in Table 4-35.
Compared to 44.2% of patients experiencing nausea, only 23.3% of respondents experienced
emesis following chemotherapy. Among patients experiencing nausea, the mean severity as
reported using a 100mm VAS was found to be 50.3 (SD=25.1). Of the respondents who
experienced emesis, almost 82.1% of them reported experiencing 1-2 emetic episodes following
chemotherapy.
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Table 4-34: Clinical Characteristics of Respondents
Clinical Characteristics

N (%)
Total N = 120

Type of Cancer
Breast

34 (28.3%)

Lung

28 (23.3%)

Colorectal

16 (13.3%)

Urogenital

19 (15.8%)

Respiratory

2 (1.7%)

Other

19 (15.8%)

Unknown

2 (1.7%)

Cycle of Chemotherapy
Chemotherapy-naïve

22 (18.3%)

Received in last 3 months

6 (5.0%)

1st cycle of new regimen

11 (9.2%)

> 1 cycle of chemotherapy

81 (67.5%)

Type of Chemotherapy Regimen
HE (Cisplatin-based)

13 (10.8%)

HE (Non-cisplatin)

55 (45.8%)

ME (30-90%)

27 (22.5%)

LE (10-30%)

23 (19.2%)

Unable to classify

2 (1.7%)

Antiemetic Regimen – Acute Phase
5-HT3RA + Corticosteroid

65 (54.2%)

Emend + 5-HT3RA + Corticosteroid

10 (8.3%)

Aloxi + Corticosteroid

20 (16.7%)

Only 5-HT3RA

13 (10.8%)

Other single agent regimena

5 (4.2%)

Other combination regimensb
a
b

6 (5%)

Includes either corticosteroid or Aloxi or Emend or compazine
Includes either Aloxi+Emend, Aloxi+Emend+corticosteroid, 5-HT3RA+Emend, Emend+Corticosteroid
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Table 4-35: Past Experience of Chemotherapy-Induced Nausea and Vomiting (CINV)
Past Experience of CINV

N (%)

Experience of nausea during last cycle
Yes

53 (44.2%)

No

37 (30.8%)

Not Applicable

30 (25.0%)

Severity of Nausea (N = 53), Mean (SD)

50.3 (25.1)

Experience of emesis during last cycle
No

62 (51.7%)

1-2 episodes

23 (19.2%)

3-5 episodes

4 (3.3%)

> 5 episodes

1 (0.8%)

Not applicable

30 (25.0%)

202

RESULTS

Reema Mody

Results for Objectives 2.1 and 2.2
Scenario 1 – Emetic Control Following Administration of Highly Emetogenic Chemotherapy
Scenario 1 of the survey described the improvement in the probability of acute and
delayed emesis control due to the addition of new drug (aprepitant) to the standard regimen of 5HT3RA and dexamethasone for prevention of CINV due to highly emetogenic chemotherapy.
The results in Table 4-36 show the level of importance that respondents place on improved
emesis control in the acute and delayed phase. The mean perceived level of importance for
reduction in the probability of acute emesis from 30% to 17% due to the addition of new drug
was 8.8 (SD=1.7) and reduction in the probability of delayed emesis from 55% to 37% was 9.2
(SD=1.5). Due to ordinal nature of the dependent variable, Wilcoxon signed rank test was used
to test for significant differences in the perceived level of importance of improvements in acute
emesis and delayed emesis. The null hypothesis tested was that there are no significant
differences in the perceived importance of the acute emesis control and delayed emesis control. It
is evident from the results shown in Table 4-36 that the respondents perceived delayed emesis
control to be of greater importance as compared to the acute emesis control.
The WTP results for scenario 1 are shown in Table 4-37. Though all respondents
preferred the addition of the new drug to the standard regimen compared to receiving only the
standard regimen, approximately 91% (N =109) gave positive WTP value for receiving the new
drug for a 3-day regimen. Out of 11 respondents who reported that they would not pay anything
out-of-pocket to receive the new drug, two gave zero values reflective of “protest zeroes”. The
remaining nine respondents genuinely placed zeroes as they were unable to afford out-of-pocket
payments for the new drug. Thus, among 109 respondents who gave a positive WTP value for the
3-day regimen of the new drug, the mean WTP was $89.90 (SD=101.90) and median was $60.00.
Due to the non-normal distribution of the WTP amounts, Mann-Whitney U test was used
to test whether the maximum WTP differed based on the order of scenarios presented. The
results in Table 4-38 indicate that the WTP amounts for scenario 1 did not differ significantly
based on the order of scenarios presented. The results are presented for the sample without
protest zeroes and for the sample with only positive WTP values.
Respondents were also asked to state the reasons for preferring the addition of the new
drug to the standard regimen. About 60.0% of the respondents provided a reason for preferring
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the new regimen for prevention of CINV due to highly emetogenic chemotherapy. A majority of
respondents (N = 18) reported that they would take anything that would prevent them from
getting “sick”, and nausea and vomiting were unpleasant and painful. Sixteen respondents
reported that they prefer the new drug as it will increase their ability to eat more, maintain their
weight, sleep well, go to work and get on with their daily activities. One sixth of the respondents
preferred the new drug in addition to the standard regimen due to its ability to better control
nausea and vomiting. The impact of nausea and vomiting on quality of life was mentioned as one
of reasons for preference of the new drug by eight respondents.
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Table 4-36: Perceived level of importance of improved emesis control (Scenario 1)
Item (N = 120)

Mean (SD)

Median

Z value
- 4.712

Perceived level of importance –
Acute emesis

8.8 (±1.72)

10.0

Perceived level of importance –
Delayed emesis

9.2 (±1.51)

10.0
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Table 4-37: Willingness-to-Pay Results for Scenario 1
WTP Values

N (%)

Non-zero values

109 (90.8%)

Protest zeroes

2 (1.7%)

Genuine zeroes

9 (7.5%)
Mean (SD)

Median

Maximum WTP amount for 3 days of aprepitant for
overall control of emesis (N = 118)

$83.1 (100.8)

$50.0

Maximum WTP amount for 3 days of aprepitant for
overall control of emesis (N = 109)

$89.9 (101.9)

$60.0
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Table 4-38: Differences in Willingness-to-Pay Based on the Order of Scenarios Presented –
For Scenario 1.
Item

Mean (SD)

Median (Range)

For sample without protest zeroes
(N = 118)
Maximum WTP amount for 3 days of
aprepitant – Version A (N = 59)

87.1 (±117.22)

45.00
(0.00-600.00)

Maximum WTP amount for 3 days of
aprepitant – Version B (N = 59)

79.1 (±81.96)

60.00
(0.00 – 300.00)

Maximum WTP amount for 3 days of
aprepitant – Version A (N = 55)

93.4 (±118.97)

50.00
(3.00-600.00)

Maximum WTP amount for 3 days of
aprepitant – Version B (N = 54)

86.4 (±81.89)

60.00
(5.00 – 300.00)

Z value

P value

-0.008

0.994

-0.189

0.850

For sample without all zeroes
(N = 109)
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Scenario 2 – Emetic Control Following Administration of Moderately Emetogenic Chemotherapy
The scenario 2 described the improved emesis control due to single injection of
palonosetron instead of the standard regimen of 5-HT3RA and dexamethasone for prevention of
CINV following administration of moderately emetogenic chemotherapy. The acute control of
emesis was assumed to be equivalent between the two regimens. The mean perceived level of
importance of reducing the chance of delayed emesis from 45% to 33% was 8.6 (SD=1.6). Out
of 120 respondents, only one did not prefer the new drug and the reasons reported were “dislike
of injection” and “12% risk reduction of emesis is not much”.
The WTP results for scenario 2 are shown in Table 4-39. Of those respondents who
preferred the new drug, approximately 91% (N =109) gave positive WTP value for receiving the
new drug for a 3-day regimen. Out of 11 respondents who reported that they would not pay
anything out-of-pocket to receive the new drug, two gave zero values reflective as “protest
zeroes”. The remaining nine respondents genuinely placed zeroes as they were unable to afford
out-of-pocket payments for the new drug. Thus, among 108 respondents who gave a positive
WTP value for the single injection of the new drug, the mean WTP was $83.5 (SD=94.5) and
median was $55.0. The results of the Mann-Whitney U test reported in Table 4-40 indicate that
the WTP amounts for scenario 2 did not differ significantly based on the order of scenarios
presented. The results are presented for the sample without protest zeroes and for the sample
with only positive WTP values.
Respondents were also asked to state the reasons for preferring the new drug to the
standard regimen in scenario 2. About 61.0% of the respondents provided a reason for preferring
the new regimen for prevention of CINV due to moderately emetogenic chemotherapy.
Approximately one fourth of respondents (N = 18) reported that they prefer the new drug as it is
to be taken as a one-time injection instead of a multi-day regimen. The other reasons for
preferring the new drug included better control of emesis, ability of get back to work, do daily
activities, ability to eat and maintain weight. The impact of nausea and vomiting on quality of
life was mentioned as one of reasons for preference of the new drug by three respondents.
Wilcoxon signed rank test was used to test if there were significant differences in the
maximum WTP based on the scenario. As shown in Table 4-41, scenario 1 the median WTP for
scenario 1 was significantly higher than that for scenario 2 for the sample without protest zeroes
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and sample without any zeroes. The level of difficulty in understanding the hypothetical
scenarios and in answering the WTP questions was assessed using a 11-point Likert type scale.
The mean level of difficulty in understanding the scenarios was 1.5 (SD=1.74) and in answering
the WTP questions was 2.5 (SD=2.5). About 4% of the study population reported a score of
greater than 5 for the level of difficulty in understanding the hypothetical scenarios. On the other
hand, about 15% of respondents reported a score of greater than 5 for the level of difficulty in
answering the WTP question.
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Table 4-39: WTP Results for Scenario 2
WTP Values*

N (%)

Non-zero values

108 (90.8%)

Protest zeroes

2 (1.7%)

Genuine zeroes

9 (7.6%)
Mean (SD)

Median

Maximum WTP amount for a single injection of
palonosetron for overall control of emesis (N = 117)

$77.1 (93.45)

$45.0

Maximum WTP amount for a single injection of
palonosetron for overall control of emesis (N = 108)

$83.5 (94.5)

$55.0

* Sample includes those who preferred new drug compared to the standard regimen (N = 119)
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Table 4-40: Differences in WTP results based on the order of scenarios presented – For
Scenario 2.
Item

Mean (SD)

Median (Range)

For sample without protest zeroes
(N = 117)
Maximum WTP amount for single
injection of palonosetron –
Version A (N = 59)

80.1 (±106.04)

45.00
(0.00-600.00)

Maximum WTP amount for single
injection of palonosetron –
Version B (N = 58)

74.0 (±79.45)

47.5
(0.00-300.00)

For sample without all zeroes
(N = 108)
Maximum WTP amount for single
injection of palonosetron –
Version A (N = 55)

85.9 (±107.55)

50.00
(3.00 – 600.00)

Maximum WTP amount for single
injection of palonosetron –
Version B (N = 53)

81.0 (±79.64)

60.00
(5.00 – 300.00)
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Table 4-41: Differences in maximum WTP amounts between scenarios
Item

Mean (SD)

Median (range)

Sample without protest zeroes
Maximum WTP for scenario 1

83.4 (±101.15)

50.00
(0.00 – 600.00)

Maximum WTP for scenario 2

77.1 (±93.45)

45.00
(0.00 – 600.00)

Sample without zeroes
Maximum WTP for scenario 1

90.4 (±102.27)

60.00
(3.00 – 600.00)

Maximum WTP for scenario 2

83.5 (±94.48)

55.00
(3.00 – 600.00)

212

Z value

P value

-2.879

0.004*

-2.879

0.004*
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Results for Objectives 2.3 and 2.4
Differences in WTP for scenario 1 based on demographic and clinical characteristics
The differences in maximum WTP amount for scenario 1 based on demographic and
clinical characteristics are presented in Table 4-42. Due to the non-normal nature of the WTP
data, non parametric statistics were employed. Mann Whitney U test was used to test for
differences in WTP for factors with two groups while Kruskal-Wallis test was used for factors
with more than two groups. To determine which groups are significantly different from each
other following a significant Kruskal-Wallis test result, post hoc tests using Mann Whitney U test
were conducted. The results displayed are for the sample with only positive WTP values.
WTP for scenario 1 differed significantly based on education level completed,
employment status and annual household income level. There were no significant differences in
WTP for scenario 1 based on age, gender, number of members in the household and marital
status. Post hoc tests showed that respondents who completed HS (Z value = -2.357, p value =
0.018) and respondents with higher than HS education (Z value = -3.514, p value = 0.000)
reported significantly higher WTP as compared to respondents who did not complete HS. There
was no significant difference in the WTP between respondents with high school education and
those with greater than high school education (Z value = -1.717, p value = 0.086). Post hoc tests
showed that respondents who reported annual household income in the range $30,000-$60,000 (Z
value = -5.207, p value = 0.000) and respondents with higher than ≥ 60,000 (Z value = -5.464, p
value = 0.000) reported significantly higher WTP as compared to respondents who with annual
household income ≤ $30,000. There was no significant difference in the WTP amount between
respondents with annual household income level in the range $30,000-$60,000 and those with ≥
60,000 (Z value = -0.512, p value = 0.609). Mann-Whitney U test showed that employed
respondents reported significantly higher WTP as compared to those who were unemployed or
retired. Results in Table 4-43 shows that there are no significant differences in WTP for scenario
1 based on clinical characteristics such as previous chemotherapy experience, previous
experience of CINV, and level of emetogenicity of the chemotherapy regimen.
Differences in WTP for scenario 2 based on demographic and clinical characteristics
Results of Bivariate Analyses
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The differences in maximum WTP amount for scenario 2 based on demographic and
clinical characteristics are presented in Table 4-44. WTP for scenario 2 differed significantly
based on highest level of education completed and annual household income level. There were no
significant differences in WTP for scenario 2 based on age, gender, number of members in the
household, employment status and marital status.
Post hoc tests showed that respondents who completed HS (Z value = -1.990, p value =
0.047) and respondents with more than HS education (Z value = -3.053, p value = 0.002)
reported significantly higher WTP as compared to respondents who did not complete HS. There
was no significant difference in the WTP between respondents with high school education and
those with greater than high school education (Z value = -1.193, p value = 0.233). Post hoc tests
showed that respondents who reported annual household income in the range $30,000-$60,000 (Z
value = -5.111, p value = 0.000) and respondents with higher than ≥ 60,000 (Z value = -4.909, p
value = 0.000) reported significantly higher WTP as compared to respondents who with annual
household income ≤ $30,000. There was no significant difference in the WTP amount between
respondents with annual household income level in the range $30,000-$60,000 and those with ≥
60,000 (Z value = -0.315, p value = 0.752).
Results in Table 4-45 shows that there are no significant differences in WTP for scenario
2 based on clinical characteristics such as previous chemotherapy experience, previous
experience of CINV, and level of emetogenicity of the chemotherapy regimen.
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Table 4-42: Differences in maximum WTP amount based on demographic characteristics –
Scenario 1
Demographic Characteristics

Mean WTP

Median (range)

Age
<45 years

78.2 (53.47)

75.00
(10.00-200.00)

45-64 years

86.6 (101.71)

50.00
(3.00-500.00)

≥65 years

102.4 (122.72)

60.00
(10.00-600.00)

Gender
Male
Female

105.8 (124.52)

60.00
(5.00-600.00)

80.0 (84.22)

60.00
(3.00-500.00)

Education Levela
Less than high school education

35.3 (24.75)

30.00
(10.00-100.00)

Completed high school education

77.8 (72.10)

60.00
(3.00-300.00)

More than high school education

121.3 (132.00)

75.00
(10.00-600.00)

Marital Status
Married
Not
Married/Single/Divorced/Widowed

95.8 (110.5)

60.00
(3.00-600.00)

67.8 (55.8)

45.00
(5.00-200.00)

Employment
Not working
Working (Part-time or Full-time)

77.3 (90.97)

45.00
(3.00-600.00)

122.7 (121.74)

75.00
(5.00-500.00)

Annual Household Income Levela
≤$30,000

37.5 (32.79)

30.00
(3.00-150.00)

$30,001 - $60,000

114.0 (85.50)

100.00
(15.00-300.00)

>$60,000

141.3 (145.03)

100.00
(10.00-600.00)
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Z value

p value

0.439

0.803

-0.813

0.416

12.678

0.002*

-0.686

0.492

-2.484

0.013*

40.595

0.000*

RESULTS

Reema Mody

Table 4-42 (Continued): Differences in maximum WTP amount based on demographic
characteristics – Scenario 1
Demographic Characteristics

Mean WTP

Median (range)

Number of Members in the
Household
Zero

63.3 (52.84)

35.00
(20.00-200.00)

One member

78.1 (93.16)

47.50
(5.00-600.00)

120.1 (122.71)

100.00
(3.00-500.00)

More than one member
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Z value

p value

5.746

0.057
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Table 4-43: Differences in maximum WTP amount based on clinical characteristics –
Scenario 1
Clinical Characteristics

Mean (SD)

Median (range)

Presence of nausea and vomiting
Neither nausea nor vomiting

86.9 (105.08)

45.00
(3.00-500.00)

Either nausea or emesis or both

109.2 (118.30)

75.00
(5.00-600.00)

58.5 (42.00)

50.00
(10.00-150.00)

Not applicable
Past chemotherapy experience
Chemotherapy naïve

59.5 (39.57)

50.00
(10.00-150.00)

Current or past experience

96.8 (110.20)

60.00
(3.00-600.00)

Level of emetogenicity
Highly emetogenic

85.9 (104.90)

50.00
(5.00-600.00)

Moderately emetogenic

102.0 (92.52)

75.00
(3.00-300.00)

Low or not emetogenic

79.2 (98.60)

60.00
(5.00-500.00)
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Z value

p value

5.060

0.080

-0.971

0.331

1.269

0.530
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Table 4-44: Differences in maximum WTP amount based on demographic characteristics –
Scenario 2
Demographic Characteristics

Mean (SD)

Median (range)

Age
<45 years

75.8 (53.94)

75.00
(5.00-200.00)

45-64 years

79.4 (88.46)

37.50
(3.00-500.00)

≥65 years

94.9 (120.67)

50.00
(8.00-600.00)

Gender
Male

94.2 (110.71)

60.00
(5.00-600.00)

Female

76.7 (82.71)

47.50
(3.00-500.00)

Education Level
Less than high school education

35.7 (23.67)

30.00
(5.00-100.00)

Completed high school education

78.3 (75.06)

60.00
(3.00-300.00)

More than high school education

105.6 (120.04)

75.00
(8.00-600.00)

Marital Status
Married

90.0 (103.14)

60.00
(3.00-600.00)

Not
Married/Single/Divorced/Widowed

59.6 (45.07)

35.00
(5.00-200.00)

Employment
Not working
Working (Part-time or Full-time)

75.9 (91.50)

40.00
(3.00-600.00)

102.3 (100.58)

75.00
(5.00-500.00)

Annual Household Income Levela
≤$30,000

36.6 (32.68)

30.00
(3.00-150.00)

$30,001 - $60,000

106.5 (80.00)

100.00
(15.00-300.00)

>$60,000

129.5 (136.11)

100.00
(10.00-600.00)
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Z value

p value

0.503a

0.777

-0.754b

0.451

8.709

0.013*

-0.770

0.442

-1.857

0.063

35.884

0.000*
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Table 4-44 (Continued): Differences in maximum WTP amount based on demographic
characteristics – Scenario 2
Demographic Characteristics

Mean (SD)

Median (range)

Number of Members in the Household
Zero

53.8 (34.45)

35.00
(20.00-100.00)

One member

79.2 (93.85)

45.00
(5.00-600.00)

More than one member

106.5 (105.88)
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75.00
(3.00-500.00)

Z value

p value

4.684

0.096
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Table 4-45: Differences in maximum WTP amount based on demographic characteristics –
Scenario 2
Clinical Characteristics

Mean (SD)

Median (range)

Presence of nausea and vomiting
Neither nausea nor vomiting
Either nausea or emesis or both
Not applicable

77.1 (85.76)
103.3 (116.34)
56.5 (41.75)
56.9 (39.28)

Current or past experience

89.6 (102.18)

79.1 (91.67)

Moderately emetogenic

93.8 (86.89)

Low or not emetogenic

75.6 (102.41)
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5.532

0.063

-0.974

0.330

1.405

0.495

42.50
(8.00-150.00)
60.00
(3.00-600.00)

Level of emetogenicity
Highly emetogenic

p value

35.00
(3.00-300.00)
75.00
(5.00-600.00)
42.50
(8.00-150.00)

Past chemotherapy experience
Chemotherapy naïve

Z value

50.00
(5.00-600.00)
75.00
(3.00-300.00)
40.00
(5.00-500.00)
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Results of Multivariate Analyses
Multivariate analyses conducted to determine the association between WTP and
demographic and clinical characteristics. The relevant covariates for inclusion in the regression
models were identified based on the results of the bivariate analyses which were presented in the
previous section. This is a recommended approach for removing unimportant covariates so that a
more manageable set of variables can be submitted to multivariate techniques (George, 1988).
The preset α value for screening variables for inclusion in the model was set at 0.15. Based on
the criteria, the variables included in the regression models were age, employment status, level of
education completed, annual household income, number of members in the household and past
experience with CINV. Correlation analysis was conducted to test for multicollinearity among
the independent variables. Although significant positive correlations of 1) annual household
income with education, 2) income with employment, and 3) education with employment were
found the magnitude of correlation was low. Thus, all three variables were included in the
regression models.
Results for Scenario 1
Table 4-46 shows results of ordinary least squares (OLS) and semi-logarithmic regression
models employed to determine the association between WTP and various respondent
characteristics for scenario 1. The use of semi-logarithmic regression model did not lead to any
changes in the significance of the variables but lead to changes in the sign of the regression
coefficients, when compared to OLS results. The results of the OLS model showed no
significant association of WTP with employment status, highest level of education completed,
number of members in the household and past experience of CINV. There was a significant
association between WTP and annual household income level. Respondents with annual
household income level between $30,001 and $60,000 were willing to pay $62.85 more and those
with >$60,000 were willing to pay $76.35 more compared to those with income ≤$30,000.
Results of the semi-log model showed significant differences in WTP amount based on
the annual household income level. Respondents with annual household income level between
$30,001 and $60,000 were willing to pay approximately 179% more as compared to those
respondents with income ≤$30,000. Similarly, respondents with annual household income
>$60,000 were willing to pay approximately 198% more compared to those respondents with

221

RESULTS

Reema Mody

income ≤$30,000. Although not significant, patients who had received chemotherapy but did not
experience nausea or vomiting reported lower WTP amounts compared to those who never had
chemotherapy. On the other hand, patients who had experienced nausea/vomiting or both in the
past reported higher WTP amounts as compared to those who never had chemotherapy.
Results for Scenario 2
Table 4-47 shows results of ordinary least squares (OLS) and semi-logarithmic regression
models employed to determine the association between WTP and various respondent
characteristics for scenario 2. The use of semi-logarithmic regression model did not lead to any
changes in the significance of the variables but lead to changes in the sign of the regression
coefficients, when compared to OLS results. The results of the OLS model showed no
significant association of WTP with employment status, highest level of education completed,
number of members in the household and past experience of CINV. There was a significant
association between WTP and annual household income level. Respondents with annual
household income level between $30,001 and $60,000 were willing to pay $62.50 more and those
with >$60,000 were willing to pay $81.27 more compared to those with income ≤$30,000.
Results of the semi-log model showed significant differences in WTP amount based on
the annual household income level. Respondents with annual household income level between
$30,001 and $60,000 were willing to pay approximately 182% more as compared to those
respondents with income ≤$30,000. Similarly, respondents with annual household income
>$60,000 were willing to pay approximately 209% more compared to those respondents with
income ≤$30,000.
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Table 4-46: Multivariate analysis to test the association between WTP and annual
household income – Scenario 1
Demographic Characteristics

Linear Regression

Semi-logarithmic

β coefficient

P value

β coefficient

P value

Age

2.078

0.043*

0.008

0.407

Employed

30.145

0.225

0.144

0.527

Completed High School

30.714

0.269

0.388

0.129

More than High School

43.980

0.148

0.437

0.117

$30,001 - $60,000

62.845

0.005*

1.045

0.000*

>$60,000

76.349

0.004*

1.122

0.000*

14.408

0.145

-0.004

0.962

Neither nausea nor emesis

15.121

0.537

-0.071

0.750

Either Nausea and/or emesis

22.805

0.344

0.203

0.358

Highest Level of Education Completed

Annual Household Income

Number of Members in the Household
Past Experience of CINV

F-statistic

3.894

6.854

Adjusted R2

19.4%

32.8%
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Table 4-47: Multivariate analysis to test the association between WTP and annual
household income – Scenario 2
Demographic Characteristics

Linear Regression

Semi-logarithmic

β coefficient

P value

β coefficient

P value

Age

1.516

0.117

0.004

0.670

Employed

6.664

0.777

0.013

0.954

Completed High School

34.826

0.186

0.396

0.126

More than High School

35.434

0.218

0.360

0.202

$30,001 - $60,000

62.499

0.003

1.058

0.000

>$60,000

81.271

0.001

1.158

0.000

9.085

0.331

-0.056

0.544

Neither nausea nor emesis

8.502

0.713

-0.111

0.627

Either Nausea and/or emesis

21.578

0.345

0.226

0.314

Highest Level of Education Completed

Annual Household Income

Number of Members in the Household
Past Experience of CINV

F-statistic

3.297

6.173

Adjusted R2

16.2%

30.3%
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Results for Objective 2.5
Net Benefit of Adding Aprepitant to the Standard Regimen
The standard regimen and the new regimen for prevention of CINV considered in
scenario 1 are shown in Table 4-48. The costs of the regimens per patient per cycle were
calculated using the drug prices presented in Table 3-7. The base case results for the cost benefit
analysis for prevention of CINV following HE chemotherapy are presented in Table 4-48. The
incremental benefit of adding aprepitant to the standard regimen of a 5-HT3RA and corticosteroid
for prevention of CINV due to HE chemotherapy was $89.90 (SD=$101.9, 95% CI = $70.77$109.03). The total cost of the new regimen and the standard regimen was $529.29 and $233.10,
respectively resulting in the incremental cost for the new regimen to be $296.11. Since the
incremental costs were greater than the benefits, the net cost of the new regimen was calculated
by subtracting the incremental benefits from the incremental costs. The net costs for the new
regimen in patients receiving HE chemotherapy was $206.21 (95% CI = $187.08 - $225.34).
Sensitivity Analysis
Sensitivity analysis was conducted to test the robustness of the results by varying the total
cost of the new and the standard regimens. The variations in costs were based on variations in
dosage and route of administration of the antiemetic drugs in the two regimens. Table 4-49
shows the results of four scenarios to study impact of variations in the prophylactic antiemetic
regimens on the net benefit of the new antiemetic regimens.
Scenario A involved replacing IV ondansetron 32mg with oral ondansetron 8mg as prior
evidence suggest equivalent efficacy of the two doses. The incremental costs of the new regimen
were still higher compared to the incremental benefits and the net costs ranged from $356.77$395.03. The incremental benefits were higher compared to the incremental costs in Scenario B
where the combination of a 5-HT3RA and corticosteroid were used in the delayed phase. The
analyses conducted with the 95% CI of WTP estimates revealed that the net benefits ranged
between -$30.09 and $8.17 and this suggests a situation of cost neutrality. For scenario C, the
net costs were insensitive to the changes in the dose of ondansetron and the delayed phase
regimen. Scenario D involved varying the dose of ondansetron in the new regimen and this
resulted in the decrease in the net costs associated with the new regimen. Overall, the results
suggest that the net costs associated with the new regimen is highly sensitive to the total costs of
225

RESULTS

Reema Mody

the new and standard regimen based on the drug dose and route of administration employed in
the study.
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Table 4-48: Incremental costs, Incremental Benefits and Net Benefit of New Antiemetic Regimen for HE Chemotherapy
Regimen

Total Costs*

Incremental
Costs (IC)

Incremental
Benefits (IB)

Net Benefit
(IC – IB)

$296.11

$89.90
($70.77-$109.03)

$206.21
($187.08-$225.34)

NEW REGIMEN
Acute phase - Aprepitant 125 mg + IV Ondansetron 32 mg + Oral
Dexamethasone 12 mg
Delayed phase – Aprepitant 80 mg (Days 2-3) Oral
Dexamethasone 8mg (Days 2-4)

$529.29

STANDARD REGIMEN – Baseline
Acute phase - IV Ondansetron 32 mg + Oral Dexamethasone 20
mg

$233.18

Delayed phase – Oral Dexamethasone 8 mg BID (Days 2-4)
*

Total cost of the regimen includes the cost of the prophylactic antiemetic drugs and the administration cost of the IV drugs
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Table 4-49: Sensitivity Analysis Results Based on Changes in the Drug Dosage and Route of Administration
Regimen

Total
Costs

Incremental
Costs (IC)

Incremental
Benefits (IB)

Net Benefit
(IC – IB)

$63.49

$465.80*

$89.90
($70.77-$109.03)

$375.90
($356.77-$395.03)

$450.35

$78.94*

$89.90
($70.77-$109.03)

-10.96
(-$30.09 -$8.17)

$280.66

$248.63*

$89.90
($70.77-$109.03)

$158.73
($138.70-$177.86)

$359.90

$126.72**

$89.90
($70.77-$109.03)

$36.82
($19.13-$55.95)

NEW REGIMEN
Acute phase - Aprepitant 125 mg + IV Ondansetron 32 mg + Oral
Dexamethasone 12 mg

$529.29

Delayed phase – Aprepitant 80 mg (Days 2-3) Oral Dexamethasone 8mg
(Days 2-4)
STANDARD REGIMEN – Scenario A
Acute phase - Oral Ondansetron 8 mg + Oral Dexamethasone 20 mg
Delayed phase – Oral Dexamethasone 8 mg BID (Days 2-4)
STANDARD REGIMEN – Scenario B
Acute phase - IV Ondansetron 32 mg + Oral Dexamethasone 12 mg
Delayed phase – Oral Dexamethasone 8 mg BID (Days 2-3) and 8mg on
Day 4 + Oral Ondansetron 8mg BID (Days 2-4)
STANDARD REGIMEN – Scenario C
Acute phase - Oral Ondansetron 8 mg + Oral Dexamethasone 20 mg
Delayed phase – Oral Dexamethasone 8 mg BID (Days 2-3) and 8mg on
Day 4 + Oral Ondansetron 8mg BID (Days 2-4)
NEW REGIMEN – Scenario D
Acute phase - Aprepitant 125 mg + Oral Ondansetron 8 mg + Oral
Dexamethasone 12 mg
Delayed phase – Aprepitant 80 mg (Days 2-3) Oral Dexamethasone 8mg
(Days 2-4)

* Calculated by subtracting total cost of the regimen from the total cost of the new regimen
** Calculated by subtracting the total cost of standard regimen – baseline ($233.18) from the cost of the new regimen –Scenario D.
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Results for Objective 2.6
Net Benefit of Using Palonosetron instead of the Standard Regimen
Scenario 2 of the WTP survey involved substituting palonosetron for preventing CINV
following ME chemotherapy instead of the standard regimen of a 5-HT3RA and corticosteroid.
The incremental costs, incremental benefits and net costs associated with the use of palonosetron
are reported in Table 4-50. The net cost of palonosetron for prevention of CINV following ME
chemotherapy for one cycle is $160.99. The net costs due to the new regimen of palonosetron
were recalculated using the 95% CI of the maximum WTP which resulted in the net costs within
the range $143.17-$178.81. Thus, the results were insensitive to the extremes in the WTP.
Sensitivity Analysis
Sensitivity analysis was conducted to test the robustness of the results by varying the total
cost of the new and the standard regimens. The sensitivity analyses were conducted by varying
the total cost of the regimens. The costs varied based on the changes in the delayed phase
regimen employed for prevention of CINV following ME chemotherapy. Table 4-51 shows the
results of two scenarios designed to study the impact of variations in the prophylactic antiemetic
regimens on the net benefit of the new antiemetic regimens. Scenario A involved calculating the
net costs of the palonosetron regimen compared to a single IV dose of ondansetron 32 mg. The
net costs decreased as compared to the base case results but were still indicative that the
incremental costs of the palonosetron regimen exceeded the incremental benefits. Scenario B
involved calculating the net costs associated with employing a combination regimen of a 5HT3RA and dexamethasone in the delayed phase of the standard regimen. Due to the high total
costs of the standard regimen under scenario B, as compared to the new regimen, the former
regimen was dominated by the new regimen.
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Table 4-50: Incremental costs, Incremental Benefits and Net Benefit of New Antiemetic Regimen for ME Chemotherapy
Regimen

Total Costs*

Incremental
Costs (IC)

Incremental
Benefits (IB)

Net Benefit
(IC – IB)

$83.50

$160.99

($65.68-$101.32)

($143.17-$178.81)

NEW REGIMEN
Acute phase - IV Palonosetron 0.25mg

$340.20

STANDARD REGIMEN
Acute phase – IV Ondansetron 8mg + IV Dexamethasone 8 mg
Delayed Phase – Oral Dexamethasone 4mg BID (Days 2-5)
*

$95.71

$244.49

Total cost of the regimen includes the cost of the prophylactic antiemetic drugs and the administration cost of the IV drugs
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Table 4-51: Sensitivity Analysis Results Based on Changes in the Drug Dosage and Route of Administration for HE Chemotherapy

Regimen

Total Costs

Incremental
Costs (IC)

Incremental
Benefits (IB)

Net Benefit
(IC – IB)

$206.41

$133.79

$83.50
($65.68-$101.32)

$50.29
($32.47-$68.11)

$389.47

-$49.27

$83.50
($65.68-$101.32)

Dominated*

NEW REGIMEN
Acute phase – IV Palonosetron 0.25mg

$340.20

Standard Regimen – Scenario A
Acute phase – IV Ondansetron 32mg
Standard Regimen – Scenario B
Acute phase - IV Ondansetron 8mg + IV Dexamethasone 8 mg
Delayed phase – Oral Dexamethasone 4 mg BID (Days 2-5) +
Oral Ondansetron 4mg BID (Days 2-5)
*

Regimen in Scenario B is dominated by the new regimen as the latter costs less and provides increased emesis protection
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CHAPTER FIVE

DISCUSSION AND RECOMMENDATIONS
The primary goal of this study was to conduct a comprehensive economic evaluation of
prophylactic antiemetic regimens for prevention of chemotherapy-induced nausea and vomiting
(CINV) following administration of highly emetogenic (HE) and moderately emetogenic (ME)
chemotherapy. The introduction of more efficacious but more costly new antiemetic agents for
prevention of CINV may pose a significant economic burden on payers, hospital formularies and
society. In Phase I of the study, two decision models were developed to quantify the costs and
benefits of the various antiemetic regimens for prevention of CINV due to HE and ME
chemotherapy. A contingent valuation survey was developed in Phase II to estimate the
monetary value of improved emesis control due to the new antiemetic regimens among cancer
patients. The detailed methodology for determination of cost-effectiveness of the alternative
antiemetic regimens and estimating the maximum willingness-to-pay (WTP) for improved
emesis control is reported in Chapter 3. The results of the decision models and the survey are
presented in Chapter 4. This chapter discusses the major study findings and their implications. It
also includes the major limitations of the study and presents the significance of the study results.
Finally some recommendations for future research are also included in this chapter.
5.1: Review of Phase I Findings
The introduction of more efficacious but more costly new antiemetic agents for
prevention of CINV may pose a significant economic burden on payers, hospital formularies and
society. Cost-effectiveness analysis is an economic evaluation method used to compare new
treatments to standard of care to make informed decision-making. The incremental costeffectiveness (ICER) was calculated as the additional cost of the new treatment divided by the
increased benefit of the new treatment. Two decision models were developed to determine the
costs, effectiveness and incremental cost-effectiveness ratios of prophylactic antiemetic regimens
for prevention of CINV due to HE and ME chemotherapy. The cost-effectiveness analyses were
conducted from both the payer and societal perspective.
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For Highly Emetogenic Chemotherapy Model
Results from the payer and societal perspectives showed that the cost for complete
control of emesis in one patient is the lowest for regimen C and the highest for regimen A. When
comparing only the resource utilization and not the effectiveness of the treatment strategies,
regimen A was approximately three times more expensive than regimen C from the payer
perspective. The lower acquisition cost of regimen C was the principal driving force that resulted
in a lower overall cost of the primary therapy. The ratio decreased to 2.5 times when the
effectiveness of the regimens were used in the calculations. However, the differential in the total
cost of the aprepitant regimen was not compensated for fully by the superior efficacy and lower
resource utilization during the delayed phase. From the payer perspective, the base-case analysis
yielded an incremental cost-effectiveness ratio (ICER) of $3,363.181 per patient with complete
control of emesis for regimen A (addition of aprepitant to the standard regimen of a 5-HT3RA
and dexamethasone) compared to regimen C (included metoclopramide in the delayed phase).
Regimens B and D were dominated by regimen C and were excluded from the ICER
calculations. The ICER for regimen A was found to be $2,881.605 per patient with complete
control of emesis from the societal perspective.
One-way sensitivity analysis was conducted to identify key variables that may have an
impact on the ICERs of the treatment regimens. The ICER of the regimens were sensitive to the
probability of no acute emesis, the probability of no delayed emesis given no acute emesis, and
the probability of receiving rescue medications in the delayed phase given no delayed emesis.
Increasing the probability of no delayed emesis given no acute emesis for regimen D resulted in
changes in the dominance status of the regimens. Regimen D was no longer dominated by
regimen C and had an ICER of $2,173 per patient with complete control of emesis from the payer
perspective and $1,787 from the societal perspective. The results were not very sensitive to
changes in the total cost of prophylactic antiemetic regimens, infusion costs, costs of IV
ondansetron and cost of aprepitant. The total costs and ICER for each regimen were not sensitive
to variations in the number of hours of lost productivity and the average wages per hour.
The cost effectiveness results were sensitive to the model including the side effects
associated with regimen C (includes metoclopramide in the delayed phase). The ICER for
regimen A decreased from both payer and societal perspectives and regimen D was excluded
from the calculations due to extended dominance. Across all the sensitivity analyses, regimen C
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remained the least expensive treatment, though the cost-effectiveness of the regimen varied with
changes in the parameter estimates.
Although simple sensitivity analysis can be helpful in identifying factors that affect CE
ratios, single value analysis can be extremely misleading. In reality, within the possible ranges of
each variable, thousands of possible combinations of values can exist. In this study, probabilistic
sensitivity analysis (second-order Monte Carlo simulation method) was conducted to take into
account all parameter variations simultaneously. Results from the probabilistic sensitivity
analyses for the HE model showed that the expected mean costs and effectiveness were similar to
those obtained in the base case analysis. There were no changes in dominance status of the
regimens, though the ICERs for regimen A were higher as compared to the base case analysis,
from the payer and societal perspectives.
This study is among the first to evaluate the cost-effectiveness of four antiemetic
regimens, new regimen A (addition of aprepitant to the standard regimen), regimen B (standard
used in aprepitant clinical trials), regimen C (recommended by ASCO 1999 guidelines) and
regimen D (most common clinical practice) for prevention of CINV following HE chemotherapy.
Currently, three studies evaluating the cost-effectiveness of adding aprepitant to the standard
regimen have been published in abstract format (Deuson, 2004; Ehlken et al., 2004; Moore et al.,
2005). These studies have evaluated the cost effectiveness of addition of aprepitant to the
standard regimen but have not compared it to regimens used commonly in clinical practice. The
results of the study may not be directly comparable to the three published economic evaluations
due to the differences in the treatment comparators, perspective, time horizons and methodology
employed.
Ehlken and colleagues (2004) conducted a study in office-based settings in Germany to
determine the incremental costs and effects associated with addition of aprepitant to the standard
regimen from the payer perspective. The ICER for aprepitant regimen was calculated to be
€21,764 per quality-adjusted life years (QALY). The published abstract does not provide any
information regarding the source of utilities for calculations of QALYs. Moore and colleagues
(2005) constructed a Markov model to compare the cost-effectiveness of three regimens:
standard therapy, addition of aprepitant to the standard regimen (strategy 1) and addition of
aprepitant to the standard regimen if CINV (strategy 2) occurs. The analysis was conducted for
five cycles of chemotherapy and the ICER was calculated to be $172,789 per QALY for strategy
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1 and $160,236 per QALY for strategy 2. The authors concluded that use of aprepitant was not
cost effective and should only be used in high-risk populations. Zbrozek and colleagues
(Zbrozek et al., 1994) also reported high cost/QALY values for ondansetron compared to
metoclopramide for prevention of acute CINV.
The high ICER for aprepitant in the previous two studies may be a function of employing
the concept of QALYs for CINV, an acute condition with short term impact on quality of life and
no proven impact on survival. Short term clinical outcome measures, for example complete
protection from emesis, may prove to be better indicators to compare the cost-effectiveness of
various antiemetic regimens. This is especially true until more robust methods are available to
determine the utilities for acute conditions which are not shown to have a direct impact on
survival of patients.
The previous economic evaluations (Ehlken et al., 2004; Moore et al., 2005) of the new
antiemetic regimen were conducted from the payer perspective and thus did not include the
indirect costs arising due to lost work productivity. The survey results from phase II of the study
showed that uncontrolled emesis affects patients’ ability to return to work and results in lost
productivity. Previous studies have also published some information about the lost work
productivity among patients and their caregivers (O'Brien et al., 1993). The addition of indirect
costs led to an increase in the total costs associated with each of the four antiemetic regimens.
However, the increase in the costs of regimen C was greater than that of regimen A which
resulted in a decrease in the ICER of regimen A from 3,363.181 to $2,881.605 per patient with
complete control of emesis. The study findings underscore the importance of controlling delayed
emesis as it results in added costs. Regimen A provides better protection during delayed phase
compared to regimen C, leading to reduced health care resource utilization which ultimately
translates into better cost-effectiveness for regimen A. Additionally, the base case results show
that compared to regimen D, the regimen A with aprepitant costs only an additional $154 to
achieve complete control of emesis in one patient but provides better overall control of emesis.
When the indirect costs are added to the direct costs, the difference in the total costs of achieving
one patient with complete protection from emesis between the two regimens decreases to $52.
Previous antiemetic drug utilization studies (DURTO, 2003; Fabi et al., 2003) have
reported the use of 5-HT3RAs in the delayed phase even though there is insufficient evidence
regarding its superiority compared to more traditional agents such as metoclopramide and
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dexamethasone (IGAR, 1997; Latreille et al., 1998a). The effectiveness of regimen C (which
includes metoclopramide in the delayed phase) had better efficacy in controlling emesis as
compared to regimen D (the common antiemetic regimen used in clinical practice) but the
efficacy became similar when the side effects of the regimen C are taken into consideration.
However, the cost of achieving one patient with complete control of emesis is lower with
regimen C. Thus, the model results provide additional evidence that use of 5-HT3RA during the
delayed phase does not result in a sufficient increase in effectiveness to offset the increase in
costs.
For Moderately Emetogenic Chemotherapy Model
The decision model for prevention of CINV following administration of moderately
emetogenic chemotherapy compared four antiemetic regimens, regimen 1 (only palonosetron),
regimen 2 (only ondansetron), regimen 3 (combination of ondansetron and dexamethasone in the
acute phase and dexamethasone in the delayed phase) and regimen 4 (combination of
ondansetron and dexamethasone in acute and delayed phase). The base case results from the
payer and societal perspectives showed that without considering the effectiveness, the cost
associated with CINV and its treatment is highest for regimen 4 and lowest for regimen 3. In the
cost-effectiveness analysis, regimen 2 was dominated by regimen 3 from both perspectives. From
the payer perspective, the ICER for regimen 1 compared to regimen 3 was $3,582.48 and the
ICER for regimen 4 compared to regimen 1 was $14,953.27 per patient with complete control of
emesis. The ICER for regimen 1 compared to regimen 4 was $3,549.02 and the ICER for
regimen 4 compared to regimen 1 was $6,499.87, from the societal perspective.
To our knowledge, only one study has conducted an economic evaluation of palonosetron
compared to the older 5-HT3RAs with and without the addition of dexamethasone (Vanscoy et
al., 2004). There have been no published cost-effectiveness evaluations comparing palonosetron
to other combination antiemetic regimens recommended for prevention of CINV following ME
chemotherapy. Vanscoy and colleagues (Vanscoy et al., 2004) conducted a pharmacoeconomic
evaluation of palonosetron in patients receiving moderately emetogenic chemotherapy. The
outcomes and resource utilization for extreme events were compared for two groups of patients,
one group receiving palonosetron and the other receiving either ondansetron, dolasetron or
granisetron. The extreme event of CINV was defined as patients with severe nausea and two or
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more emetic episodes on any day plus severe nausea on the following day, or patients with five
emetic episodes on any day and moderate to severe nausea the following day. The study was
conducted from the payer perspective and found that use of palonosetron resulted in a reduction
in extreme events, which translates into significant savings for payers. However, the study did
not examine the impact of CINV on emergency room visits, hospitalization costs or patient
productivity. The current study results cannot be directly compared to results of this study as the
latter does not report any cost-effectiveness ratios for the antiemetic regimens.
Previous economic evaluations have compared 5-HT3RAs to the traditional antiemetic
agents such as metoclopramide, or compared 5-HT3RAs against one another for prevention of
CINV due to moderately emetogenic chemotherapy (Cox & Hirsch, 1993; Kwong &
Parasuraman, 1999; Lachaine & Laurier, 2002; Lachaine et al., 1999). Kwong and Parasuraman
(Kwong & Parasuraman, 1999) reported that the cost of one additional effectively treated patient
(no emesis and no adverse event for a three-day period) with ondansetron was $258 as compared
to metoclopramide from a third-party payer perspective. However, as stated earlier, these results
cannot be compared to the current study results because of differences in the treatment
comparators, time horizon, and outcome measure.
One-way sensitivity analysis was conducted to identify key variables that may have an
impact on the ICERs of the treatment regimens. The results very sensitive to changes in 1) the
probability of no acute emesis, 2) the probability of no delayed emesis given no acute emesis, 3)
the probability of receiving rescue medications in the acute phase given no acute emesis and 4)
the probability of receiving rescue medications in the delayed phase given no delayed emesis.
The variations in these parameters changed the dominance status and the ICERs of the individual
antiemetic regimens. The ICER results were also sensitive to changes in the cost parameters.
The ICER results showed that regimen 1 was dominated by regimen 3 when the cost of regimen
1 was increased by 20%, cost of regimen 4 was decreased by 20%, the cost of palonosetron was
increased by 20% and the cost of ondansetron was decreased by 20%. A probabilistic sensitivity
analysis was conducted to take into account all parameter variations simultaneously. This
resulted in removal of regimen 1 from the ICER calculations due to extended dominance by a
blend of regimen 3 and regimen 4. Compared to the base case estimates, the ICER of regimen 4
compared to regimen 3 decreased from $3,655.35 to $1,446.30 per patient with complete control
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of emesis from the societal perspective. Thus, overall sensitivity analysis results show that the
model estimates were very sensitive to variations in cost and efficacy parameters.
The sensitivity of the ICER results to changes in the parameter may be explained in part
by the following. The calculation of the ICER for regimen 4 over regimen 3 resulted in
$3,593.01 from payer perspective and $3,655.35 from the societal perspective. These ICER
estimates for regimen 4 are very similar to the ICER estimates for regimen 1. Also, as mentioned
earlier, regimens 1 and 4 have very similar effectiveness (0.695 and 0.699, respectively) and only
differ in costs associated with CINV and its treatment. Thus, the economic evaluation of regimen
1 and 3 can be conducted using the cost-minimization method. However, due to the inclusion of
both regimens in the model, and little differences in their effectiveness, the ICER results for the
antiemetic regimens are very sensitive to any changes in the efficacy parameters. Additional
analyses were conducted by removing regimen 4 from the decision model and the ICER for
regimen 1 compared to regimen 3 was $3,682 per patient with complete control of emesis from
the payer perspective and $3,233 per patient with complete control of emesis from the societal
perspective. Probabilistic sensitivity analysis was also conducted for the new model with the
three regimens. The ICER for regimen 1 compared to regimen 2 was approximately twice that
obtained from the base case of the new model, however, the dominance status of the regimens
remained the same.
Summary of Results for Phase I
When making treatment decisions, supportive care providers should select the most costeffective treatment, bearing in mind that it may not be the least expensive. Even in a costsensitive managed care environment, the treatment with the lowest CE ratio may not always be
the first choice. The definition of a cost-effective therapy should be based on the comparisons to
the CE ratios of treatments for various diseases. In this case, it could be compared to other
supportive care treatments for cancer. Although the threshold for determining whether an
intervention is cost-effective is hard to define and generalize, less than $50,000 per life-year
gained is generally considered acceptable for therapeutic interventions and more than $100,000
per life-year gained is generally considered excessive (Mark et al. 1995). Nevertheless, many
interventions that cost as much as $100,000 per year of life saved have been accepted (Hillman
and Kim, 1995). The interpretation of acceptable cost-effectiveness ratios usually depend on the
individual decision makers and their budget constraints.
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The available data do not allow direct comparisons of the CE ratios obtained in this study
to those using life-years gained as effectiveness measures in the literature. Some studies have
used life years gained while others have used quality adjusted life years gained. Even among
economic evaluations that report cost per QALY, utilities from different sources have been
applied (Ehlken et al., 2004; Moore et al., 2005; Zbrozek et al., 1994). All economic evaluations
of antiemetic regimens employing utilities have reported very high cost per QALY estimates
which fall above the acceptable cutoff of $100,000/QALY. Although, regimen C which includes
metoclopramide in the delayed phase has the lowest cost per patient with complete control of
emesis in patients receiving HE chemotherapy, it may not be the first choice of treatment by
providers due to its side effects profile and multi dosing regimen per day. The ICER for the
aprepitant regimen from payer perspective was calculated to be $3,363 per patient with complete
control of emesis, which lies within the acceptable cutoff mentioned earlier. The sensitivity
analysis results show that the ICER for regimen A remains below the acceptable threshold of
$50,000 per QALY. Thus, it can be considered cost effective in preventing CINV for patients
receiving highly emetogenic chemotherapy.
In addition to the economic factors, another factor that plays a role in selecting an
intervention is patient preference. As indicated by the qualitative data from our survey results,
almost 25% of patients preferred a single IV dose of palonosetron for prevention of CINV
compared to the multi dosing regimen of other antiemetic drugs. Clinicians and health care
providers will most likely take patient preference into consideration when choosing the optimal
antiemetic intervention. However, patient preferences have not been incorporated in a
quantifiable manner in the decision models. If patients show preference for single IV dose of
palonosetron compared to a three-day regimen for prevention of CINV following ME
chemotherapy, the ICER of the palonosetron regimen will be more cost-effective compared to
other combination regimens.
The criteria for the effectiveness measure in clinical trials and economic evaluations for
antiemetic agents are not explicitly established (Lachaine & Crott, 2003). In some previous
economic evaluations the efficacy criteria adopted was complete control of emesis or both nausea
and emesis (Ballatori et al., 1994) while in other studies lack of antiemetic side effects were also
a criteria for efficacy (Kwong & Parasuraman, 1999). In the current study, for the HE
chemotherapy model the base case analysis considered the control of emesis as the effectiveness
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measure. However, scenario analysis was also conducted where the lack of side effects of
regimen 4 was a criterion for effectiveness. Most of the previous economic evaluations were
limited to the acute phase of CINV and underestimates the costs associated with CINV and its
treatment. The previous evaluations were conducted to determine the cost-effectiveness of single
drug antiemetic regimens with multi-dosing regimens which is no longer relevant. With the
current guidelines and recommendations, combination regimens are the standard of practice and
multi-dosing regimens are replaced by single dose administration. Thus, the current study
provides economic results about the commonly employed antiemetic regimens in the
recommended dosing schedule.
5.2: Review of Phase II Findings
Cost effectiveness analysis (CEA) and cost-utility analysis (CUA) are the most popular
techniques used to conduct economic evaluation of healthcare interventions. These are most
commonly employed to determine the incremental costs for receiving the incremental benefits,
measured as clinical outcomes or life-years saved or QALYs gained. Although these methods
provide helpful ways to determine cost-effective health care interventions, it is not feasible to
employ them for acute conditions such as CINV where individuals experience the condition for a
very short time period and may not be willing to forego future life years. In such scenarios,
monetary valuation of benefits of the health care intervention may be more appropriate and can
be used to determine the net benefit of the intervention. The net benefit values can be used to
create a monetary rank order of disparate healthcare interventions for resource allocation using
fixed budgets.
The primary goal of phase II was to determine the monetary value that patients with
cancer place on improved emesis control. A contingent valuation survey was developed to
measure patients’ valuation of emesis control and data were collected by conducting face-to-face
interviews with the study participants. This monetary value of benefits was then used to
calculate the net benefit of the new antiemetic regimens compared to the standard regimen
employed for prevention of CINV following HE and ME chemotherapy. The global perspective
was used to develop the hypothetical scenarios for WTP estimation. The clinical, economic and
quality of life outcomes associated with the antiemetic prophylaxis were explicitly presented to
the respondents. Patients with cancer placed high importance on the risk reduction of acute and
delayed emesis offered by the new antiemetic regimens. All 120 study participants preferred the
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addition of aprepitant to the standard regimen compared to only the standard regimen. In the
case of palonosetron, only one respondent preferred to receive the standard regimen due to
dislike of injection and not enough emesis risk reduction for the palonosetron regimen. The
WTP estimate was determined for the entire time period for which nausea and vomiting is
associated with HE chemotherapy.
There have not been any published studies reporting the WTP for receiving a single IV
dose of palonosetron instead of the standard regimen for prevention of CINV following ME
chemotherapy. Our results showed that respondents were willing to pay on average $83.50 for a
single dose regimen of palonosetron to receive a 12% reduction in delayed emesis.
Approximately 91% of the study respondents were willing to pay for improved emesis control
obtained due to the addition of aprepitant to the standard regimen for CINV due to HE
chemotherapy. The WTP for improved emesis control due to the addition of aprepitant to a
three-day regimen of a 5-HT3RA and dexamethasone for each cycle of chemotherapy was found
to be $89.90. This amount was for a 13% reduction in the incidence of acute emesis and 18%
reduction in the incidence of delayed emesis following administration of HE chemotherapy.
The present study is the first to determine the monetary value of improved emesis control
in the United States. A previous study conducted in Spain, Greece, Italy and Canada reported the
monetary value that patients with cancer place on improved emesis control following cisplatin
chemotherapy (Dranitsaris et al., 2001b). The study determined the maximum WTP separately
for the acute and delayed phases of emesis. For a 10% improvement in acute emesis, a WTP in
the range of $6-$54 per day was reported. Similarly for a 20% improvement in delayed emesis, a
WTP in the range of $6-$45 per day for 4 days was reported. The study was conducted based on
hypothetical benefits and not actual benefits of aprepitant as obtained from randomized clinical
trials. Due to the differences in the methodology employed, our results could not be compared
directly to those reported by Dranitsaris and colleagues. However, if the estimates from the
previous study are used to estimate the maximum WTP for a period of three days, the results
would be $8 for Greece, $70 for Italy, $114 for Canada, and $144 for Spain. The results of our
study and the previous study (Dranitsaris et al., 2001b) show that patients’ monetary valuation of
benefit and quality of life are probably related to cultural differences and variations in the
healthcare systems among the countries.
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The qualitative data from the study participants showed that patients prefer the modest
benefits offered by the new antiemetic regimens because nausea and vomiting affect their ability
to return to work, ability to enjoy food, and their overall quality of life. Additionally, about onefourth of the patients prefer palonosetron due to its single IV dosing regimen compared to the
multi-day dosing pattern of the standard antiemetic regimen. However, in spite of what cancer
patients reported about the importance of avoiding CINV, only about 6% of patients interviewed
were willing to make out-of-pocket payments to cover the additional costs of the new drugs. It is
suggested that this may be due to the fact that cancer patients face a number of chemotherapyrelated complications such as hair loss, neutropenia, anemia mucositis etc, in which nausea and
vomiting is only a part of the problem (Ortega, Dranitsaris, & Puodziunas, 1998). Ortega and
colleagues reported similar results based on a WTP study which was conducted to estimate the
monetary value of epoetin alfa for chemotherapy-induced anemia (Ortega et al., 1998). Only
about 4% of cancer patients were willing to pay the actual costs of epoetin alfa for
chemotherapy-induced anemia.
In the present study, WTP was measured using the ex-post or user based perspective.
Neumann and Johannesson (1994) explored WTP for in vitro fertilization using both ex-post and
ex-ante scenarios (Neumann & Johannesson, 1994). The study results showed that the implied
WTP per baby is much higher for the insurance-based approach than the user-based approach.
Hypothetically, user-based and insurance-based approaches should provide equivalent WTP but
in general, since individuals are more risk averse about health care issues, the two methods
results in different WTP. The method selected for determining WTP is important, since the
insurance-based approach is expected to provide a higher mean WTP than the user-based
approach (Gafni, 1996). In another study, the WTP estimates for benefits of epoetin alfa therapy
obtained from the general population were higher compared to those obtained from cancer
patients receiving chemotherapy (Ortega et al., 1998). Our study, which was conducted using
user-based perspective among cancer patients, may have resulted in underestimation of the
monetary value of the benefits of the new antiemetic regimens. The study, if conducted in the
general population using the insurance-based perspective would be able to capture the non-user
values or externalities associated with the use of antiemetic regimens.
The WTP survey included two scenarios: one for HE chemotherapy and one for ME
chemotherapy. It is suggested that the WTP values offered for a question are partly determined
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by the value provided for previous questions (Smith et al., 1999a). Thus, in this case it may result
in order bias whereby the respondents may give WTP amounts for the second scenario based on
those provided for the first scenario (Stewart, O'Shea, Donaldson, & Shackley, 2002;
Venkatachalam, 2004). To avoid order bias, two versions of the survey were offered alternately
to the respondents. Also, results of the bivariate statistical analyses showed that order in which
the scenarios were presented did not bias the WTP values.
Many people are not willing to provide a monetary valuation for health gains because
either they are opposed to paying for health or they oppose the suggestion of paying out of pocket
(Smith, Olsen, & Harris, 1999d). The protest is usually expressed as zeroes or high WTP
amounts. Smith and colleagues (Smith et al., 1999d) have recommended that WTP studies
should report the proportion of zero responses and the protest bids. Individuals who oppose the
valuation of health in monetary terms or think that they should not have to pay for health care
intervention give a very high valuation or zeros for maximum WTP. These are called as protest
bids. An assessment should be conducted to separate the genuine zeroes from the protest zeroes
in the WTP study. In the current study, approximately 10% of the population reported zero bids
as their WTP amounts. Out of these respondents, only about 2% were categorized as protest
zeroes. A review of WTP literature showed that based on the format of the WTP question used
in the study, the proportion of protestors ranged from 9.3% for the payment card method, 18.1%
for the open ended format to 23.7% for the dichotomous choice method (Reaves, Kramer, &
Holmes, 1999). The proportion of zero bids and protest zeroes in our study which employed the
payment card method was either lower or comparable to the proportions reported in the literature
(Donaldson, Thomas et al., 1997; Smith et al., 1999d). The lower proportion of zero bids for
studies employing the payment card method may be because the payment card format may ease
the valuation task faced by the survey respondents. Additionally, since the present data were
collected using face-to-face interviews, participants had an opportunity to ask questions and
clarify doubts.
Due to the hypothetical nature of contingent valuation studies, it is difficult to assess the
validity of the WTP responses (O'Brien et al., 1998; Smith et al., 1999c). Ideally to establish
criterion validity, one would compare the hypothetical values with actual observed market
purchases. However, such a market does not exist for comparison and other methods need to be
employed to determine the validity of the WTP results. One method suggested to assess the
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construct validity of WTP responses is based on the premise that most goods and services have a
positive income elasticity, i.e. higher incomes should be associated with higher WTP (Smith et
al., 1999c). This theoretical construct can be tested by assessing the association of WTP amounts
with respondents’ income level (Neumann & Johannesson, 1994; Smith et al., 1999c). The
theoretical validity of the study can also be assessed by regressing the WTP on a group of
independent variables believed to be predictors of WTP (Neumann & Johannesson, 1994). The
results of the semilogarithmic models for scenarios 1 and 2 showed the positive association of
WTP amounts to the annual household income level of the respondents. The positive effect of
income is consistent with the results of other WTP studies in the literature and establishes the
construct validity of the survey results (Davey et al., 1998; Dranitsaris et al., 2001a).
Consistent with findings of a previous study (Dranitsaris et al., 2001a), clinical
characteristics of the respondents, such as past experience of nausea and emesis did not have a
significant influence on the WTP estimates for scenarios 1 and 2 . Though the multivariate
results were not significant, it was found that patients who were chemotherapy naïve reported
higher WTP compared to those who had received chemotherapy in the past but had not
experienced CINV. The higher WTP amounts reported by chemotherapy naïve patients can be
explained in part based on the patients’ pre-treatment expectation of CINV. Previous research
has shown that patients’ pre-treatment expectation of nausea and emesis are significant predictor
of CINV (Molassiotis et al., 2002; Montgomery et al., 1998; Roscoe et al., 2000). The patients
may have pre-conceived expectancy regarding side effects of chemotherapy based on information
either obtained from oncologists or nurses, or from their past experience with nausea and
vomiting (may be due to pregnancy or motion sickness) or from other information sources such
as television, friends and family (Roscoe et al., 2000). Thus chemotherapy naïve cancer patients
may have pre-treatment expectations of experiencing side effects of chemotherapy which could
have resulted in higher WTP amounts for the new regimen with a higher probability of
preventing CINV.
In the present study, all respondents received a prophylactic antiemetic regimen for
prevention of acute emesis following chemotherapy. Consistent with the results of a previous
antiemetic drug utilization study (DURTO, 2003), the current study results showed that more
than half of the respondents received the combination regimen of a 5-HT3RA and dexamethasone
for prevention of acute CINV. This regimen is consistent with the ASCO, NCCN and MASCC
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recommended guidelines for prevention of CINV (R. J. Gralla et al., 1999; MASCC, 2004;
NCCN, 2005). Since the respondents in our study were unable to provide complete information
about the antiemetic regimens prescribed for prevention of delayed CINV, we could not
determine its consistency with the recommended guidelines. The existing antiemetic regimens
provide reasonably good protection against emesis but past studies have reported their
inadequacy in controlling nausea (IGAR, 1995a, 2004; Molassiotis et al., 2002). This is reflected
in the current study with approximately 44% of respondents experiencing nausea in spite of
prophylactic antiemetic regimens. Past studies have shown that nausea is ranked as the most
incapacitating side effects by cancer patients (Boer-Dennert et al., 1997; Griffin et al., 1996). It
has been shown that nausea has a greater impact than vomiting on patient outcomes, overall
functioning, emotional status, enjoyment of eating and quality of life (Foubert & Vaessen, 2005).
Thus, there is need for more effective control of acute and delayed nausea following
chemotherapy.
The WTP estimates obtained from the contingent valuation survey were used as the
monetary valuation of benefits of the new antiemetic regimens for prevention of CINV and were
used in cost-benefit analysis (CBA). The net cost of the new antiemetic regimens were
calculated from the payer’s perspective by subtracting the incremental benefits of the new
regimen from the incremental costs due to the new regimen. If the value obtained is positive, it is
termed as net costs and if the value obtained is negative, it is termed as net benefits. The addition
of aprepitant to the standard regimen results in a net cost of $206.21 per chemotherapy cycle. On
an average, patients with cancer received six cycles of chemotherapy resulting in additional costs
of $1,237.26. Similarly, the incremental costs of using a single IV dose of palonosetron were
higher than the incremental benefits, resulting in a net cost of $160.99 per chemotherapy cycle.
The sensitivity analyses results showed that the incremental costs remained higher compared to
incremental benefits when the cost of standard regimen for scenario 1 was increased. The high
costs of the new antiemetic regimens were not justified by the benefits of the regimen as valued
by the cancer patients receiving chemotherapy. This study is among the first to use CBA to
conduct economic evaluation of antiemetic regimens for prevention of CINV. CBA has been
used to determine the economic value of other supportive cancer care interventions, such as
epoetin alfa for prevention of chemotherapy-induced anemia, amifostine for chemotherapyinduced toxicity (Dranitsaris, 1997; Ortega et al., 1998), comparing antineoplastic agents
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(Dranitsaris, Elia-Pacitti, & Cottrell, 2004), and in the area of diabetes care (Davey et al., 1998;
Dranitsaris, Longo, & Grossman, 2000).
5.3: Implications of Study Findings
The study results will be a valuable addition to the scientific literature in the field of
supportive cancer care, pharmacoeconomics, and economic evaluation methodologies. In
addition to its academic importance, the study results have implications for payers and clinicians.
Implications for Payers
The cost-effectiveness estimates for the prophylactic antiemetic regimens for prevention
of CINV following HE and ME chemotherapy, obtained from the phase I of the study, has
implications for third-party payers. The comparators in the decision model were based on the
published guidelines, common regimens used in clinical practice and the addition of new
antiemetic agents to the standard regimens. The dosage schedule and duration of therapy was
also based on recommendations and clinical practice. Thus, the study attempted to provide cost
effectiveness estimates for real-life use of antiemetic agents. The drug formulary administrators
of managed care organizations can use the parameter estimates and the structure of the decision
model to create budget impact models for their populations.
The costs associated with using 5-HT3RA in the delayed phase (regimen 4) for
prevention of CINV due to moderately emetogenic chemotherapy was higher as compared to the
palonosetron regimen without any comparable increase in antiemetic effectiveness. This is
consistent with previous results which report use of costly 5-HT3RAs for delayed phase with no
added benefits. Hospital and managed care organizations can promote the dissemination of the
recommendations for appropriate antiemetic use so as to decrease costs without any impact on
the benefits.
The monetary valuation of the improved emesis control provided by the two new
antiemetic regimens allowed us to quantify the clinical, economic and humanistic outcomes
associated with CINV and its treatment. This comprehensive evaluation of benefits using WTP
estimates can be used to calculate the net benefits of prophylactic antiemetic regimens compared
to other interventions, either other antiemetic regimens or other competing healthcare
interventions. The WTP estimates used in CBA can be used by decision makers such as HMO
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and drug formulary committees for resource allocation decisions. In a fixed budget scenario, a
rank-ordering of the existing health care programs based on their net benefits can be done and
compared with the net benefit of the new antiemetic regimen. This will help in reallocation of
resources as interventions with smaller net benefits can be replaced with those regimens with
higher net benefits.
Implications for Clinical Practice
The results from Phase II of the study suggest that control of nausea is not adequately
achieved with the current antiemetic regimens and is an area for further research for
pharmaceutical companies. The results obtained from Phase II also have implications for the
oncologists and nurses. Patients place high importance on receiving even a modest improvement
in the control of CINV. Nausea and vomiting is perceived by cancer patients to affect their
quality of life, ability to eat and return to work. Oncologists and nurses should be cognizant of
the level of importance that control of CINV has for patients so that they provide the best
prophylactic treatment for prevention of CINV. In addition, there is a scope for improvement
among clinicians with respect to adhering to the recommendations for utilization of the
antiemetic agents.
5.4: Study Limitations
Both phases of the study have limitations and these are discussed below. These
limitations need to be considered when deriving inferences from the reported results.
Limitations of Phase I
1. A decision model for economic evaluation is only as good as the data that is used to populate
the model. An ideal data source would be a randomized, double-blind study examining the
efficacy and the resource utilization associated with all the treatment alternatives. Since such
a study is not available, cost and efficacy parameters were synthesized from a number of
published studies and expert opinion. The impact of uncertainty in the parameter estimates
on the results was evaluated by conducting sensitivity analysis.
2. The base case analysis assumes that the study populations in the source studies used for
parameter estimates are comparable in their demographic and clinical characteristics. In
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reality, this is possible only through randomization of the cohort to each treatment strategy
included in the model. However, it is doubtful that such a randomized controlled clinical trial
would be conducted in the near future.
3. In an attempt to balance a valid representation of the clinical path of CINV and its treatment
and to keep the model transparent enough for the end-user to understand, a simple decision
model was constructed. It was assumed in the base case that rescue medications were given
for two days. It was also assumed that patients who receive rescue medications for
breakthrough emesis and subsequently do not receive outpatient care were able to control
their nausea and emesis and do not require any more medications. However, in clinical
practice, patients may be switched to another rescue medication if the first agent does not
work. Thus, the rescue medications may differ for each day during the delayed phase. It is
difficult to decide on the sequence of the rescue medications and the level of control achieved
by them.
4. The cost-effectiveness estimates of the antiemetic regimens are for a single cycle of
chemotherapy and for chemotherapy naïve patients. The results cannot be generalizable for
multiple cycles of chemotherapy or for patients who have previous chemotherapy experience.
5. It is reported widely that patient characteristics such as age and gender are associated with
incidence of CINV. It would be useful to determine the ICER of the new antiemetic
regimens in high-risk populations based on age and gender classification. However, the
current decision model did not consider patient differences and their impact on ICER. This is
due to lack of sufficient data regarding the efficacy and cost parameters in the different
gender and age groups.
6. The indirect costs due to caregiver burden, requiring home help etc. due to uncontrolled
delayed emesis were not included in the model. Also, the estimates for lost work
productivity were based on one published study and future studies should collect primary
information about work-days lost due to CINV.
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Limitations of Phase II
7. The WTP survey was conducted among cancer patients receiving care at the Mary Babb
Randolph Cancer Center in Morgantown, WV. The study population may not be
representative of the general United States population and thus it limits the generalizability of
the study results.
8. WTP estimates were obtained from the user-based perspective because the users are most
familiar with the health outcomes being described. However, this may result in
underestimation of the WTP for improved emesis control as it does not include the dollar
valuation by the nonusers.
9. The contingent valuation method of estimating WTP for health benefits is associated with
several biases, such as hypothetical bias and strategic bias. The validity of the WTP
responses were established by determining the positive association of respondents’ income to
their WTP amounts. Strategic bias is said to exist when respondents deliberately give WTP
amounts that differs from their true WTP. Although, respondents were instructed to imagine
that their insurance does not pay for the drug, respondents know that in reality their insurance
will pay for it and may thus provide higher WTP values.
10. Hypothetical bias is said to occur due to the hypothetical nature of the WTP question itself.
In addition, the WTP amounts are based on stated preferences rather than observation of
actual behavior. Thus, it difficult to validate the WTP results obtained using surveys by
actual observation of the behavior in the market.
11. The payment card format of WTP elicitation is susceptible to range bias. In this study, we
tried to minimize range bias by conducting a pilot study to determine the range for the final
payment card and also instructed the respondents to give the exact WTP amount, if it is
greater than the highest amount on the payment card. However, respondents may still be
restricted in their responses based on the range provided.
5.5: Recommendations for Future Research
The economic evaluations in this study were conducted for a single cycle of
chemotherapy. However, chemotherapy is administered for an average of 6 cycles and it is
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important to demonstrate the cost-effectiveness of the antiemetic regimens over multiple cycles
of chemotherapy. As mentioned earlier, the model is only as good as the data used to develop the
model. The model should be populated with estimates of effectiveness and costs for each
antiemetic regimen obtained from their use in clinical practice. Future economic evaluations
should be conducted to determine the cost-effectiveness of the addition of aprepitant to a
combination of palonosetron and dexamethasone for prevention of CINV due to highly
emetogenic chemotherapy. Future research should be targeted at developing a decision model
that incorporates compliance with antiemetic regimens, and patient preference for antiemetic
agents to make it more relevant to clinical practice.
The contingent valuation study for determining WTP amounts for the aprepitant-based
regimen and palonosetron should be conducted among the general population using the ex-ante
perspective. This will provide the actual societal value of the new antiemetic regimens including
the user, non-user and externality values. The externality values are obtained from a section of
the general population who are not currently non-diseased and not at future risk but will be
willing-to-pay for making the intervention available to the others. The WTP estimates thus
obtained can be then utilized in CBA conducted form a societal perspective. In the US health
care system, people make co-payments to receive health care services. Thus, WTP estimates for
improved emesis control using increased co-payments as payment vehicle should be conducted in
the United States general population. Such a study would allow us to compare the differences in
WTP amounts for supportive cancer care such as prevention of CINV, based on the payment
vehicle used.
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5.6: Conclusions
The three-drug combination (regimen A) of aprepitant, a 5-HT3RA and dexamethasone in
the acute phase and aprepitant and dexamethasone in the delayed phase incurred the highest cost
for prevention of CINV following highly emetogenic chemotherapy. The lowest cost for
prevention of CINV following highly emetogenic chemotherapy was incurred by the combination
regimen (regimen C) of a 5-HT3RA and dexamethasone in the acute phase, and dexamethasone
and metoclopramide in the delayed phase. When the side effects of regimen C were included in
the model, it increased the costs incurred. The results showed that regimen A provided the
highest effectiveness, i.e. patients with complete control of emesis. The combination regimen of
5-HT3RA and dexamethasone in the acute and the delayed phase was dominated and not
considered cost-effective.
For prevention of CINV due to moderately emetogenic chemotherapy, the costs were
highest for the combination regimen of 5-HT3RA and dexamethasone in the acute and the
delayed phase (regimen 4), followed by the regimen with single dose of palonosetron (regimen
1), and followed by the regimen with a single dose of ondansetron (regimen 2). The least costs
were incurred by the combination regimen (regimen 3) of 5-HT3RA and dexamethasone in the
acute and only dexamethasone in the delayed phase. The palonosetron regimen had similar
effectiveness as regimen 4 and thus, the two regimens could be compared using costminimization analysis. The results could not be compared to any cutoff values to determine
whether the regimens were cost-effective because there is no established criterion regarding cost
for achieving one patient with complete control of emesis. If the current threshold for acceptable
ICER values of intervention, i.e. below $50,000 per QALY is employed, the new regimens for
prevention of CINV following chemotherapy would be considered as cost-effective.
The study results emphasizes that cancer patients receiving chemotherapy place a high
level of importance in achieving better control of nausea and emesis. It also reiterates that
uncontrolled CINV has a significant impact on patients’ health-related quality of life (HRQOL).
Although, based on the $50,000 per QALY threshold, the new regimens were considered costeffective, the cost-benefit analysis results showed that the incremental costs of the new regimen
exceeded the incremental benefits of the new regimens. However, in the present study the
incremental benefits were from the patients’ perspective and may be an underestimation of the
societal benefits of the intervention. Future research should determine the willingness-to-pay for
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improved emesis control from the general population so as to capture both the user and non-user
values.
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APPENDIX I – Expert Panel Survey
1. In your practice, among 50 patients receiving single-day chemotherapy and prophylactic
antiemetic medications, on an average, how many patients require intravenous infusion of
saline or additional care by the oncologist/nurse during the first 24 hours?

2. Do you give prescriptions for rescue medications for delayed phase breakthrough emesis
on the day of chemotherapy or when patients call up or comes in with uncontrolled
CINV?

3. Please tell the most common rescue medications that you prescribe for breakthrough
emesis during the acute and delayed phase?

4. Now please consider the 5 days following single-drug chemotherapy administration. In
your practice, among 50 patients receiving chemotherapy, on an average, how many
patients call up the oncologist/nurse for uncontrolled CINV?

5. On an average, how much time do you spend on the phone with the patient to enquire
about CINV?

6. In your practice, among 50 patients receiving single-drug chemotherapy Out , on an
average how many patients have to come back to the outpatient clinic for additional
medical care (such as saline infusion and rescue antiemetic agents) for uncontrolled
CINV?
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APPENDIX II – Oncologist Script for Patient Recruitment
Hello Ms/Mr _____________, I would like to talk to you about a study that a pharmacy
student is doing as part of her Ph.D dissertation. She is conducting a study among patients at
the cancer center to determine what it the value they place on certain new drug treatments
available to prevent some side effects of chemotherapy. It will take about 20 minutes of your
time. If you are interested in knowing more about the study and being a part of it I can
introduce her to you.
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APPENDIX III – Version A of the Willingness-To-Pay Survey
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING QUESTIONNAIRE
Interviewer:
Hello, I am Reema Mody, a PhD student in the School of Pharmacy at West Virginia
University. Dr. __________________ (name of the attending oncologist) should have
explained briefly about the research study that I am conducting.
{Hand over the cover letter attached in the Section C of the protocol}
This is the information sheet that explains the study in detail. The interview has five sections
and will take about 25-30 minutes to complete. We can go over the information letter
together or you may read it and let me know if you have any questions regarding the study.
{After the participant finishes reading the cover letter}
Will you participate in the study?
{If No},
Thank you for your time.
{If Yes},
I would like to assure you that the information you provide would be kept strictly
confidential. You are not required to give your name or any contact information. Your
participation in the study is voluntary and you can withdraw from the study at any time. You
do not have to answer any questions that may make you uncomfortable. The scenarios that I
will describe in this study are entirely imaginary and have nothing to do with your condition.
Your responses are valuable for this research and will increase the understanding of how
patients with cancer value the benefits provided by different drugs to prevent nausea and
vomiting due to chemotherapy.
May I begin the interview?

{If Yes}
“Before I ask you any questions, here is some information about cancer, chemotherapy and
its related side effects. We can go over the material together”.
{Place Insert A – Section1 in front of the participant and go over the material together}.
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INSERT A
SECTION 1:Cancer, Chemotherapy and Nausea and Vomiting due to Chemotherapy

WHAT IS CANCER?
Cancer is a disease that affects various body tissues. If not treated, cancer can spread
and can be fatal. But not everyone who gets cancer will die from it. As you know,
cancer can be treated with surgery, radiation and chemotherapy. Our study focuses on
two specific side effects of chemotherapy.

CHEMOTHERAPY AND ITS SIDE EFFECTS
Chemotherapy is the use of drugs to kill cancer cells. Chemotherapy is usually given in
4-6 cycles over a period of 4-6 months. But chemotherapy drugs may sometimes cause
side effects. Nausea and vomiting are two side effects of chemotherapy. Nausea and
vomiting due to chemotherapy is called Chemotherapy-induced Nausea and Vomiting
(CINV). While these two side effects are not fatal, they can sometimes be so severe that
some patients refuse further treatment for their cancer.

NAUSEA AND VOMITING DUE TO CHEMOTHERAPY
Nausea is having a sick feeling in the stomach, and vomiting is throwing up. Patients
can experience both nausea and vomiting or each by itself. Nausea and vomiting can
occur within 24 hours of chemotherapy and can last for 1 to 5 days after chemotherapy.
If nausea and vomiting are not prevented or controlled, it can sometimes lead to loss of
appetite, loss of nutrients and electrolytes. Patients may not feel like doing anything,
may not be able to cook and clean, and may not be able to go to work. Frequent
vomiting can sometimes be dangerous because it can lead to loss of fluids from the
body.
There are some drugs available to prevent nausea and vomiting due to chemotherapy.
These drugs are to be taken before chemotherapy and for 3-4 days after chemotherapy.
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Interviewer:
“Do you have any questions about this information?”
{If No},
“Since you have no questions about this section, we will go to the section 2 of this interview.
Here I will be asking some questions about your past experiences with chemotherapy and
nausea and vomiting associated with it”.
If the participant has questions, answer their questions before moving to Section 2.
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SECTION 2 - BACKGROUND INFORMATION
Interviewer will ask the following questions:
1. What type of cancer have you been diagnosed with? ________________
2. Can you tell me which cycle of chemotherapy are you receiving today?
□ Received in the last 3 months □ 1st cycle (never had chemotherapy)
□ 4th cycle
□ 1st cycle of new chemotherapy □ 2nd cycle
□ 3rd cycle
□ > 5th cycle
□ 5th cycle
3. Chemotherapy regimen:
________________________________________________________________________
________________________________________________________________________
4. Antiemetic regimen:
Prechemotherapy antiemetics
____________________________
____________________________

Postchemotherapy antiemetics
________________________________
________________________________

5. Did you experience nausea in the 4-5 days following your last chemotherapy cycle?
□

Yes

□

No □

Don’t know

If ‘Yes’, continue with Q6. If ‘No’ or ‘Don’t know’, go to Q7.
6. {Show the scale below to the participant}
Can you please mark X on this line to describe the severity of nausea that you experienced in
the 4-5 days following your last chemotherapy cycle?

0

50

100

Moderate Nausea

No Nausea

Severe nausea

7. Did you experience vomiting episodes in the 4-5 days following your last chemotherapy
cycle?
□

Yes

□ No

□

Don’t know

If ‘Yes’, continue with Q8. If ‘No’ or ‘Don’t know’, go to the next section.
8. Can you tell me on an average, how many episodes of vomiting you experienced per day
during your last chemotherapy cycle? {Explain the meaning of episodes of vomiting as two
bouts separated from each other by at least 1 minute}.
□ 1-2 episodes

□

3-5 episodes

□
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{After completion of section 2}
Interviewer:
“Now, let’s move on to the Section 3 of this interview. Here, I will be describing to you two
scenarios about chemotherapy, nausea and vomiting, and its treatment. The scenarios are
completely imaginary and does not relate to your condition. Dr. ______________ (attending
oncologist) may have discussed the course of treatment for your condition and the possible side
effects with you. The scenarios that I am going to talk about are developed only for the purpose
of this study”.
Interviewer:
“Imagine a scenario where the doctor has told you that you will be receiving certain
chemotherapy drugs to treat cancer. As I mentioned earlier, the scenario is entirely imaginary”.
“The doctor says that if drugs are not given to prevent nausea and vomiting, 99 out of 100
patients will experience nausea and vomiting within the first 24 hours of chemotherapy, and 75
out of 100 patients will experience nausea and vomiting for 3-4 days after chemotherapy.
However, there are treatments available that can prevent nausea and vomiting due to
chemotherapy”.
“In this study we are considering two treatments that can prevent nausea and vomiting due to
chemotherapy”.
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INSERT B

Treatment A

Treatment B
(NEW DRUG + Treatment A)

Treatment A should be taken before
chemotherapy and for 3 days after
chemotherapy.

Treatment A should be taken before
chemotherapy and for 3 days after
chemotherapy. In addition,
NEW DRUG is to be taken before
chemotherapy and for 2 days after
chemotherapy.

30 out of 100 patients will experience nausea
and vomiting within 24 hours of
chemotherapy

17 out of 100 patients will experience nausea
and vomiting within 24 hours of chemotherapy
HAVE NAUSEA
AND VOMITING

HAVE NAUSEA
AND VOMITING

17%

30%

83%

70%

HAVE NO NAUSEA
AND VOMITING

HAVE NO NAUSEA
AND VOMITING

With Treatment A, 55 out of 100 patients
will experience nausea and vomiting for 3-4
days after chemotherapy

With Treatment B, 37 out of 100 patients will
experience nausea and vomiting for 3-4 days
after chemotherapy
HAVE NAUSEA
AND VOMITING

HAVE NAUSEA
AND VOMITING

37%

55%

63%

45%
HAVE NO NAUSEA
AND VOMITING

HAVE NO NAUSEA
AND VOMITING
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{Show the Insert B and explain to the participant}
“Imagine that you are currently taking treatment A to prevent nausea and vomiting due to
chemotherapy. This treatment has to be taken before chemotherapy and for three days after
chemotherapy. Based on studies, out of 100 patients receiving Treatment A, 30 patients will have
nausea and vomiting during 24 hours of chemotherapy.
“Now, imagine that there is another treatment B available, which is the addition of the new drug
to the old treatment A. This new drug is to be taken in addition to the old treatment before
chemotherapy and for two days after chemotherapy. Out of 100 patients receiving treatment B,
17 patients will have nausea and vomiting within 24 hours of chemotherapy. Thus, with the new
treatment B, the chance of nausea and vomiting is reduced from 30% to 17%.
9. {Show the scale below to the respondent}
Indicate on this scale how important would it be for you to reduce your chance of having
vomiting and nausea within the first 24 hours after chemotherapy from 30 in 100 to 17 in
100.
{Point out the appropriate pie charts on Insert B}
0

1

2

3

4

Not at all
important

5

6

7

8

9

Somewhat
important

10
Very
important

“Now, with the old Treatment A, out of 100 patients who receive it, 55 patients will have nausea
and vomiting for 3-4 days after chemotherapy. With the new treatment B, out of 100 patients
who receive it, 37 patients will have nausea and vomiting for 3-4 days after chemotherapy. Thus,
with the new treatment B, the chance of nausea and vomiting is reduced from 55% to 37%.
10. {Show the scale below to the respondent}
Indicate on the scale below how important would it be for you to reduce your chance of
vomiting and nausea for 3-4 days after chemotherapy from 55 in 100 to 37 in 100.
{Point out the appropriate pie charts on Insert B}
0
Not at all
important

1

2

3

4

5
Somewhat
important
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Interviewer: “Assume that the two treatments cause similar side effects.
11. Will you be willing to take the new drug along with treatment A if the new drug was available
at no extra cost in preference to only treatment A?
□

Yes

□

No

□

Don’t know

Please state reasons for your answer
________________________________________________________________________
________________________________________________________________________
Interviewer:
Assume that the two treatments cause similar side effects. But the new treatment B costs more
than the old treatment A due to the addition of the new drug.
One way of measuring the value of the new drug is to ask you how much money you would be
willing to pay to receive the new drug.
Now imagine that your drug insurance plan will not cover the cost of the new drug. This means
that you will have pay extra out-of-pocket for 3-day treatment, before chemotherapy and 2 days
after chemotherapy, with the new drug for every cycle of chemotherapy. Now, this is simply a
method of measuring the value you placed on the new drug and there is no right or wrong
answer to this question.
Keeping in mind your own income level, thinking realistically about how much you can afford to
pay, please look at this scale and indicate the maximum amount that you would be willing to
pay for new drug to be taken for 3 days? Also please keep in mind that you have to pay this
amount every month for 4 cycles in equal installments”.
12. Please state the maximum amount that you would be willing to pay for new drug to be
taken for 3 days?
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$1.00
$1.50
Put a O around the maximum
amount that you are sure you
would be prepared to pay.

$2.00
$2.50
$3.00
$4.00
$5.00
$6.00
$8.00
$10.00
$15.00
$20.00
$25.00
$30.00
$35.00
$45.00
$60.00
$75.00
$100.00
$125.00
$150.00
$200.00
$250.00
$300.00
$400.00
$500.00
$650.00
$800.00
$1,000.00
More than $1000
please specify the exact amount.

If more than $1,000,

$________________________
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If the maximum WTP is $0, go to Q13. If the maximum WTP is any other value, go to the next
section.
13. If the maximum WTP in Q12 is $0, please check one of the following options:
□ $0 is what it would be worth to me to prevent nausea and vomiting due to chemotherapy
□ People should not have to pay out of pocket for medication to prevent nausea and vomiting
due to chemotherapy
□ I cannot afford to pay out of pocket for medications to prevent nausea and vomiting due to
chemotherapy
□ I object the question
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SCENARIO 2
Interviewer:
“Now, lets move on to Section 4 of this interview. Similar to the first scenario, the second
scenario is also completely imaginary. The scenario that I am going to talk about is developed
only for the purpose of this study.
“Imagine a scenario where the doctor has told you that you will be receiving certain
chemotherapy drugs to treat the cancer. These drugs are different from the one described in the
earlier scenario. The doctor says that if drugs are not given to prevent nausea and vomiting,
approximately 60 patients will experience nausea and vomiting within the first 24 hours of
chemotherapy, and 55 out of 100 patients will experience nausea and vomiting for 3-4 days after
chemotherapy. However, there are treatments available that can prevent nausea and vomiting due
to chemotherapy.
“In this study we are considering two treatments that can prevent nausea and vomiting due to
chemotherapy”.
{Show and explain Insert C to the participant}.
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INSERT C

Treatment X

Treatment Y

Treatment X should be taken before
chemotherapy and for 3 days after
chemotherapy.
Treatment X is given as an injection
before chemotherapy and is to be taken
orally (by mouth) for the remaining 3
days after chemotherapy

Treatment Y should be taken before chemotherapy
Treatment Y is given as an injection before
chemotherapy

Treatment X and Treatment Y have similar chances of reducing nausea and vomiting within 24
hours of chemotherapy.
42 out of 100 patients will experience
nausea and vomiting within 24 hours of
chemotherapy
HAVE NAUSEA
AND VOMITING

42 out of 100 patients will experience nausea and
vomiting within 24 hours of chemotherapy
HAVE NAUSEA
AND VOMITING

42%
42%
58%

58%

HAVE NO NAUSEA
AND VOMITING

HAVE NO NAUSEA
AND VOMITING

45 out of 100 patients will experience
nausea and vomiting for 3-4 days after
chemotherapy
HAVE NAUSEA
AND VOMITING

33 out of 100 patients will experience nausea and
vomiting for 3-4 days after chemotherapy
HAVE NAUSEA
AND VOMITING

33%
45%

55%

67%

HAVE NO NAUSEA
AND VOMITING

HAVE NO NAUSEA
AND VOMITING
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“Imagine that you are currently taking treatment X to prevent nausea and vomiting due to
chemotherapy. This treatment has to be taken as an injection before chemotherapy and by mouth
for three days after chemotherapy. Based on studies, out of 100 patients receiving Treatment A,
42 patients will have nausea and vomiting during 24 hours of chemotherapy.
“Now, imagine that there is a new treatment Y available, which is to be taken as an injection only
before chemotherapy. Out of 100 patients receiving treatment B, 42 patients will have nausea and
vomiting within 24 hours of chemotherapy. Thus, treatments X and Y have similar chances of
preventing nausea and vomiting within 24 hours of chemotherapy”.
“Now, with the old treatment X, out of 100 patients who receive it, 45 patients will have nausea
and vomiting for 3-4 days after chemotherapy. With the new treatment Y, out of 100 patients
who receive it, 33 patients will have nausea and vomiting for 3-4 days after chemotherapy. Thus,
with the new treatment Y, the chance of nausea and vomiting is reduced from 45% to 33%.
14. {Show the scale below to the respondent}
Indicate on the scale below how important would it be for you to reduce your chance of
vomiting and nausea for 3-4 days after chemotherapy from 45 in 100 to 33 in 100.
{Point out the appropriate pie charts on Insert C}
0
Not at all
important

1

2

3

4

5
Somewhat
important
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{Keep the Insert C in front of the respondents}
Interviewer: Assume that the two treatments cause similar side effects.
15. Will you be willing to take the new drug Y if it is available at no extra cost in
preference to treatment X?
□

Yes

□

No

□

Don’t know

Please state reasons for your answer
_____________________________________________________________________
_____________________________________________________________________
Interviewer:
“Assume that the two treatments cause similar side effects. But the new treatment Y costs
more than the old treatment X. One way of measuring the value of the treatment Y is to
ask you how much money you would be willing to pay to receive treatment Y.
Now imagine that the cost of the new drug is not covered by your drug insurance plan.
This means that you will have to pay extra out-of-pocket to receive treatment Y for one
day for every chemotherapy cycle. Now, this is simply a method of measuring the value
you placed on the treatment Y. There is no right or wrong answer to this question.
Keeping in mind your own income level, thinking realistically about how much you can
afford to pay, please look at the scale and indicate the maximum amount that you would
be willing to pay to for treatment Y for one day? Remember that you have to pay this
amount for 4 chemotherapy cycles in equal installments”.

16. Please state the maximum amount that you would be willing to pay for new drug to be

taken for 1 day?
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$1.00
$1.50
$2.00
$2.50
$3.00
$4.00
$5.00
Put a O around the maximum
amount that you are sure you
would be prepared to pay.

$6.00
$8.00
$10.00
$15.00
$20.00
$25.00
$30.00
$35.00
$45.00
$60.00
$75.00
$100.00
$125.00
$150.00
$200.00
$250.00
$300.00
$400.00
$500.00
$650.00
$800.00
$1,000.00
More than $1000
If more than $1,000, please specify the exact amount.
$_______________________
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If the maximum WTP is $0, go to Q17. If the maximum WTP is any other value, go to Q18.
17. If the maximum WTP in Q17 is $0, please check one of the following options
□ $0 is what it would be worth to me to prevent nausea and vomiting due to chemotherapy
□ People should not have to pay out of pocket for medication to prevent nausea and vomiting
due to chemotherapy
□ I cannot afford to pay out of pocket for medications to prevent nausea and vomiting due to
chemotherapy
□ I object the question
Interviewer:
“Now I will be asking some questions about the level of difficulty you had in doing the interview”
18. {Show the scale below to the participant} On the scale shown, please indicate the level of
difficulty you had in understanding the scenarios and the questions along with it.
0

1

2

3

4

Not at all
difficult

5

6

7

8

9

Somewhat
difficult

10
Extremely
difficult

19. {Show the scale below to the participant} On the scale shown, please indicate the level of
difficulty you had in answering the questions (Q.12 and Q. 16) on the maximum amount that
you are willing to pay for the new drug and Treatment Y?
0
Not at all
difficult

1

2

3

4

5
Somewhat
difficult

6

7

8

9

10
Extremely
difficult

Interviewer: This is the last section of the interview and it related to (present the Section 5 of the
questionnaire) your background, such as age, race, education, employment, etc.
{Read out the questions in Section 5}.
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SECTION 5: DEMOGRAPHIC INFORMATION
{Interviewer will read the questions}
20. What is your age?

_______ (years)

21. What is your gender?

□

Male

□

Female

22. What is your race?
□ Caucasians □ African American

□ Asian

□ Other (Please specify) _________

23. {Show the question} Please mark the highest level of education completed?
□ Never attended school

□ Elementary school

□ High school graduate or GED
□ College graduate

□ Some high school
□ Some college or technical school

□ Other (Please specify) _____________

24. What is your marital status?
□ Married

□ Single (Never married)

□ Widowed

□ Living together (not married)

□ Divorced

25. {Show the question} Which category best describes your employment status?
□ Full time worker (≥30 hours per week)
□ Working at home

□ Part time worker (< 30 hours per week)

□ Student □ Not working

26. {Show the question} Please indicate your approximate total annual household income.
□ ≤ $15,000

□ $15,001 - $30,000

□ $60,001 - $75,000

□ $30,001 - $45,000

□ $75,001 - $100,000

□ $45,001 - $60,000

□ > $100,000

27. Please state the number of members living in your household (Excluding yourself)
________________
28. {Show the question} What type of insurance do you have?
□ Private

□ Medicare

□ Medicaid

□ Worker’s compensation

□ HMO

□ None

□ Other (Please specify) __________________

{After completion of Section 5} Record the time taken to complete the interview: ________
“Thank you so much for the time and effort you have taken to complete this interview. The
information you have provided is valuable to this study. As a token of my appreciation, please
accept this gift”.
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